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Abstract
Randomised preference trial of medical versus surgical 
termination of pregnancy less than 14 weeks’ gestation 
(TOPS)
SC Robson,1* T Kelly,1 D Howel,1,3 M Deverill,2 J Hewison,4 MLS Lie,2 
E Stamp,2 N Armstrong2 and CR May2
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
2Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
3School of Mathematics and Statistics, Newcastle University, Newcastle upon Tyne, UK
4Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
*Corresponding author
Objectives: To determine the acceptability, efficacy 
and costs of medical termination of pregnancy (MTOP) 
compared with surgical termination of pregnancy 
(STOP) at less than 14 weeks’ gestation, and to 
understand women’s decision-making processes and 
experiences when accessing the termination service.
Design: A partially randomised preference trial and 
economic evaluation with follow-up at 2 weeks and 3 
months.
Setting: The Royal Victoria Infirmary, Newcastle upon 
Tyne, UK.
Participants: Women accepted for termination of 
pregnancy (TOP) under the relevant Acts of Parliament 
with pregnancies < 14 weeks’ gestation on the day 
of abortion. A further group of women attending 
contraception and sexual health clinics participated in a 
discrete choice experiment (DCE).
Interventions: STOP: all women ≥ 6 weeks’ and < 14 
weeks’ gestation were primed with misoprostol 400 µg 
2 hours before the procedure. STOP was performed 
under general anaesthesia using vacuum aspiration. 
MTOP: all women < 14 weeks’ gestation were given 
mifepristone 200 mg orally, returning 36–48 hours later 
for misoprostol.
Outcome measures: Main outcome measure was 
acceptability of TOP method. Secondary outcome 
measures included strength of preference by willingness 
to pay (WTP); distress, using the Impact of Event Scale 
(IES); anxiety and depression; satisfaction with care; 
experience of care; frequency and extent of symptoms 
including self-assessment of pain; clinical effectiveness; 
and complications. A DCE was used to identify 
attributes that shape women’s preferences for abortion 
services.
Results: The trial recruited 1877 women, 349 in the 
randomised arms and 1528 in the preference arms. 
Of those in the preference arms, 54% chose MTOP. 
At 2 weeks after the procedure more women having 
STOP would choose the same method again in the 
future. Acceptability of MTOP declined with increasing 
gestational age. The difference in acceptability between 
STOP and MTOP persisted at 3 months. At 2 weeks 
after TOP, women in the preference arms were prepared 
to pay more to have their preferred option. There was 
no difference in anxiety or depression scores in women 
having MTOP or STOP. However, women randomised 
to MTOP had higher scores on subscales of the IES at 
both 2 weeks and 3 months. There was no difference in 
IES scores between MTOP and STOP in the preference 
arm. Women were more likely to be satisfied overall 
and with technical and interpersonal aspects of care if 
they had STOP rather than MTOP. Experience of care 
scores were lower after MTOP in both randomised and 
preference arms. During admission women undergoing 
MTOP had more symptoms and reported higher mean 
pain scores, and after discharge reported more nausea 
and diarrhoea. There were no differences in time taken 
to return to work between groups; around 90% had 
returned to work and normal activity by 2 weeks. Rates 
of unplanned or emergency admissions were higher 
after MTOP than after STOP. Overall complication 
rates were also higher after MTOP, although this only 
achieved statistical significance in the preference arm. 
Overall, STOP cost more than MTOP due to higher 
inpatient standard costs. Even though complication 
rates were higher with MTOP, it was still more cost-
effective. DCE identified three attributes with an almost 
equal impact on women’s preferences: provision of Abstract
iv
counselling, number of days delay to the procedure, and 
possibility of an overnight stay.
Conclusions: MTOP was associated with more 
negative experiences of care and lower acceptability. 
Acceptability of MTOP declined with increasing 
gestational age. MTOP was less costly but also less 
effective than STOP. The majority of women choosing 
MTOP were satisfied with their care and found the 
procedure acceptable.
Recommendations for further research:
An audit of provision of MTOP and STOP in England 
and Wales is urgently required. Further studies 
exploring the barriers to offering women the choice 
of method of TOP are needed, together with research 
on the acceptability and effectiveness of (1) MTOP and 
manual VA in pregnancies below 9 weeks’ gestation and 
(2) MTOP and dilatation and evacuation after 14 weeks’ 
gestation.
Trial registration: Current Controlled Trials 
ISRCTN07823656.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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HTA Health Technology Assessment
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Objectives
To determine the acceptability, efficacy and costs 
of medical termination of pregnancy (MTOP) 
compared with surgical termination of pregnancy 
(STOP) at less than 14 weeks’ gestation, and to 
understand women’s decision-making processes 
and experiences when accessing the termination 
service and taking part in the trial.
Design
A partially randomised preference trial and 
economic evaluation with follow-up at 2 weeks and 
3 months. 
Setting
The Royal Victoria Infirmary, Newcastle upon 
Tyne, UK, a large tertiary unit providing both 
MTOP and STOP up to 20 weeks’ gestation to 
women throughout the north-east of England. The 
termination service is nurse practitioner-led and 
undertakes around 1800 terminations per year.
Participants
Participants were women accepted for termination 
of pregnancy (TOP) under clause C of the 
Human Fertilisation and Embryology Act (1990) 
amendment of the Abortion Act (1967) with 
pregnancies less than 14 weeks’ gestation (based on 
ultrasound) on the day of abortion. A further group 
of women attending contraception and sexual 
health clinics in Newcastle upon Tyne participated 
in a discrete choice experiment.
Interventions
Surgical termination of 
pregnancy
All women ≥ 6 weeks’ and < 14 weeks’ gestation 
were primed with misoprostol 400 µg 2 hours 
prior to the procedure. All STOP procedures 
were performed under general anaesthesia using 
vacuum aspiration (VA) by two consultants each on 
a dedicated operating list.
Medical termination of 
pregnancy
All women < 14 weeks’ gestation were given 
mifepristone 200 mg orally. They returned 36–48 
hours later to the gynaecological day-case ward for 
prostaglandins (detailed below).
1.  Women ≤ 9 weeks’ gestation were given 
misoprostol 800 µg vaginally, followed 4 hours 
later by misoprostol 400 µg if no abortion had 
occurred. Subsequently if abortion did not 
occur by 1630–1700 and there was no excessive 
bleeding, women were discharged home with 
2-week follow-up scan review.
2.  Women ≥ 9+1 weeks’ gestation were given 
misoprostol 800 µg vaginally followed by 
misoprostol 400 µg every 3 hours up to a 
maximum of four doses. If by midnight no 
abortion had occurred, mifepristone 200 mg 
orally was administered followed by gemeprost 
1 mg vaginally 3-hourly from 0800 up to a 
maximum of five doses. If abortion had not 
occurred by 0800 the following morning, 
STOP was arranged.
Main outcome measures
The main outcome measure was acceptability 
determined by responses to the question: ‘If you 
ever have another termination of pregnancy, would 
you opt for the same method?’
Secondary outcome measures included strength of 
preference by willingness to pay (WTP) using the 
payment card method; distress using the Impact 
of Event Scale (IES); anxiety and depression 
using the Hospital Anxiety and Depression Scale 
(HADS); satisfaction with care using a 5-point 
Likert scale; experience of care using a semantic 
differential rating scale; frequency and extent of 
symptoms including self-assessment of pain using 
a visual analogue scale; clinical effectiveness using 
unplanned/emergency admission requiring an 
overnight stay and complications.
Executive summaryExecutive summary
x
A discrete choice experiment was used to identify 
key factors (attributes) that shape women’s 
preferences for abortion services.
Results
The trial recruited 1877 women: 349 in the 
randomised arms and 1528 in the preference arms. 
Of those in the preference arms, 54% chose MTOP. 
When questioned 2 weeks after the procedure 
more women having STOP would choose the same 
method again in the future {adjusted difference 
24.9% [95% confidence interval (CI) 15.8 to 34.9%] 
in the randomised arm and 15.9% [95% CI 12.2 
to 19.6%] in the preference arm}. Acceptability of 
MTOP declined with increasing gestational age. 
The difference in acceptability between STOP and 
MTOP persisted at 3 months.
There was no difference in the maximum amount 
women were willing to pay for their preferred 
method prior to the procedure. At 2 weeks after 
TOP, women in the preference arms were prepared 
to pay more to have their preferred option, but 
there was no difference in the mean maximum 
WTP values between MTOP and STOP in the 
randomised or preference arms.
There were no differences in anxiety or depression 
between women having MTOP and STOP as 
measured by HADS. However, women randomised 
to MTOP had higher scores on the intrusion 
subscale of the IES at 2 weeks and both the 
intrusion and avoidance subscales at 3 months. 
There was no difference in IES scores between the 
MTOP and STOP groups in the preference arms.
Women were more likely to be satisfied overall and 
with the technical and interpersonal aspects of care 
if they had STOP rather than MTOP whether in 
the preference arms or randomised arms. 
Experience of care as determined by median 
semantic differential scores were lower after MTOP 
in both randomised and preference groups. MTOP 
was felt to be more unpleasant, more disagreeable, 
harder and more painful while STOP was felt to be 
milder, more agreeable, faster and safer. 
During admission women undergoing MTOP 
had more symptoms and reported higher mean 
pain scores. Compared with women having STOP, 
more women having MTOP reported nausea 
and diarrhoea after discharge. There were no 
differences in time taken to return to work between 
groups; around 90% of women had returned to 
work and normal activity by 2 weeks.
Rates of unplanned or emergency admissions were 
higher after MTOP than STOP (4.2% versus 0.7% 
respectively). Overall complication rates were also 
higher after MTOP (5.0% versus 2.6% respectively), 
although this difference only achieved statistical 
significance in the preference arm.
The overall cost of STOP was greater than 
MTOP (£498 versus £287 respectively) due to 
higher inpatient standard costs. Even though 
complication rates were higher with MTOP, the 
medical procedure was more cost-effective based 
on the measure of effectiveness used (successful 
completion of TOP on the day of admission).
A discrete choice experiment identified three 
service attributes that had an almost equal 
impact on women’s preferences: the provision 
of counselling, the number of days delay to the 
procedure and the possibility of the need for an 
overnight stay. Women would be prepared to wait 
approximately one extra day to ensure access 
to post-termination counselling and to avoid an 
overnight stay following a termination.
Qualitative substudy
Women wanted quick access to abortion, but were 
concerned about what professionals thought of 
them. Women also found accessing the service 
via family planning clinics easier than via general 
practitioner surgeries. Once in the hospital service, 
quick assessment and treatment was important to 
them.
Women participated in the trial because by helping 
others they were able to feel compensated in some 
way for the unpleasant experience of undergoing 
termination. Some felt a general ethical obligation 
to help while others gained different levels of 
personal benefit; some women found talking about 
their experiences cathartic.
Some women found the concept of letting the 
computer ‘choose’ difficult to understand. For 
those with a strong pre-existing preference the trial 
design meant that women could still benefit by 
both choosing which method they preferred and 
participate in the trial to help others.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Conclusions
MTOP was associated with more negative 
experiences of care and lower acceptability. 
Acceptability of MTOP declined with increasing 
gestational age. MTOP was less costly, but also less 
effective than STOP. Women value the option to 
choose their preferred abortion method. However, 
the majority of women choosing MTOP were 
satisfied with their care and found the procedure 
acceptable, suggesting that a patient-centred 
abortion service should offer the choice of medical 
or surgical abortion up to 14 weeks of pregnancy.
Recommendations for 
further research
An audit of provision of MTOP and STOP in 
England and Wales is urgently required. Further 
studies exploring the barriers to offering women 
the choice of method of TOP are needed, together 
with research on the acceptability and effectiveness 
of (1) MTOP and manual VA in pregnancies below 
9 weeks’ gestation and (2) MTOP and dilatation 
and evacuation after 14 weeks’ gestation.
Trial registration
This trial is registered as ISRCTN07823656.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
1
Scientific background
Unwanted pregnancy is a major health issue: 
worldwide an estimated 53 million abortions 
are performed each year, resulting in up to 
100,000 maternal deaths.1 In 2007 nearly 
200,000 pregnancy terminations were performed 
in England and Wales, of which 38% were 
performed in NHS hospitals and 50% in approved 
independent sector locations under NHS contract. 
The majority of abortions are performed before 
13 weeks of pregnancy (90%) and by surgical 
methods (65%).2 In 2000, 64 of 194 (33%) units 
with facilities for termination of pregnancy (TOP) 
before 13 weeks provided both medical and 
surgical methods, while among the 130 units with 
only one method available, surgical termination 
of pregnancy (STOP) was the only option in 79%.3 
Prior to 14 weeks’ gestation surgical termination 
can be performed by vacuum aspiration (VA). 
This procedure, performed under general 
anaesthesia, has been the method of choice since 
the 1960s; VA is currently used in 57% of abortions 
performed prior to 10 weeks’ gestation and 89% 
of those performed at 10–12 weeks’ gestation.4 
The technique is safe and efficacious; major 
complications (uterine perforation, pelvic sepsis 
and haemorrhage requiring blood transfusion) 
occur in 0.2–0.9% of cases.5–7 However, up to 5% 
of women return to hospital with post-abortion 
symptoms, of whom 50–65% require surgical 
evacuation for retained products.6,7 Complication 
rates increase with gestation,5–8 with incomplete 
abortion reported in up to 12% of cases ≥ 12 
weeks’ gestation.7 Cervical preparation with 
prostaglandins facilitates cervical dilatation and 
reduces complications.9 If the woman is under 
18 years of age or at > 10 weeks’ gestation, 
misoprostol 400 µg vaginally 3 hours prior to 
surgery is recommended.9
Medical abortion using mifepristone, an anti-
progesterone, and prostaglandins has been 
available since the 1980s. For abortions at up to 63 
days’ gestation, evidence suggests that mifepristone 
(200 mg orally) followed 36–48 hours later by 
either gemeprost (1 mg vaginally) or misoprostol 
(800 µg vaginally) are equally safe and effective, 
with 94–97% of women achieving complete 
abortion.10–13 Because of much lower costs, 72% of 
units use misoprostol.3 Complete abortion rates 
with single-dose mifepristone/misoprostol fall from 
98.5% at ≤ 49 days’ gestation to 96.7% at 50–63 
days,12 but are much lower after 63 days.14 For 
women at 49–63 days, if abortion has not occurred 
4 hours after administration of misoprostol, a 
second dose (400 µg vaginally or orally) may 
be administered.9 Between 64 and 91 days’ 
gestation, efficacy is increased if the initial dose 
of misoprostol is followed by repeated doses of 
400 µg.15 However, even using up to a maximum of 
five further doses, the need for surgical evacuation 
increased from 0.9% at 9–10 weeks to 7.9% at 
12–13 weeks.15
A Cochrane systematic review of medical versus 
surgical methods of first-trimester TOP identified 
only six relevant trials, mostly with small 
numbers.16 Prostaglandins used alone seemed to 
be less effective and more painful compared with 
surgical abortion; only two trials of mifepristone/
prostaglandins were included.17,18 The review 
suggested there was inadequate evidence to 
comment on the acceptability and side effects 
of medical versus surgical abortions and called 
for trials to address the efficacy of currently used 
methods and women’s preferences. This Cochrane 
review included the only partially randomised 
preference trial of medical and surgical TOP 
between 10 and 13 weeks.18 Side effects (vomiting, 
diarrhoea and abdominal pain) were higher in the 
medical group, although there was no difference 
in the rates of major complications up to 8 weeks 
after the procedure. Subsequent to the review there 
has been one further partially randomised trial 
of medical versus surgical methods at < 64 days’ 
gestation.13,19 In addition to suggesting that surgical 
abortion had higher success rates, this study 
proposed that more women were satisfied with a 
surgical procedure.13
Available evidence suggests that 17–85% of women 
requesting first-trimester TOP have a preference 
for either a medical or surgical procedure.16–18,20 
The most common reason cited for preferring 
medical termination of pregnancy (MTOP) is the 
avoidance of surgery and/or anaesthesia.16,21 The 
large variation in reported preference rates may be 
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explained by factors such as gestational age, prior 
experience and time to access the procedure.16,20–22 
Preference for STOP appears to increase with 
gestational age;17,18 early in pregnancy women 
appear to perceive the medical procedure as easier 
and more natural, while later it is perceived as 
more stressful (related to concerns about pain and 
seeing the fetus).20–22 If a woman has a preference 
for one method she is unlikely to be enrolled in a 
randomised trial or she may refuse the allocated 
method.21 To represent the full range of service 
users, randomised trials need to include preference 
arms.
Service users’ evaluations of the care they have 
received are clearly important in the context of 
current initiatives to develop a more patient-
centred NHS. Patient satisfaction with their 
care is the most commonly used indicator in 
research on patient evaluations,23 but definitions 
of satisfaction vary, and different measures 
incorporate different dimensions of the construct, 
such as adequacy, suitability and acceptability. A 
common problem with satisfaction measures is 
that they exhibit ceiling effects, i.e. most patients 
report being satisfied, and distinctions between 
care of different quality are often not observed. 
This is likely to be a particular problem in areas 
such as TOP, where patients are widely observed 
to experience a sense of relief after the procedure. 
Most studies of women’s views about TOP have 
reported procedure acceptability; typically women 
have been asked whether they would opt for the 
same method in the future or recommend the 
method to a friend.16,21,24 Data from randomised 
trials indicate that acceptability of both methods 
before 9 weeks’ gestation is high (63–92%), with 
2–36% of women randomised to STOP preferring 
a medical procedure in future and 22–37% of 
women randomised to MTOP preferring STOP.16,18 
Where women have a preference for one method, 
typically ≥ 90% would choose the same method 
in the future.17,20–22,24 Acceptability may be lower 
at later gestations; in the only randomised trial 
of abortion methods at 10–13 weeks’ gestation, 
more women opted for VA again than medical 
abortion (79% versus 70% respectively).18 However, 
response rates were low (< 50%). The results 
reported above are based on the ‘single question 
with a binary outcome’ approach to assessing 
acceptability. Such measures are simple to collect 
and report, but provide limited information, 
particularly about why respondents hold the views 
they do. One supplementary approach is to ask 
respondents to rate specific features of their care, 
thereby providing information about the reasons 
underlying acceptability judgements. Using a 
semantic differential rating scale, Henshaw et al.17 
identified that in randomised women, medical 
abortion rated lower on six of the bipolar adjectives 
with pain showing by far the largest difference. 
VA was also rated less painful in women allocated 
according to preference.
The psychological effects of TOP have recently 
been reviewed.25 The authors concluded that 
TOP rarely causes immediate or lasting negative 
psychological consequences in healthy women. 
Indeed several studies reported positive outcomes 
such as relief.25 Henshaw et al.17 performed a 
partially randomised preference trial of TOP at 
< 9 weeks’ gestation and found no differences in 
depression, anxiety or low self-esteem 2 weeks after 
the procedure26 nor, in a much smaller number, 
2 years later.27 Whether MTOP is associated with 
more adverse psychological consequences after 9 
weeks’ gestation is not known.
Although many studies have reported the outcomes 
of first-trimester TOP, very few have randomised 
the method of abortion, and only one has included 
women beyond 9 weeks of pregnancy, despite 
the fact that this group constitutes over 40% of 
TOPs.18 There is a need for a partially randomised 
preference trial comparing VA with current 
methods of medical abortion. In addition to 
patient acceptability, the trial needs to determine 
the clinical effectiveness and cost-effectiveness of 
the two methods.
There is a clear policy impetus to understand, 
qualitatively, women’s preferences for medical or 
surgical TOP and the decision-making processes 
that lead both to these preferences and to 
encounters with health services. The personal 
and political sensitivities that surround TOP 
have important consequences for research in the 
field. The most important of these is resistance to 
inquiry into decision-making and action where this 
may threaten the moral viability of the woman’s 
decisions. This means that although TOP is 
one of the most common procedures in the UK, 
little work has been done that will contribute to 
robust understanding of preferences for types of 
procedures. Instead, the objective of much research 
in the field has been aimed at understanding 
decision-making on termination in relation to 
promoting access or reducing delays in referral to 
clinical services. Recently, this approach has led 
to an important qualitative study in the UK. In 
this study, Kumar et al.28,29 have shown that most 
women prefer not to discuss their decision with 
clinicians, but prefer instead to receive information 
and prompt referral. Unease about discussing DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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personal aspects of termination has also been 
registered among professionals, especially nurses 
and midwives (this may also explain the paucity 
of social science research in the field).30 Factors 
affecting the choice of method of termination 
are already known to be highly complex.31 The 
problem of decision-making and preferences 
around termination is, therefore, quite unlike any 
other arena of clinical research, especially other 
areas where approaches to shared decision-making 
have become prominent in recent years.32
The intensive investigation of the experiences and 
preferences women had within the trial provided 
a point of departure for the qualitative substudy. 
This drew on data collected within the economic 
substudy of strength of preferences, and was 
an optional final phase of the trial experienced 
by a subgroup of 30 women. Qualitative 
substudies within trials tend to be used either 
as initial (reconnaissance) studies to assist in 
decision-making about instrument design, study 
organisation and recruitment; or as formative 
process evaluations of ongoing work.33 In the 
present study, we intended to take a different tack, 
using the qualitative investigation as a means 
of illuminating women’s responses to (1) the 
experience of participating in the trial and (2) 
their perspectives on the results of the economic 
study of strength of preference. Directly focusing 
on these topics will provide useful data, but will 
also indirectly open up earlier decision-making 
processes and questions of access to investigation. 
A key problem in qualitative studies of personally 
sensitive experiences and actions is that of the 
participant being forced to construct an account 
that provides a justification for action in the face 
of anticipated moral judgements by an external 
authority;34 this makes for bias in accounts. We 
have adopted an approach to study design and 
data collection that was explicitly intended to 
move the focus of participants’ accounts away 
from personal justification towards a wider 
explanatory perspective. We did this by asking 
participants to act as lay interpreters of data 
collected elsewhere in the study (see Chapter 3, 
Discrete choice experiment) and focused on the 
preferences and action of ‘notional others’,35 using 
this interpretive function as a starting point for 
their own accounts. This approach meant that its 
design and application did not risk confounding 
recruitment and retention of participants, or other 
data collection, where these were already likely to 
be a challenge.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Design
This was a partially randomised controlled 
preference trial comparing MTOP and STOP 
at less than 14 weeks’ gestation. The principal 
outcome was acceptability of termination 
method as determined by preference for a future 
method of termination. This design ensured the 
inclusion of women who had a prior procedure 
preference (preference group) and those who did 
not (randomised group), and therefore reflects 
the population of a normal clinical setting. A 
substantial qualitative component was utilised 
to gather information about women’s motives 
for joining the trial, their personal experiences 
of seeking termination and their decision-
making process. Data collected using ‘strength of 
preference’ and the model developed from conjoint 
economic analysis were used as the focus to obtain 
women’s perspectives. The study was approved by 
the Newcastle and North Tyneside Research Ethics 
Committee 2 (Reference 05/Q0906/38).
Participants
Participants were women accepted for TOP 
under clause C of the Human Fertilisation and 
Embryology Act (1990) amendment of the 
Abortion Act (1967) with pregnancies < 14 weeks’ 
gestation (based on ultrasound assessment of fetal 
size) at the time of abortion between 18 July 2005 
and 31 January 2008 (31 months).
Inclusion criteria
1.  Women who had an unwanted pregnancy of 
< 14 weeks’ gestation.
2.  Women who were able to give written consent.
3.  Women < 16 years of age who were deemed 
Fraser competent36 by the nurse practitioner 
and had a parent or legal guardian present 
who was also willing to give written consent.
Exclusion criteria
1.  Women with a pre-existing medical disorder 
that was an indication for either MTOP or 
STOP.
2.  Non-English-speaking women (apart from 
French, Mandarin, Cantonese, Bengali, Urdu 
and Arabic) due to limited availability of 
interpreters.
3.  Previous participation in the trial.
4.  Current participation in a ‘drug’-related trial.
5.  Lack of availability of either MTOP or STOP 
within 10 days of outpatient assessment.
Setting
The trial was conducted at the Royal Victoria 
Infirmary (RVI), Newcastle upon Tyne, UK. The 
hospital is a large tertiary unit that provides both 
medical and surgical TOP up to 20 weeks’ gestation 
to women throughout the north-east of England. 
The unit undertakes around 1800 terminations 
per year. The termination service has undergone 
continual development over the last 15 years in 
response to the needs of the women who access 
it. Women referred from primary care (general 
practice or sexual and reproductive health clinics) 
are seen by one of three nurse practitioners in 
assessment clinics which run 5 days per week. 
Towards the end of the trial, because of increasing 
referrals to the service, additional clinics were 
started on one evening and on a Saturday morning.
Recruitment
All women being referred to the TOP service were 
given an information leaflet by their referring 
health professional. The leaflet contained 
information about abortion services at the RVI 
as well as an explanation of medical and surgical 
TOP and common complications. When women 
arrived in the outpatient clinic they were given 
a patient information sheet about the Newcastle 
upon Tyne  TOPS study and asked to read it 
before seeing the nurse practitioner. Women at 
< 14 weeks’ gestation who were accepted for TOP 
had the two methods of abortion explained. The 
nurse practitioner emphasised that there was no 
evidence that one method was superior to the 
other, that women, therefore, had a choice of 
method and that research was being conducted into 
women’s preferences for abortion method. Women 
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interested in participating were immediately 
referred to the research nurse in an adjacent room. 
The research nurse explained the study, answered 
any questions and, where appropriate, took written 
consent.
Within a few months of starting the trial, it became 
obvious that fewer recruited women than expected 
were prepared to have their method of abortion 
determined by randomisation. The potential 
factors contributing to this were extensively 
discussed by both the Trial Management Group 
and Trial Steering Committee, and changes to 
the recruitment procedure were proposed to try 
to increase recruitment to the randomised arm. 
An action plan was agreed and after approval 
by Newcastle and North Tyneside Research 
Ethics Committee, the following changes were 
implemented from 7 August 2006:
1.  The information leaflet about the service at 
the RVI (Appendix 1) was amended to indicate 
that there was no medical evidence that one 
method of TOP was ‘better’ than the other 
and that research was being undertaken into 
women’s preferences on abortion method. 
The amended leaflet was sent to all referring 
general practices and sexual and reproductive 
health clinics with a covering letter to 
encourage professionals to give this to referred 
women.
2.  The research patient information sheet 
was amended to emphasise the value of 
randomisation and to better explain the 
process.
3.  The dialogue used by the nurse practitioners 
when introducing the trial was standardised.
Randomisation
Participants with no preference, and willing to be 
allocated a procedure at random, were randomised 
using a purpose-designed computer system with 
web-based access for trial personnel (PowerTrial). 
All randomised allocations of procedure were 
performed by the research nurse and the allocation 
was concealed from the research nurse and 
participant until recruitment to the randomised 
arm had been completed; data entry of specific 
relevant information on the randomisation page 
of the database confirmed eligibility and allowed 
procedure assignment to take place. Allocation to 
medical or surgical arms was by a random sequence 
utilising a block size of 4. Randomisation was 
stratified according to gestation (< 9 weeks and 
9–14 weeks) and for previous TOP.
Participants with a preference for MTOP or STOP 
were assigned to their method of preference. Thus 
there were four groups of participants in the trial:
1.  randomised surgical (RS)
2.  randomised medical (RM)
3.  preference surgical (PS)
4.  preference medical (PM).
Interventions
Surgical termination procedure
Women randomised to, or with a preference for, 
STOP were admitted to the gynaecological day unit 
on the morning of the procedure. All women were 
primed with misoprostol 400 µg vaginally at least 
2 hours prior to the anticipated time of STOP. All 
STOP procedures were performed under general 
anaesthesia. Gestational age was confirmed on 
the operating table prior to cervical dilatation 
by ultrasound measurement of fetal crown–
rump length or biparietal diameter or by pelvic 
examination. Following cervical dilatation with 
graded Hegar dilators, VA was performed using 
an aspiration curette size (in mm) equivalent to 
the gestational age (in weeks). A 12-mm aspiration 
curette was used for all VA procedures ≥ 12 weeks’ 
gestation. Virtually all STOP procedures were 
performed by two consultant gynaecologists each of 
whom had a weekly dedicated operating list. In the 
absence of excessive bleeding or other problems, 
women were discharged 1–2 hours after the 
procedure. In line with the recommendations of the 
Royal College of Obstetricians and Gynaecologists 
(RCOG),9 STOP was only performed after 6 weeks’ 
gestation because of the higher failure rate at very 
early gestations. The appointment for STOP was 
timed in line with this recommendation.
Medical termination procedure
Women undergoing MTOP were given 
mifepristone 200 mg orally and observed for 1–2 
hours on the gynaecology ward. In the absence of 
vomiting they were allowed home, to return to the 
ward at 0800 36–48 hours later. 
Women ≤ 9 weeks’ gestation were given misoprostol 
800 µg vaginally. A further dose of misoprostol 
400 µg was given 4 hours later, vaginally or orally 
(depending on vaginal bleeding), if no abortion 
had occurred.9 Subsequently, if abortion did not 
occur and bleeding was not excessive, women were 
routinely discharged between 1630 and 1700, with 
an appointment for outpatient review 2 weeks later. 
At the time of the review all women underwent an DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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ultrasound scan to exclude an ongoing pregnancy 
or retained products of conception (RPC). 
Women ≥ 9+1 weeks’ gestation were given 
misoprostol 800 µg vaginally followed by 
misoprostol 400 µg every 3 hours up to a maximum 
of four doses if no abortion had occurred. 
If abortion had not occurred by midnight a 
further dose of mifepristone 200 mg orally was 
administered followed by gemeprost 1 mg vaginally 
3-hourly from 0800 up to a maximum of five 
doses. If abortion had still not occurred by 0800 
the following morning, MTOP was deemed to have 
failed and STOP arranged. In all cases expelled 
products were examined to confirm they were 
complete; if there was any doubt, an ultrasound 
scan was performed. Cases where the placenta was 
retained after expulsion of the fetus (confirmed 
by ultrasound examination and/or speculum 
examination) without significant bleeding were 
managed with a further dose of misoprostol 
400 µg vaginally. Failure to pass the placenta after 
a further 3–4 hours was managed with surgical 
evacuation of RPC. Uterotonic agents were not 
used routinely during TOP procedures.
All women were given doxycycline 100 mg orally 
twice daily for 7 days, commencing on the day 
before or the day of the procedure. All women 
undergoing STOP were given metronidazole 
1 g rectally at the time of the abortion.9 Pain 
relief was available for all women, comprising 
paracetamol 1 g orally, diclofenac 75 mg orally or 
pethidine 100 mg intramuscularly.9 Non-sensitised 
rhesus D-negative women were given anti-D 
immunoglobulin 1250 iu intramuscularly prior to 
discharge from hospital.
Objectives
The aim of this partially randomised preference 
trial was to determine the acceptability, efficacy 
and costs of medical compared with surgical TOP 
at < 14 weeks’ gestation. There was also a need to 
understand women’s decision-making processes 
and experiences when accessing the termination 
service and taking part in research.
Primary objective
The primary objective was to determine 
acceptability as revealed by preference for future 
TOP method at 2 weeks post procedure in women 
randomised to medical or surgical TOP.
Null hypothesis
The null hypothesis was ‘In women without prior 
preference, medical and surgical terminations are 
equally acceptable’.
Secondary objectives
The secondary objectives were to compare surgical 
and medical procedures by assessing:
1.  strength of preference
2.  psychological sequelae
3.  satisfaction with care
4.  experiences of care
5.  frequency and severity of procedure-related 
symptoms
6.  clinical effectiveness
7.  costs and cost-effectiveness.
Qualitative substudy
The aim of the substudy was to better understand 
the foundations of women’s preferences and 
decision-making about method of termination. The 
objectives were:
1.  to identify, describe and understand women’s 
motives for joining the trial and their 
experiences of participation in it
2.  to identify, describe and understand women’s 
personal experiences of seeking termination 
and decision-making about method of 
termination
3.  to identify, describe and understand women’s 
perspectives on data collected on ‘strength of 
preference’ and the model developed from 
conjoint economic analysis.
Data collection
Baseline demographic data, including medical 
history and method of any previous termination, 
level of education, occupation and income, was 
collected by the nurse practitioner or research 
nurse from all participants. Contact details, 
including where possible mobile telephone 
numbers and availability, were also collected. 
All participants were invited to return for an 
outpatient assessment 2 weeks after the procedure 
and all assessments were undertaken in a hospital 
or community clinic. Outcome data were collected 
at 2 weeks (by structured interview and/or 
questionnaire) and at 3 months (by questionnaire) 
after the procedure (Table 1). For women who did 
not attend their 2-week follow-up visit, collection Methods
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TABLE 1  Table of events
Visit 1 (baseline) Visit 2 (TOP) Visit 3 (post TOP)
Up to –2 weeks 0 +2 weeks +3 months
Inclusion/exclusion screening ✗
Written informed consent ✗
Randomisation if applicable ✗
Reason for preference if applicable ✗
Demography + baseline data ✗
Medical history ✗
Concomitant medication ✗ ✗
Ultrasound ✗
Strength of preferencea ✗ ✗
Termination procedure ✗
Visual analogue scale ✗
Physical progress ✗
Acceptability ✗ ✗
Satisfaction with care ✗ ✗
Experience of care ✗ ✗
Impact of Events Scale ✗ ✗
Hospital Anxiety and Depression Scale ✗
Consent for qualitative interviewb ✗
a  Only determined prior to procedure in the preference group.
b  Qualitative interviews to be completed prior to 3-month time point.
of outcome data, as previously agreed, was 
undertaken via telephone interview, mobile text 
message and postal- or web-based questionnaire. 
All follow-up contacts and telephone interviews 
were conducted by a research nurse.
After the trial commenced, the distributions of the 
time it took women to respond to the questions 
asked at the 2-week and 3-month follow-ups were 
established. In view of these distributions, the Trial 
Management Group decided only to use responses 
(referred to as ‘timely responses’) if the date they 
were provided was within 4 weeks of the intended 
time after the procedure, i.e. 2-week data were 
accepted if it was provided within 42 days of TOP, 
and 3-month data were accepted if it was provided 
within 60–120 days after TOP.
Outcome measures
Acceptability
This was determined at 2 weeks and 3 months after 
the procedure by responses to the closed question 
‘If you ever have another termination of pregnancy, 
would you opt for the same method?’ This simple 
question has been used in previous preference 
trials of TOP,17,18 and has the advantage of being 
easily determined by telephone, questionnaire or 
text message.
Strength of preference
Willingness to pay (WTP) was used as a measure 
of strength of preference for medical or surgical 
TOP. This technique is being increasingly used in 
health technology assessment37 and has been used 
previously for assessing strength of preference for 
abortion method.27,38 An instrument was designed 
in order to frame a hypothetical scenario where 
women imagined that they had been offered 
their non-preferred method and that they had to 
pay an additional amount of money from their 
own income to obtain their preferred method. 
The economic theory underlying this design is 
part of welfare economic theory, which posits 
that individuals will choose their preferred set 
of goods (in this case, type of termination) from 
the total set of goods available subject to each set 
incurring some cost that must be met from some DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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fixed budget/income. Therefore, assuming full 
information, i.e. individuals know all the costs, the 
maximum amount that someone states they would 
be ‘willing to pay’ to get a new set indicates whether 
that set is preferred to the other. This is because 
this amount implies an opportunity cost, i.e. 
assuming that their current set was the preferred 
one, paying this extra amount must entail the 
loss of something that they wanted. This amount 
also entails a strength of preference to the extent that 
the greater the amount stated, the greater the 
opportunity cost, i.e. the more that the individual 
is willing to give up ceteris paribus. The bigger 
the income, the greater the amount of goods can 
be afforded. Therefore, observing a correlation 
between income and WTP is a useful test of validity.
Interviews were conducted using the payment card 
method,39 with all women in the preference arm 
at baseline (following recruitment to the study) 
prior to admission for the procedure. Women were 
asked to state their maximum WTP amount for the 
termination method they had chosen. Interviews 
were also conducted on all women in both the 
randomised and preference arms at 2 weeks after 
the procedure when they were asked to state their 
maximum WTP amount to receive their preferred 
option at a future date. In order to avoid arbitrary 
units (and to encourage elicitation of the maximum 
amount) an approach was used that presented 
actual amounts in order. Mean WTP for each TOP 
method was estimated by calculating the sample 
mean for women in the randomised and preference 
arms. There are potential sources of bias with 
WTP elicitation. For example, stating zero might 
be due to a misunderstanding or suspicion that 
the scenario is not hypothetical or the assumption 
that it is the price that is wanted. Mean WTP was 
therefore also calculated excluding zero payers. A 
comparison was then made between mean WTP for 
MTOP and STOP (stratified by method to which 
women were randomised) and between randomised 
and preference arms to test the hypothesis that 
women who already have a preference (indicated 
by actual choice of procedure) will have a stronger 
subsequent preference (indicated by stated WTP for 
hypothetical future procedure). Finally, the validity 
of women’s responses was tested by examining 
the correlation between stated WTP and level of 
income.
Distress, anxiety and depression
Distress was measured using the Impact of Event 
Scale (IES) at 2 weeks and 3 months after the 
procedure. This 15-item scale, with subscales for 
intrusion and avoidance, measures subjective 
distress to a specific event (in this case TOP),40 
and is most likely to detect a difference in actual 
experience of having one procedure rather than 
another. Anxiety and depression were measured 
using the Hospital Anxiety and Depression 
Scale (HADS) at 2 weeks and 3 months after the 
procedure. This is a widely used 14-item self-report 
scale designed for medical patients.41 Depression 
is the main problem service providers have been 
concerned about.25 Both the IES and HADS have 
been used in women after TOP.25–27
Satisfaction with care
The methodological pitfalls of measuring 
satisfaction with care have been reviewed.42 Women 
were asked to rate the quality of care during the 
termination and the counselling and support 
after the procedure using a 5-point Likert scale 
(from excellent to poor) at 2 weeks and 3 months 
after the procedure. Measures in which patients 
are asked to rate the quality aspects of their care 
show greater response variability than measures 
which seek direct ratings of satisfaction43 and are 
better predictors of whether patients will return 
to the same doctor in the future.43 For analysis 
we distinguished those who rated their care as 
excellent from the remainder as this provided 
better discrimination.44 Ratings of care were 
supplemented by information on satisfaction with 
care from the qualitative substudy.
Experience of care
To provide information about the reasons 
underlying acceptability judgements, we used a 
semantic differential rating technique administered 
at 2 weeks and 3 months post procedure. This 
instrument used a pair of opposite adjectives 
(e.g. painless–painful) as end points on a graphic 
Likert scale. Women were asked to indicate their 
experience by placing a mark on the scale. Twelve 
bipolar adjectives were used, scored along an 
evaluation dimension representing a positive or 
negative attitude ranging from 3 to –3. Rating 
scores are quick and easy to complete and have 
been used previously to measure attitude towards 
TOP.17,45
Frequency and extent of 
symptoms
The incidence of nausea, vomiting, diarrhoea, 
dizziness and abdominal pain on the day of the 
procedure was recorded as well as an assessment of Methods
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the severity of pain, using a 10-cm visual analogue 
scale (VAS), and analgesic use. Symptoms after 
discharge were ascertained at the 2-week follow-
up contact by the research nurse. These included 
the duration and severity of vaginal bleeding and 
pain as well as the length of time off work and time 
taken to return to normal activity.18
Medication use was recorded at baseline and at the 
time of the termination procedure by abstraction 
from the medical notes. Women were also asked 
about concomitant medications at the 2-week 
follow-up contact.
Clinical effectiveness
Previous studies have used a variety of measures of 
clinical effectiveness, but emphasis has been placed 
on failed TOP (with an ongoing viable pregnancy), 
incomplete abortion and presumed pelvic 
infection. Based on our proposed sample size (see 
below), the precision with which differences in 
each of these complications could be detected was 
limited. Hence a combined measure of clinical 
effectiveness that captures unplanned time spent in 
hospital, a key outcome for women, was used.
Unplanned or emergency admission was defined 
as (1) any unplanned admission requiring an 
overnight stay on the day of TOP or (2) emergency 
admission requiring an overnight stay after 
discharge from hospital following the primary 
procedure. Women were asked to report any 
attendances at their general practitioner (GP) 
surgery or hospital and any admissions at 2 weeks 
and 3 months after the procedure to ensure that 
all data on adverse outcomes were collected. The 
indication for referral and subsequent management 
were abstracted from the hospital or primary care 
notes. It was assumed that this outcome would 
capture all women with significant procedure-
related morbidity due to (1) incomplete abortion, 
missed abortion or ongoing pregnancy (all of 
which require surgical evacuation) and (2) pelvic 
infection without RPC. Further, there is evidence to 
suggest that women who experience a failed TOP 
(requiring surgical evacuation) or excessive pain 
and or bleeding that results in admission are more 
likely to classify the experience as unsatisfactory46 
and to opt not to have the same procedure again in 
the future.24,46
Total procedure-related complications were also 
compared. A complication was defined by any of 
the following:
1.  Haemorrhage: estimated blood loss > 500 ml.47
2.  Incomplete abortion: products of conception 
passed, but clinical or ultrasound evidence of 
RPC.15
3.  Failed TOP: no products of conception passed 
and cardiac activity present on ultrasound.15
4.  Suspected pelvic infection (in the absence 
of RPC): based on the clinician’s assessment 
[abnormal vaginal bleeding ± abdominal 
pain with uterine tenderness ± pyrexia 
(temperature ≥ 37.5°C)] and treatment 
(prescription of antibiotics).48
Sample size
The sample size was determined by the main 
comparison of acceptability (as assessed by 
the proportion of women who would opt for 
the same TOP method again) between women 
randomised to medical or surgical TOP. Assuming 
the acceptability of medical termination to be 
75%,17,18,20 responses from 335 women in each 
randomised arm were needed to detect a difference 
in acceptability of 10% (i.e. from 75% to 85%) with 
a significance level of 5% and power of 90%. This 
difference in the level of acceptability between 
MTOP and STOP was deemed important for both 
consumers and providers; a similar difference was 
sought by Ashok et al.18 in their large randomised 
comparison of abortion methods.
Based on the sample size calculation we therefore 
needed primary outcome data on 670 women 
randomised to medical or surgical TOP at < 14 
weeks’ gestation. In order to achieve this number 
we calculated that:
•  1116 women would need to be randomised 
(assuming primary outcome data would not be 
available from 40% of women)
•  2232 women would need to be recruited 
(assuming 50% of women agreeing to 
participate in the study would have a 
preference for medical or surgical TOP)
•  3188 women would need to be approached 
(assuming 30% of women accepted for TOP 
would decline involvement in the study).
All three assumptions were based on the experience 
from our earlier pilot trial conducted at the RVI 
involving women requesting TOP at 9–13 weeks’ 
gestation. For reasons detailed in Kumar et al.28 we 
believed that our assumption of 60% follow-up was 
conservative. Previous trials conducted in the UK DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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had reported that 54%17 and 82%18 of recruited 
women undergoing TOP at < 9 weeks and 9–13 
weeks, respectively, were prepared to have their 
method of TOP determined by randomisation. 
Thus our estimate that 50% of women agreeing to 
follow-up would be prepared to be randomised was 
also thought to be conservative. The proportions 
of women accepted for TOP who agreed to join 
these two prior randomised preference trials were 
not reported. Data from non-randomised studies 
conducted in the UK suggested that 87–92% of 
similar women were prepared to participate in 
studies involving follow-up (including psychological 
questionnaires) after TOP, suggesting that our 
assumption of 70% (based on the pilot study) was 
realistic.
Statistical methods
The study was designed to ensure the inclusion 
of women who had a prior procedure preference. 
Participants with a preference for either medical 
or surgical termination could choose one or the 
other (preference groups). Participants with no 
preference, who were willing to be allocated a 
procedure at random (randomised groups), were 
randomised using a computer system. The analysis 
strategy was similar to that used in a partially 
randomised preference trial of treatment for 
depression.49 All data analysis was on an intention-
to-treat basis, according to the inclusion/exclusion 
criteria.
The partially randomised preference design allows 
the following questions to be investigated:
1.  Are the women who choose a procedure 
different from those who are randomised to 
one?
2.  Which TOP procedure is more acceptable and 
effective?
3.  Do women allocated to procedure of their 
choice fare better than those who are 
randomised?
Women effectively chose to be in one of three 
groups: preference for MTOP (PM), preference 
for STOP (PS) or randomised to either (RM 
or RS). Therefore, question 1 was answered by 
comparing the distributions of baseline variables 
between these three groups to see if there were any 
differences. Overall tests for equality of the three 
groups was carried out (chi-squared for comparison 
of proportions or ANOVA for comparison of 
means), and if there was a statistically significant 
difference between them, comparisons were made 
firstly between the two preference arms and then 
between combined preference versus combined 
randomised arms.
According to the original protocol, the primary 
comparisons for question 2 should have been 
carried out between the randomised arms of 
the study. However, from an early stage in data 
collection it was clear that there would be far too 
few women willing to be randomised for analysis 
to be definitive, so primary comparisons were 
carried out between women in the preference 
arms of the trial. The main comparison of the 
primary outcome was between the two preference 
arms at 2 weeks, and then at 3 months. This was 
then repeated for the two randomised arms, and 
then for the combined preference arms compared 
with the combined randomised arms (to answer 
question 3). 
Acceptability (proportions willing to have the 
same termination procedure again) was compared 
via binomial regression including key baseline 
variables as covariates in the model (previous TOP, 
previous live birth, mother’s age, educational level 
and gestation at TOP). However, the comparisons 
of the randomised groups did not adjust for these 
covariates: multivariate models would not converge 
because of the smaller sample size, but the groups 
are likely to be balanced on these covariates via the 
random allocation. Possible interactions between 
intervention and gestation, and intervention 
and past history of TOP were considered. These 
possible interactions are illustrated by plotting the 
proportion finding the procedure acceptable by 
gestation in weeks using a Lowess smoother for 
the two intervention groups. Where there was a 
statistically significant interaction, the difference 
in acceptability between intervention groups was 
estimated at three gestational age epochs.
The secondary outcomes were compared between 
the two preference arms, then between the 
two randomised arms, and then for combined 
preference arms compared with combined 
randomised arms. Mean ratings on the 
psychological scales were compared by multiple 
linear regression while adjusting for the key 
baseline variables listed above. Satisfaction with 
care was collected on a 5-point scale (poor to 
excellent), but was recoded as whether or not 
the women assessed their care as ‘excellent’: the 
trial arms were compared using binary regression 
adjusting for key baseline variables.Methods
12
For other binary variables (e.g. occurrence of 
symptoms in the days after the termination, 
whether women had returned to work/normal 
activities at 2 weeks) unadjusted comparisons were 
made between trial arms with 95% confidence 
limit (CI) for the differences. Similar unadjusted 
comparisons were made between trial arms to 
compare the mean VAS pain scores (with 95% CI). 
The distributions of the semantic differential scales 
(7-point scales), strength of bleeding scale (5-point 
scale) and time to return to work and normal 
activity (in days) were compared between groups via 
Mann–Whitney tests. All analyses were done using 
stata, version 8.50
Costs and cost-effectiveness 
analysis
Cost data relating to NHS resource use (both 
primary and secondary care) were collected 
following established methods51 up to 3 months 
post TOP. This included data relating to the 
initial procedure, hospital stay, follow-up care 
as inpatients, any additional interventions and 
outpatient appointments. Data relating to GP 
consultations and referrals/admission to other 
secondary care units were collected using the 
postal questionnaire and, if agreed previously, by 
telephone.
For the costing exercise the resource quantities 
used and the unit cost (of the resource) for each 
method of TOP were determined. The total cost 
of each TOP method is the sum of the products of 
the quantity of units and unit cost. Obtaining data 
on resource use and the unit costs of each resource 
item was sometimes difficult given that some 
information was either not routinely collected or 
not accessible. For such costs, assumptions guided 
by expert clinical opinion were used.
Total individual cost was estimated as the sum of 
standard and individual-level costs.
1.  Standard costs do not vary by individual patient 
and were reported in two parts: initial clinic 
attendance (which is assumed to be the same 
for both methods of TOP); and TOP procedure 
costs (which are assumed to vary only by 
procedure and not by patient). 
2.  Individual-level costs are informed by individual-
level data. The number of patients who 
consumed at least one unit of resource was 
determined and the mean number of units 
calculated by dividing the total number of units 
by the sample size. Total mean individual cost 
was calculated as the sum of the product of the 
unit cost and the mean number of units. 
Strictly, staff costs could vary per individual, but as 
actual staff times were not collected per individual 
they are included in standard costs. For consistency, 
staff costs are reported, as with all other costs, in 
the form of a marginal cost, i.e. the extra cost that 
would be incurred to buy another unit of the item. 
Staff costs for the TOP procedure were estimated 
by taking the total staffing cost from the NHS 
Trust attributed to the ward and then estimating 
the proportion of bed days for TOP out of all 
procedures carried out on that ward. All drug costs 
were taken from the British National Formulary, 
No. 55, and refer to the price per unit actually 
administered (as opposed to purchased). The mean 
cost of an overnight stay was provided by the local 
NHS Trust and includes overheads. Evacuation of 
RPC was assumed to cost the same as STOP.
Overheads were assumed to be 28% in accordance 
with the local NHS Trust. Staff unit costs were 
expressed per minute (calculated by multiplying 
annual salary by the duration of the time assumed 
to be spent per TOP patient divided by the total 
possible patient contact time). Total patient contact 
time was estimated from 42 weeks per year at 37.5 
hours per week and assuming 0.7 of that time 
to be spent on patient contact.52 The following 
salaries were used: nurse practitioner, £48,102.83; 
outpatient nurse, £18,098.00; and phlebotomist, 
£16,294.48.
A cost-effectiveness analysis was undertaken using 
standard methods whereby the average incremental 
cost-effectiveness ratio (ICER) was estimated as 
mean change in cost divided by mean change in 
effectiveness.51 Cost was estimated as total NHS 
cost (as above). The measure of effectiveness 
was number of successful TOPs, where success 
was defined as completion of the TOP without 
an unplanned overnight stay and without any of 
the pre-specified complications. A 95% CI was 
estimated using bootstrapping in order to deal with 
the problem of a ratio of two variables (i.e. cost and 
effectiveness).53
Discrete choice experiment
In order to identify key factors that shape women’s 
preferences for termination services, a discrete 
choice experiment (DCE) was conducted. This 
technique measures the strength of an individual’s DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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preference for various attributes of a clinical 
intervention,54 and has been used successfully in 
research relating to the provision of services for 
women.55
The sampling frame for this part of the study was 
non-pregnant women attending contraception and 
sexual health (CoSH) clinics in Newcastle upon 
Tyne, UK. This sampling strategy was chosen as 
it reduced the research burden on the main trial 
sample and did not interfere with the process 
whereby pregnant women in the trial formed 
and stated preferences (for medical or surgical 
termination). Further, results from a non-pregnant 
sample might be less influenced by immediate 
emotional responses.
Women attending three CoSH clinics in Newcastle 
upon Tyne (The Flat, Graingerville and Armstrong 
Road) were given a patient information sheet 
about the DCE study by the receptionist and 
were asked to read it before seeing the doctor or 
nurse practitioner. Those women who expressed 
an interest in participating were referred to the 
research nurse, who explained the study, answered 
any questions and, where appropriate, took written 
consent.
DCE design and attributes
A DCE is characterised by a number of attributes 
that are used to describe a particular aspect of a 
choice, in this case alternative means of receiving 
health care. A provisional list of attributes was 
selected based on a review of the relevant literature 
and after seeking expert opinion from medical and 
nursing practitioners working in the field. These 
attributes were then shown to a small sample of 
non-pregnant women (n = 8) to ensure they were 
consistent with their views. The final attributes 
used in the TOP DCE are shown in Table 2. They 
cover aspects of the process and outcome that 
occur before the termination takes place (waiting 
time), during the termination (being awake, need 
for painkillers, and the possibility of an overnight 
stay), and after the termination (the provision 
of counselling). The explanations/definitions of 
each attribute that were shown to respondents in 
preparation for the DCE are shown in the right-
hand column of Table 2.
Table 3 shows that each of the five attributes was 
assigned two levels, producing a total of 32 (25) 
possible combinations of attributes, hereafter 
referred to as ‘termination scenarios’. As this is 
too many scenarios to be considered by any one 
respondent, an orthogonal fractional factorial 
design56 was used to reduce the number of 
scenarios to 16.
In order to be able to present respondents with a 
set of choices between two scenarios (A and B), the 
16 scenarios generated by the orthogonal design 
were designated as Choice A. These 16 scenarios 
were then ‘rolled over’, i.e. the attribute levels in 
the original 16 combinations were changed so 
that an attribute that was coded as level 0 in the 
Choice A scenarios became level 1 for the Choice B 
scenarios. The 16 additional scenarios to be used as 
Choice B were then randomly allocated to each of 
the original 16 scenarios (Choice A) to produce 16 
(A or B) choice sets. Table 4 shows an example of a 
choice set, in which respondents had to indicate a 
choice of A, B, or neither (‘refused’).
Based on prior research,54 a sample size of 100 
women was judged to provide precise parameter 
estimates with the number of attributes and choices 
used.
Econometric analysis
DCEs draw upon Lancaster’s economic theory 
of value57 and random utility theory.58 Equation 
1 shows that the latent utility Uiq for the ith 
alternative (termination scenario) for the individual 
q is made up of two components:
Uiq + Viq = εiq  [1]
where Viq = α + β1X1 + β2X2 + β3X3 + 
β4X4 + β5X5 + β6X6 and is the deterministic 
or explainable part of utility, and where iq is 
the random component that represents the 
unobservable influences that affect utility. Viq is a 
linear function of the attribute levels characterising 
termination care (X1 to X6), where the coefficients 
β1 to β6 are estimated in the model and α is 
a constant term that detects any unobservable 
influences affecting individual’s choices. The 
unobservable influences are assumed not to be 
related in any systematic way with the observed 
effects thus collapsing all such influences into iq.59 
Assuming the error term to be Gumbel distributed 
produces a multinomial logit model.60
For purposes of the analysis the data were coded 
using effects codes61 (shown in Table 3). When using 
effects codes the sign of the coefficient indicates 
which of the attribute levels is preferred. Thus, a 
negative result for the attribute of being conscious Methods
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TABLE 2  Discrete choice experiment: attribute definitions
Attribute Explanation
Will I be conscious during the 
termination process?
For some types of termination of pregnancy you will be unconscious, which means that you 
will be asleep and you will not see the fetus (this is what the baby is called from 8 weeks 
of pregnancy until birth). For other types of termination of pregnancy you will stay awake 
during the procedure and pass the pregnancy very much like a miscarriage. You might see 
the fetus. If the procedure occurs early in the pregnancy, it will be difficult to recognise the 
fetus
Will I be given counselling after 
the termination?
After the procedure you will be given a contact number to ring after discharge in case 
you want to talk to a trained counsellor about the way you are feeling. This will give you 
an opportunity to talk in confidence with someone who will listen carefully without 
judgement, so that you can be supported to find how to resolve the issues that are making 
you feel the way that you do
How many days would I wait 
from my initial appointment to 
having the termination?
Your initial appointment to request a termination would be with your GP or a family 
planning clinic. An appointment to have the termination will then be made with the clinic 
that does the termination. The time between the initial appointment and having the 
termination is how long you would wait
Will I need painkillers? You might experience tummy pain. This can happen just before or after the termination. The 
pain feels like the pain many women experience at the beginning of their monthly period. 
If you do not need painkillers, this means that you have no or little pain. If you do need 
painkillers, this means that you do have pain, but most women only need tablets, although 
sometimes women need something stronger, e.g. an injection
Will I have to stay overnight in 
hospital after the termination?
If the pregnancy is no more than 9 weeks, you will go home the same day. Where a drug is 
used to cause the termination and if the pregnancy is over 9 weeks, you might have to stay 
overnight. This is because it might take up to 15 hours for the drug to work
TABLE 3  Discrete choice experiment: characteristic descriptions and levels
Attribute Levels (effects code used in analysis)
Will the woman be conscious during the termination process? Yes (1)
No (–1)
Will the women be offered post-termination counselling? Yes (1)
No (–1)
What will be the number of days delay from the initial appointment to 
procedure?
7 days (1)
14 days (–1)
Will analgesics be required for pain relief? Yes (1)
No (–1)
Will the procedure involve an overnight stay in hospital? Yes (1)
No (–1)DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 4  Discrete choice experiment: example of a choice card
Attribute Choice A Choice B
Will I be conscious during the termination process?  Yes No
Will I be given counselling after the termination? Yes No
How many days would I wait from my initial appointment to having the termination? 7 days 7 days
Will I need painkillers? Yes No
Will I have to stay overnight in hospital after the termination? Yes Yes
would indicate that the preferred level is the one 
coded as –1, i.e. the woman prefers not to be 
conscious. 
The trade-offs that women would make between 
termination attributes was determined by 
calculating the marginal rate of substitution (MRS). 
For a linearly additive model, the MRS between two 
attributes is the ratio of the coefficients of those two 
attributes.60
Qualitative substudy
We used a model of preference developed from the 
DCE as the basis for a semi-structured interview. 
A conventional model of qualitative analysis was 
used.62 The analytic product of this work was: 
(1) a comparative model of preferences and 
their normative constraints, and (2) a model of 
contextual features that affect decision-making 
about TOP.
Inclusion and exclusion criteria for the substudy 
were the same as the trial. The sample recruited 
to the substudy was neither intended to be 
statistically representative nor to be a maximum 
variation sample; sampling was purposive and 
sequential in order to achieve maximum variation 
and representation from each arm of the trial. We 
expected a high rate of refusal to join the substudy 
and of attrition among those who did. This meant 
that although inclusion and exclusion criteria were 
the same as for the main trial, the sample entering 
the qualitative substudy was highly selected. The 
aim was to recruit 32 women, eight from each arm 
(i.e. PM, PS, RM and RS).
Women entering the trial between December 2006 
and September 2007 were provided with a patient 
information sheet about the substudy on discharge 
after their procedure. At the 2-week follow-up, 
research nurses asked women if they had read the 
information and would like to participate in the 
substudy. Those who agreed to be interviewed 
provided their contact details (mostly mobile 
telephone numbers). With their verbal consent, the 
researcher sent a letter to provide written details of 
the interview date and place (with a map provided 
where needed) and contact numbers for the 
interviewee to ring if necessary. The researcher also 
used text messaging to send reminders, confirm 
appointments and provide directions.
Data collection
Participants were given a choice of three locations 
to hold the interview: 10 chose to be interviewed at 
home, seven at the hospital and 13 at the research 
institute where the researcher was based. Women 
were interviewed at a mean of 10 (range 6–16) 
weeks after the procedure. The women were asked 
to sign a consent form stating that they had read 
the information sheet, had had the opportunity to 
ask questions and had voluntarily agreed to take 
part in the study. The interview covered women’s 
experience of entering and participating in the 
trial and their understanding of the trial. They 
also gave accounts of their experience of referral 
pathways into the service and clinical trial and 
their experiences of termination and its outcome. 
The duration of the interviews averaged 50 
(range 27–64) minutes. Interviews were recorded 
using a digital recorder and were transcribed by 
an experienced medical secretary who removed 
identifying personal details. All transcripts were 
then edited for accuracy.
Data analysis
Anonymised transcripts formed the formal data 
for qualitative analysis. Following the conventional 
model of constant comparative analysis of a 
transcribed data set,62 transcripts were interpreted 
iteratively, identifying and elaborating themes 
within participants’ accounts. Thematic analysis 
was facilitated by qsr nvivo 7 software. Descriptive 
and factual themes (or nodes) arose out of the topic Methods
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TABLE 5  Qualitative analysis: analytic themes/nodes
Parent node Child node Description
Trial participation Feelings about participating Feelings about being a trial participant
Understanding about the research What participants understood about the research, e.g. its 
purpose and the benefits
Information and data collection What participants thought of the information and data 
collection procedures
Reasons for taking part The reasons that participants gave for taking part in the trial 
and substudy
Benefits from participating How they personally benefited by participating
Any concerns Any doubts, fears or anxieties about participating
Experiences of the 
different stages
  Narrative accounts of the different stages
Discovery Experience of finding out about the pregnancy
Referral Experience of referral services; issues of access, etc.
Assessment Experience at the TOP and trial assessment clinic
Procedure Experience of undergoing the procedure
Discharge Experience of discharge from the hospital
Post-TOP health care Experience of health care after the procedure
Decision-making Having the TOP How participants came to a decision to have a TOP
Random or preference How participants came to a decision about which arm of the 
trial to join
Surgical or medical How participants came to a decision on method of 
termination
Having a choice Participants’ thoughts on the importance of patient choice
TOP at home Participants’ thoughts on having the procedure at home
Local anaesthetic What participants thought of having a local anaesthetic
Outcome Satisfaction and future preference
Significant others   The influence of partners, next of kin, friends, work 
colleagues, etc. in decision-making
  Male partner The influence of their reproductive partner in their decision-
making
Experiences of health 
care
  Narrative accounts of particular aspects of their experience
  Health-care professionals Experience of treatment by health-care professionals
  Clinic layout and privacy Waiting and visitor areas, toileting facilities and private space
  Practical issues Concerns about travel, child care, hospital directions, 
appointments rather than with patient care
  Counselling Personal experiences of counselling
  Waiting time Personal experiences of waiting
Meanings and attitudes 
to TOP
  More specific attitudes to TOP that include perception 
of the fetus and their relationship to it. Includes others’ 
perceptions of abortion
Women’s preferences   Women’s responses to the results of the DCE: views and 
preferences
  Being unconscious
  Counselling
  Waiting time
  Overnight stay
  PainkillersDOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Parent node Child node Description
  Additional features Any features to be considered in addition to those in the 
DCE
Social background   Employment, household and other contextual information 
about participants’ circumstances
Medical history   References to episodes of illness previous to TOP; compares 
past experiences of health care
Symptoms and side 
effects
  Includes sickness, vomiting, pain, bleeding, dizziness, tiredness, 
loss of appetite
Thoughts and 
reflections
  Additional thoughts and reflections, e.g. about emotional 
reaction, coping, reproductive future
Employment issues   The impact of pregnancy and TOP on paid employment, e.g. 
application for time off
Information sources   Identification of lay sources of information for decision-
making on TOP, e.g. internet
Other influences   Additional influences to decision-making, e.g. religion, chance 
encounters, previous TOP
Implications for patient 
care
  References suggesting scope for improvements in patient 
care
TABLE 5  Qualitative analysis: analytic themes/nodes (continued)
guide while referential nodes were drawn from the 
literature review and analytical questions arising 
from reading and interrogating the data. Themes 
were indexed and searches for discrete instances of 
codeable items of speech were undertaken in both 
cumulative comparisons (i.e. between interviews 
in the same arm of the trial) and condition 
comparisons (i.e. across interviews gathered from 
different arms of the trial). A coding frame of 46 
parent and child nodes was created63 (Table 5) and 
the nodes were checked for consistency under each 
theme. Each interview was also coded as a case 
with attributes, e.g. age, education and income 
for base data information. Interviewees’ responses 
to the DCE were also coded as case attributes 
for an analysis of their preferences. In order to 
guard against the fragmentation of data through 
this ‘code and retrieve’ method of data analysis, 
fieldwork notes summarising the main points 
were written after each interview by the research 
associate, and individual interviews were examined 
as whole documents by the trial coinvestigator 
responsible for the substudy. Comparisons across 
the interviews within individual nodes were then 
carried out and the data collated and analysed 
thematically under headings such as Trial 
Participation, Decision-making, Significant Others 
and Experiences of Health Care.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Participant flow
Between 18 July 2005 and 31 January 2008, 
4406 women were seen by the abortion service 
requesting TOP; 1324 women were ineligible for 
the study (Table 6). Of the 3082 eligible women 
with a viable pregnancy < 14 weeks’ gestation, 634 
(20.6%) were not approached because of logistic 
problems (Table 7) and 41 women (1.3%) were 
not referred to the research nurse by the nurse 
practitioner because of complex psychological or 
social problems.
Chapter 3 
Results
TABLE 6  Reasons for ineligibility
Reason Number (%)
Gestation > 14 weeks (at time of TOP) 523 (39.5)
Undecided about abortion decision (referred to counsellor) 273 (20.6)
Non-supported foreign language 137 (10.3)
Miscarriage 118 (8.9)
Previous participant in trial 92 (6.9)
Decision to continue with pregnancy 48 (3.6)
Under 16 years unaccompanied 41 (3.1)
Requirement for medical review 23 (1.7)
Not pregnant 20 (1.5)
Medical indication for TOP method 18 (1.4)
TOP declined by nurse practitioner 12 (0.9)
Unable to give consent 10 (0.8)
Other 9 (0.7)
Total 1324 (100)
TABLE 7  Logistic reasons for not approaching suitable women
Reason Number (%)
Lack of TOP availability within 10 days 329 (51.9)
Research nurse not available 182 (28.7)
Database problem 79 (12.5)
No room available for research nurse in clinic 24 (3.8)
Evening clinic 10 (1.6)
Other 10 (1.6)
Total 634 (100)
Of the 2407 suitable women approached by the 
research nurse, 530 (22%) declined to take part 
in the study and 1877 were enrolled. Of these, 
349 women agreed to be randomised and 1528 
women were enrolled in the preference arms, of 
whom 705 (46%) preferred STOP and 823 (54%) 
preferred MTOP (Figure 1). Twenty-two women 
(1.2%) enrolled in the trial were recruited with the 
aid of an interpreter, the biggest group speaking 
Mandarin (n = 11).
A total of 76 women (4.0%) did not attend for the 
abortion procedure: 58 (3.8%) in the preference Results
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Total population
(< 14 weeks)
n = 3082
Approached
n = 2407
Declined
n = 530
Recruited
n = 1877
Randomised
n = 349
Preference
n = 1528
Not approached
Technical reasons n = 634
Clinical n = 41
Randomised
Surgical (RS)
n = 187
DNA TOP
n = 11
Withdrawn
n = 2
Withdrawn
n = 1
Withdrawn
n = 14
Withdrawn
n = 13
RS
n = 162
No 1º
outcome
n = 37
No 1º
outcome
n = 3
RS
n = 125
MTOP
n = 9
No 1º
outcome
n = 28
No 1º
outcome
n = 3
RM
n = 115
STOP
n = 8
MTOP
n = 12
DNA TOP
n = 7
RM
n = 143
STOP
n = 11
DNA TOP
n = 34
PS
n = 652
No 1º
outcome
n = 167
No 1º
outcome
n = 2
PS
n = 485
MTOP
n = 3
No 1º
outcome
n = 216
No 1º
outcome
n = 5
PM
n = 557
STOP
n = 8
MTOP
n = 5
DNA TOP
n = 24
PM
n = 773
STOP
n = 13
Randomised
Medical (RM)
n = 162
Preference
Surgical (PS)
n = 705
Preference
Medical (PM)
n = 823
FIGURE 1  Newcastle upon Tyne TOPS recruitment process.
arm and 18 (5.2%) in the randomised arm. A 
further 30 women (1.6%) were withdrawn from 
the study: 27 (1.8%) in the preference arm and 
3 (0.9%) in the randomised arm. The reasons 
for withdrawal are shown in Table 8. Thirteen 
women (1.6%) in the PM group subsequently 
underwent STOP and five women (0.7%) in the 
PS group subsequently underwent MTOP. Eleven 
women (7.0%) randomised to a medical procedure 
subsequently had STOP and 12 women (6.4%) 
randomised to a surgical procedure subsequently 
had MTOP. In most cases this followed a request 
from the participant, presumably reflecting a 
change in preference.
Primary outcome data at 2 weeks post abortion 
were collected from 1310 (70%) women: 755 
(58%) by telephone questionnaire, 279 (21%) by 
postal questionnaire, 170 (13%) by questionnaire 
administered at the time of the follow-up clinic 
attendance, 53 (4%) by web-based questionnaire 
and 53 (4%) by text messaging. Satisfaction and 
experiences of care scales were completed by 1175 
and 1173 women, respectively, while IES and 
HADS were completed by 773 and 775 women 
respectively. Acceptability data at 3 months post 
abortion were available from 436 women, mostly 
(n = 383) from postal questionnaires. However, only 
403 (21%) responses were collected between 60 and 
120 days.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 8  Reasons for withdrawal from trial
Reason for withdrawal RS RM PS PM
Total  
(number of women)
Withdrew consent to data use 0 0 0 1 1
Withdrew consent to study continuation 1 1 7 9 18
Adverse event 0 0 1 0 1
>15 weeks’ gestation on day of TOP 0 0 1 0 1
Extrauterine pregnancy 0 0 1 0 1
Method indicated 1 0 1 0 2
Miscarried prior to any intervention 0 0 3 3 6
Total 2 1 14 13 30
Recruitment
Two research nurses and a midwife were 
responsible for recruitment during the trial. 
Table 9 shows that there was little difference in 
their recruitment rates to the preference and 
randomised arms of the trial. However, there were 
some differences between the health professionals 
who undertook the initial clinical assessment 
and introduced the research nurse (Table 10). 
Nurse practitioner 1 had a higher proportion of 
randomised women than nurse practitioners 2 and 
3.
Recruitment rates before and after the change 
in recruitment strategy are shown in Table 11. 
Although recruitment to the randomised arm 
increased slightly after 7 August 2006, this increase 
was not statistically significant. The slightly higher 
rate was not sufficient to recruit the planned 
numbers to the randomised arm of the trial.
Stated reason(s) for choice 
of method in preference 
arm
A total of 1516 (99%) women in the preference arm 
gave a reason for their preference. Of these, 232 
(15%) stated two reasons. Reasons were grouped 
into seven broad categories (Table 12). The most 
frequently cited reason related to awareness during 
the procedure; 479 (32%) women who preferred 
MTOP wanted to be awake/avoid a general 
anaesthetic, while 213 (14%) who preferred STOP 
wanted to be asleep. A desire not to pass and see 
the fetus was the principal reason in a further 114 
(8%) of women who preferred STOP. Prior personal 
experience of TOP or miscarriage/labour was the 
primary reason stated by 161 (11%) of women, with 
almost half preferring STOP. Temporal reasons 
were reported by 240 (16%) women, with those who 
wanted the minimum number of visits/length of 
stay predominantly choosing STOP, while a shorter 
time to MTOP was important for some women. 
Of the remaining reasons, 156 (10%) related to 
one procedure (mostly MTOP) being perceived as 
‘easier’, ‘less traumatic’ or being associated with 
fewer complications/side effects.
Baseline comparisons
Table 13 shows comparisons of the baseline 
characteristics of women who chose each allocation 
method. There were small but statistically 
significant differences between the three groups 
on a number of these variables. Figures 2 and 3 
illustrate the distribution of mother’s age and 
gestational age at recruitment in the preference 
groups, and between randomised and preference 
groups. There was a statistically significant 
difference in the mean mothers’ ages in the three 
groups; while there was no difference between 
the preference arms, mean age was higher in the 
preference arms compared with the randomised 
arms by 1.2 years. Within the preference arms, 
the mean gestational age at recruitment (as 
determined by ultrasound) was 6 days longer for 
those women choosing STOP over MTOP. There 
was no significant difference in mean gestational 
age between the randomised and preference arms.
There was no significant difference in the 
proportion of women having a previous TOP 
between the three groups. Previous live-birth 
status was not recorded in 330 women. Further 
analysis indicated that this related to one nurse 
practitioner who had assumed leaving the field 
blank was the same as recording no prior live Results
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TABLE 9  Recruitment rates: research nurses
Research nurse/midwife n Preference (%) Randomised (%)
1 1085 81.9 18.1
2 465 80.7 19.4
3 327 80.7 19.3
Total 1877 81.4 18.6
TABLE 10  Recruitment rates: nurse practitioners and other health professionals
Health professional n Preference (%) Randomised (%)
NP1 814 78.5 21.5
NP2 502 82.7 17.3
NP3 366 85.2 14.8
Othersa 195 83.0 16.9
Total 1,877 82.4 17.6
NP, nurse practitioner.
a  Refers to one nurse practitioner who started late in the trial and two doctors who undertook a small number of clinics 
because of organisational needs.
TABLE 11  Recruitment rates before and after strategy change
n Preference (%) Randomised (%)
Before 634 82.5 17.5
After 1243 80.9 19.2
Total 1877 81.4 18.6
birth. It was therefore assumed that these women 
had no previous live births. The percentage of 
women who had had previous live births did not 
differ significantly between the randomised and 
preference arms. However, in the preference arms 
there were a higher proportion of women (6%) 
in the surgical group who had had one or more 
previous live births.
The percentage of women who smoked did not 
differ significantly between the preference and 
randomised arms. However, there were more (7%) 
smokers in the surgical group of the preference 
arm than the medical group. There was little 
difference in educational attainment between the 
preference and randomised arms of the trial, but 
within the preference arms 7% more women were 
only educated up to GCSE level in the surgical 
group compared with the medical group.
The primary outcome (acceptability at 2 weeks 
after termination) was available on 74% of women 
who entered the trial. A further analysis was 
undertaken to determine whether those women 
who provided data on the primary outcome were 
typical of all women who had entered the trial. 
Table 14 shows the results of comparing baseline 
characteristics for those providing and not 
providing primary outcome data. It can be seen 
that any differences are small, the only statistically 
significant difference being that those on whom the 
primary outcome was available smoked slightly less.
Primary outcome: 
acceptability
Two weeks after termination
The results of the crude and unadjusted 
comparisons of acceptability between trial arms are 
shown in Table 15. There was a clear difference in DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 12  Stated reason(s) for preferred method of termination
Category Stated reason for preference Reason 1 Reason 2 Medical Surgical
Procedural Fear of general anaesthesia/desire to be awake 479 0 479 0
Desire to be asleep 213 1 1 213
Fear of needles 15 11 22 4
Dislike of taking tablets 14 7 0 21
MTOP more ‘natural’ 17 12 29 0
Fetus Desire not to see/pass fetus 114 5 0 119
Experience Personal experience (of TOP or miscarriage/labour) 161 6 86 81
Other people’s experience 40 21 31 30
Time/stay Minimum time in hospital 89 28 33 84
Minimum visits to hospital 87 10 6 91
Time to wait for procedure 64 14 56 22
Perceived 
‘ease’/risk
‘Easier’/’better’ emotionally or psychologically 76 38 74 40
Fewer side effects/risks/complications 36 35 50 21
Less violent/‘barbaric’/‘traumatic’ 44 20 51 13
Pain Less painful 33 10 5 38
Other Gestation 20 9 20 9
Contraception (wanted IUCD/implant) 8 1 0 9
Other (e.g. confidentiality) 6 4 8 2
Total 1516 232
IUCD, intrauterine contraceptive device.
TABLE 13  Comparison of baseline characteristics of women who chose each TOP allocation method
Preference
Randomised 
(n = 328) p-valuea Medical (n = 786) Surgical (n = 657)
Mean age (years) 24.3 (SD 6.3) 24.9 (SD 6.2) 23.3 (SD 5.7) 0.001
Mean gestational age (days) 57.4 (SD 12.6) 62.8 (SD 13.5) 59.7 (SD 13.0) < 0.001
No previous TOPb (%) 77 75 79 0.35
No previous live birthc (%) 75 68 72 0.04
Smoked (%) 39 47 41 0.02
Alcohold (%) 74 72 73 0.53
Drug used (%) 4 4 2 0.06
Education up to GCSE leveld (%) 52 58 56 0.04
Support at homed (%) 31 30 26 0.21
Chlamydia 0.51
Negative (%) 73 76 72
Positive (%) 5 5 5
Unknown (%) 22 19 23
GCSE, General Certificate of Secondary Education; SD, standard deviation.
a  p-values from ANOVA or chi-squared tests.
b  n = 65 unrecorded observations.
c  n =  330 unrecorded observations assumed to be no previous live birth.
d  n = 9–18 unrecorded observations for these variables.Results
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FIGURE 2  Distribution of mothers’ ages (compared within preference arms and between combined preference and randomised arms).
FIGURE 3  Distribution of gestational ages (at ultrasound compared within preference arms and between combined preference and 
randomised arms).
acceptability between STOP and MTOP: women 
in the surgical arms were more likely to opt to 
have the same method again compared with those 
having a medical termination (either within the 
preference or randomised arms). Women in the 
preference arms were slightly more likely to regard 
their TOP method as acceptable compared with 
randomised women.
For women in the preference arms the interaction 
between past TOP and preference arm was not 
statistically significant. There was a significant 
interaction between gestation and preference 
arm. This is illustrated in Figure 4a which shows 
the smoothed proportions in the two arms by 
gestational age. The difference in acceptability 
between preference arms increased with gestation, 
so the model estimated these differences at three 
different gestational ages, assuming a linear 
trend in gestation. However, for the comparisons 
of randomised arms, and the comparison of 
preference to randomised arms, there was no DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 14  Comparison of baseline characteristics of women for whom outcome was available or missing
Primary outcome
p-valuea Available (n = 1310) Missing (n = 461)
Mean age (years) 24.5 (SD 6.2) 24.0 (SD 6.1) 0.11
Mean gestational age (days) 59.5 (SD 13.2) 60.7 (SD 13.2) 0.09
No previous TOPb (%) 77 75 0.35
No previous live birthc (%) 72 72 0.87
Smoked (%) 41 47 0.02
Alcohold (%) 73 75 0.45
Drug used (%) 3 5 0.22
Education up to GCSE leveld (%) 54 59 0.08
Support at homed (%) 29 31 0.4
GCSE, General Certificate of Secondary Education; SD, standard deviation.
a  p-values from t-tests or chi-squared tests. 
b  n = 65 unrecorded observations.
c  n =  330 unrecorded observations assumed to be no previous live birth.
d  n = 9–18 unrecorded observations for these variables.
TABLE 15  Acceptability of procedure at 2 weeks after termination (i.e. percentage that would opt for same method again)
PS (n = 488) 96.5% Crude difference 15.7% (95% CI 12.0 to 19.2)
Adjusted differencea
Overall 15.9% (95% CI 12.2 to 19.6)
At 6 weeks 9.8% (95% CI 4.2 to 15.4)
At 9 weeks 17.6% (95% CI 13.4 to 21.8)
At 12 weeks 25.4% (95% CI 16.6 to 34.1)
PM (n = 565) 80.9%
RS (n = 134) 94.0% Crude difference 24.9% (95% CI 15.8 to 34.9)
RM (n = 123) 69.1%
Preference combined (n = 1052) 88.1% Crude difference 6.0% (95% CI 0.9 to 11.1)
Adjusted difference 8.2% (95% CI 2.9 to 13.4) Randomised combined (n = 257) 82.1%
a  Adjusted differences are estimated from a binary regression model adjusting for key baseline factors.
statistically significant interaction between trial 
arm and gestation (Figure 4b). The difference in 
acceptability was, therefore, estimated across all 
gestational ages.
Three months after termination
The crude and unadjusted comparisons of 
acceptability between trial arms at 3 months are 
shown in Table 16. The interactions between past 
TOP and trial arm, and between trial arm and 
gestational age were not statistically significant. 
Therefore, all comparisons were made across 
all gestations. There was still a clear difference 
in acceptability between STOP and MTOP at 3 
months after the procedure; women in the surgical 
arms were more likely to opt to have the same 
method again (either within preference or within 
randomised arms). Women in the preference 
arms were slightly more likely to regard their TOP 
method as acceptable, but this difference was not 
statistically significant.Results
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FIGURE 4  Acceptability by gestation at 2 weeks post termination: (a) comparing preference arms; and (b) comparing randomised arms.
TABLE 16  Acceptability of procedure at 3 months after termination (i.e. percentage that would opt for same method again)
PS (n = 135) 95.6% Crude difference 16.6% (95% CI 9.8 to 23.4)
Adjusted differencea 14.7% (95% CI 8.6 to 20.8) PM (n = 190) 79.0%
RS (n = 42) 95.2% Crude difference 25.8% (95% CI 9.4 to 42.2)
RM (n = 36) 69.4%
Preference combined (n = 325) 85.9% Crude difference 2.5% (95% CI –6.6 to 11.6)
Adjusted differencea 2.8% (95% CI –6.2 to 11.8) Randomised combined (n = 78) 83.3%
a  Adjusted differences are estimated from a binary regression model adjusting for key baseline factors.
Comparisons between results 
at 2 weeks and 3 months after 
termination
Characteristics of those who provided 
information
Far fewer women provided timely information 
on acceptability at 3 months post termination 
compared with that at 2 weeks. The subgroup of 
women who responded at 2 weeks was considered 
and split into those who did and did not respond 
at 3 months. It was found that those women who 
failed to respond at 3 months tended to be slightly 
younger (mean age 24.2 versus 25.1; p = 0.03) 
and less well educated [57% versus 46% educated 
to General Certificate of Secondary Education 
(GSCE) or less; p < 0.001). There was no significant 
difference between responders and non-responders 
on gestational age and numbers of previous 
terminations.
Changes in acceptability between 2 
weeks and 3 months 
There were only 382 women for whom timely 
information on acceptability was available at both 
2 weeks and 3 months after TOP. Only 7% of 
responses had changed over time, and these are 
shown in Table 17. Overall, the proportion willing 
to have the same method again had reduced from 
87.3% to 85.1%, a difference of 2.2% (95% CI –0.6 
to 4.9).
Willingness to pay
A total of 1389 (91%) women in the preference 
arm completed the WTP scenario (761 requesting 
MTOP and 628 requesting STOP); 397 (28.6%) 
recorded zero (zero WTP group), while 93.8% of 
respondents were willing to pay up to £1000. There 
was no statistically significant difference in the 
mean WTP between women with a preference for 
MTOP compared to those with a preference for 
STOP whether or not zero payers were included 
(Table 18).
A total of 132 (37.5%) women in the randomised 
group completed the WTP scenario at 2 weeks, 
although 19 failed to state their choice of TOP 
method; 59 women (45.0%) recorded zero 
(zero WTP group), while 97.7% of respondents 
were willing to pay up to £1000. There was no DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 17a  Comparison between acceptability at 2 weeks and 3 months after termination: all arms combined
3 months: yes 3 months: no
2 weeks: yes 318 19
2 weeks: no 7 38
TABLE 17b  Comparison between acceptability at 2 weeks and 3 months after termination: separately by trial arm
PM PS RM RS
3 months: 
yes
3 months: 
no
3 months: 
yes
3 months: 
no
3 months: 
yes
3 months: 
no
3 months: 
yes
3 months: 
no
2 weeks: 
yes
136 13 122 2 23 3 37 1
2 weeks: 
no
4 26 2 4 1 7 0 1
TABLE 18  Mean WTP for requested TOP method in preference group
Medical Surgical p-value 95% CI for mean difference
Including zero payers
n 761 628
Mean WTP (£) 372.70 (SD 778.61) 431.85 (SD 855.23) 0.51 –113.12 to 55.96
Excluding zero payers
n 538 454
Mean WTP (£) 527.18 (SD 881.13) 597.36 (SD 955.65) 0.23 –184.72 to 44.38
SD, standard deviation.
statistically significant difference in the mean WTP 
between women with a future preference for MTOP 
compared to those with a future preference for 
STOP whether or not zero payers were included 
(Table 19).
Table 20 shows the mean WTP for a future TOP 
according to method of TOP to which women 
were randomised. Again there were no statistically 
significant differences between the groups. 
However, it is worth noting that WTP for switching 
choice of TOP method was consistently greater 
than the amount women were willing to pay to have 
the same method again; the differences for women 
randomised to MTOP were of borderline statistical 
significance.
A total of 549 (35.9%) women in the preference 
group completed the WTP scenario at 2 weeks (300 
from the preference MTOP group and 249 from 
the preference STOP group), although 31 failed 
to state their choice of TOP method; 140 women 
(25.5%) recorded zero (zero WTP group), while 
96.7% of respondents were willing to pay up to 
£1000. There was no difference in the mean WTP 
between women with a future preference for MTOP 
compared to those with a future preference for 
STOP whether or not zero payers were included 
(Table 21).
Table 22 shows the mean WTP for a future TOP 
according to the method of original preference. 
There were no statistically significant differences 
between the groups. As in the randomised group, 
WTP for switching choice was greater than the 
amount women were willing to pay to have the 
same TOP method again.Results
28
TABLE 19  Mean WTP for a future TOP method in randomised group
Medical Surgical p-value 95% CI for mean difference
Including zero payers
n 49 73
Mean WTP (£) 192.86 (SD 248.23) 215.55 (SD 616.17) 0.81 –206.41 to 161.03
Excluding zero payers
n 32 35
Mean WTP (£) 295.31 (SD 253.33) 449.57 (SD 834.09) 0.32 –461.07 to 152.55
SD, standard deviation.
TABLE 20  Mean WTP for a future TOP according to original randomised group
Method of termination Mean WTP (£) for future TOP preference p-value 95% CI for mean difference
Including zero payers
Medical Medical (n = 42)
179.76 (SD 197.42)
Surgical (n = 19)
482.63 (SD 1127.83)
0.09 –659.33 to 53.59
Surgical Medical (n = 7)
271.43 (SD 467.13)
Surgical (n = 54)
121.57 (SD 221.82)
0.15 –57.27 to 356.97
Excluding zero payers
Medical Medical (n = 28)
269.64 (SD 184.52)
Surgical (n = 12)
764.17 (SD 1358.96)
0.06 –1016.65 to 27.61
Surgical Medical (n = 4)
475.00 (SD 554.53)
Surgical (n = 54)
285.43 (SD 263.90)
0.28 –160.04 to 539.17
SD, standard deviation.
TABLE 21  Mean WTP for future TOP method in preference group
Medical Surgical p-value 95% CI for mean difference
Including zero payers
n 227 291
Mean WTP (£) 328.90 (SD 409.37) 357.47 (SD 538.12) 0.51 –113.12 to 55.97
Excluding zero payers
n 177 211
Mean WTP (£) 421.81 (SD 419.26) 493.01 (SD 576.85) 0.17 –173.62 to 31.22
SD, standard deviation.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 22  Mean WTP for a future TOP method according to original preference group
Method of termination Mean WTP (£) for future TOP preference p-value 95% CI for mean difference
Including zero payers
Medical Medical (n = 225)
321.16 (SD 408.56)
Surgical (n = 65)
408.56 (SD 474.16)
0.15 –31.44 to 203.60
Surgical Medical (n = 2)
750.00 (SD 353.55)
Surgical (n = 54)
391.53 (SD 551.42)
0.36 –412.25 to 1129.19
Excluding zero payers
Medical Medical (n = 175)
418.06 (SD 419.32)
Surgical (n = 33)
470.91 (SD 580.58)
0.53 –220.55, 114.85
Surgical Medical (n = 2)
750.00 (SD 353.55)
Surgical (n = 178)
497.11 (SD 577.71)
0.54 –556.33, 1062.11
SD, standard deviation.
TABLE 23  Mean WTP for future TOP method according to preferred method (in preference and randomised arms)
Future preferred TOP method Trial arm n Mean WTP (£)
Medical Preference 227 328.90 (SD 409.36)
Randomised 49 192.86 (SD 248.23)
Surgical Preference 291 357.47 (SD 538.12)
Randomised 73 215.55 (SD 616.17)
SD, standard deviation.
Mean WTP for a future TOP was £341.80 [standard 
deviation (SD) 478.35] in the preference arm 
(n = 549) compared with £225.84 (SD 546.90) in 
the randomised arm (n = 131). This difference 
was statistically significant (mean £115.96; 95% CI 
21.99 to 209.940; p = 0.016). Table 23 compares 
mean WTP for future TOP according to preferred 
method in the two trial arms. Women in the 
preference arm showed a consistently higher WTP 
for their choice of next TOP: for women preferring 
a future MTOP, those in the preference arm were 
prepared to pay an extra £136.04 (95% CI 16.33 to 
255.75; p = 0.026); for women preferring a future 
STOP, those in the preference arm were prepared 
to pay an extra £141.93 (95% CI –0.82 to 284.67; 
p = 0.051).
Table 24 shows the mean WTP in each income 
band in the two arms of the trial. In both arms 
there were statistically significant differences 
between mean WTP in the different income groups 
[p < 0.0001 analysis of variance (ANOVA)]. There 
was a correlation between WTP and income in 
the preference arm (correlation coefficient 0.194, 
p < 0.0001) but not in the randomised arm.
Psychological rating scales 
at 2 weeks and 3 months 
after admission
The differences in the mean scores on the 
psychological rating scales between pairs of 
trial arms are shown in Table 25. Differences 
between groups were consistently small. The only 
statistically significant differences at either time 
point were a higher score in the IES intrusion 
subscale at 2 weeks after MTOP compared 
with STOP in both preference and randomised 
comparisons. At 3 months after termination, both 
avoidance and intrusion subscales of the IES were 
higher in the medical compared with the surgical 
arm in those women who had been randomised. 
These comparisons were not statistically significant 
in the preference arms.Results
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TABLE 24  Relationship between stated income and WTP for 
future TOP method
Stated income n Mean (£)
Preference arm
£0 150 248.80 (SD 380.30)
< £10,000 206 301.94 (SD 362.82)
£10,000–£19,999 136 467.94 (SD 671.34)
£20,000–£30,000 43 347.44 (SD 370.00)
> £30,000 14 682.14 (SD 610.68)
Total 549 341.80 (SD 478.34)
Randomised arm
£0 41 124.39 (222.39)
< £10,000 35 318.28 (550.74)
£10,000–£19,999 29 137.93 (175.66)
£20,000–£30,000 15 181.67 (340.23)
> £30,000 5 1240.00 (2110.21)
Total 125 233.32 (558.64)
SD, standard deviation.
Satisfaction with care
This was reported on a 5-point scale (excellent 
to poor) and is summarised as the proportion 
of women who rated aspects of their care as 
excellent. Table 26 shows the comparisons of these 
percentages across trial arms. Women were more 
likely to be satisfied overall and with technical 
and interpersonal aspects of care if they had a 
surgical rather than medical termination. This was 
found in comparisons within preference arms and 
within randomised arms. There was no difference 
in satisfaction with waiting when comparing both 
within preference arms and randomised arms. 
None of the differences in satisfaction with care 
between combined preference and randomised 
arms were statistically significant.
Experience of care: 
semantic differential scales
Women rated their experience on 12 different 
scales defined by pairs of opposite adjectives. 
Scores could vary between –3 (most ‘negative’) 
to +3 (most ‘positive’). The distribution of these 
scores is compared between the two preference 
arms at 2 weeks after termination in Figure 5. 
The distributions were similar shapes in both 
arms for some scales (e.g. predominantly positive 
scores for ‘Dangerous–Safe’ indicating that most 
women found both procedures very safe), but quite 
different for other scales, e.g. Painful–Painless 
scores were predominantly negative (‘painful’) for 
women in the medical arm and predominantly 
positive (‘painless’) in the surgical arm.
Table 27 summarises these distributions by 
reporting the median scores for each pair of trial 
arms compared at 2 weeks. There was a significant 
difference in the distribution of scores between 
the two preference arms on all scales, and for all 
but one scale when the randomised arms were 
compared. In all cases, the experience of care had 
more responses towards the negative end of the 
scale in the medical compared with the surgical 
arms. No significant differences were found 
between the combined preference and randomised 
arms.
The information at 2 weeks after TOP was sought 
via postal questionnaires, clinic visits, telephone 
calls and online completion. Approximately 
half of the women provided information over 
the telephone and in these cases only six of the 
scales were used: these are the scales with the 
larger sample size. However, the nurses collecting 
information over the telephone found that women 
quite often requested clarification of the meaning 
of the ‘Passive–Active’ scale. For this semantic 
differential scale the distribution of responses 
was quite different (Figure 6) for women where 
responses were obtained by telephone compared 
with other routes. This was not the case for other 
scales. These results must, therefore, be interpreted 
with considerable caution, as they suggest that 
some women used the scale differently if they had 
the chance to clarify issues with researchers.
Table 28 compares the median semantic differential 
scores for the two preference arms at 3 months 
after termination. Although far fewer completed 
the questionnaire at this time point, the patterns 
are similar to those at 2 weeks. Those experiencing 
a surgical termination rated their experience of 
care more highly than those having a medical 
termination on all scales.
There was some interest in how the experience of 
care scores had changed between 2 weeks and 3 
months for those women who had responded on 
both occasions. The distributions of the differences 
are shown in Figure 7. A positive difference 
indicates that the experience was less ‘positive’ at 
3 months than at 2 weeks. It can be seen that while 
many women gave the same or very similar scores 
on the two occasions, others changed their scores DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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FIGURE 5  Comparison of semantic differential score distributions (between preference arms at 2 weeks).
considerably (in both directions). One scale which 
had fewer women reporting the same score on both 
occasions was ‘Passive–Active’; this may be due to 
the fact that data were collected by telephone on 
49% of women at 2 weeks, but on only 1% at 3 
months, and the distribution of responses varied 
with the data collection method.
Symptoms during 
admission and 2 weeks after 
termination
Women were questioned about symptoms and 
pain they experienced during admission, and then 
again at 2 weeks after the procedure. The results 
are shown in Table 29. During admission, in the 
preference arms, there was a statistically significant 
difference for all symptoms, with a higher 
percentage of women reporting symptoms and 
higher mean pain scores during MTOP than STOP. 
The differences were largest for nausea, vomiting 
and pain. The same differences were seen in the 
randomised arm with the exception of dizziness 
(where only one woman reported this symptom 
in the medical group). There were no significant 
differences in symptoms between the preference 
and randomised arms during admission.
At the 2-week follow-up the only significant 
difference between the preference arms was the 
percentage of women reporting diarrhoea, which 
was again higher in the MTOP group. In the 
randomised arms more women reported nausea 
and diarrhoea after medical termination. There 
were no significant differences between the two 
combined arms (preference and randomised) at 
2-week follow-up.
Table 30 shows the amount of bleeding experienced 
after discharge as reported at the 2-week follow-
up. Compared with STOP, women had more 
bleeding after a medical procedure in both the 
preference and randomised arms. The difference 
in the distribution of amount of bleeding in the 
preference arms is illustrated in Figure 8. There was 
no significant difference in the amount of bleeding 
between women in the randomised and preference 
arms.
Time taken to return to 
work and normal activity
There were 255 unemployed women who were not 
included in the analysis of time taken to return to 
work. Table 31 shows that there were no differences 
in the distributions between groups undergoing 
medical and surgical termination in either the 
preference or the randomised arms. However, there 
was a significant difference between preference 
and randomised arms, with slightly more women 
returning to work immediately in the randomised 
arm (Figure 9).
Table 32 shows that the time taken to return to 
normal activity was very similar to time taken to 
return to work, with no significant differences in 
the distributions between medical and surgical 
groups in either arm. Again, the difference 
in distribution between the randomised and 
preference arms was statistically significant, with 
more women in the randomised arm reporting an 
immediate return to normal activity (Figure 10).
There were no differences in percentage of women 
returning to work and normal activity by 2 weeks Results
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FIGURE 6  Comparison of responses on the ‘Passive–Active’ scale (obtained over the telephone or by other routes).
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between medical and surgical groups in the 
preference arm, or between the preference and 
randomised arms (Table 33).
Clinical effectiveness
Unplanned or emergency 
admission 
A total of 63 women had a procedure-related 
admission (Table 34). In 16 cases this was ‘planned’, 
i.e. anticipated, and in most cases this was 
because of a lack of support/supervision at home 
for the night after the TOP; 33 women had an 
unplanned admission on the day of the TOP. In 
most cases this was an overnight stay because of 
late passage of products of conception, symptoms 
or complications. Six women were readmitted as 
an emergency after their initial discharge, mostly 
because of RPC.
Table 35 shows a comparison of planned and 
unplanned admissions/overnight stays in the two 
arms of the trial. There were no differences in 
planned admissions between women undergoing 
MTOP and STOP. However, more women having 
an MTOP had an unplanned admission. This 
difference was statistically significant in both the 
randomised and preference arms.
Complications
All women who entered into the trial have been 
included in the reporting of complications. A 
total of 72 women experienced complications as 
a result of the termination, including one woman 
who was also categorised as a serious adverse event 
(SAE). Eleven of the women who experienced 
complications subsequently withdrew from the trial. 
A breakdown of complications by trial arm is given 
in Table 36. In the preference group the percentage 
of women experiencing complications was 2.4% 
higher in the group undergoing MTOP. This 
pattern was also seen in the randomised arms, but 
the difference was not statistically significant. 
Table 37 provides a detailed list of complications. A 
total of 48 women had a clinical diagnosis of RPC, 
two associated with haemorrhage; 28 presented as 
an emergency after discharge from hospital (with 
vaginal bleeding with or without abdominal pain), 
four had RPC diagnosed at the 2-week outpatient 
review and 16 were kept in hospital overnight 
because of failure to pass ‘complete’ products. 
Of the 48 women with suspected RPC, 34 had an 
evacuation under general anaesthesia (26 in the 
emergency admission group and 8 in the overnight 
stay group), eight had products of conception 
removed from the cervix/vagina (with a subsequent 
scan suggesting no additional intrauterine products 
of conception), four were managed medically (with 
misoprostol) and two were managed expectantly. 
In those cases managed medically or expectantly 
an ultrasound scan subsequently showed no 
intrauterine products of conception.
Fifteen women experienced haemorrhage during 
their initial admission (including the SAE case), of 
whom four received a blood transfusion. Eleven 
women were suspected of intrauterine infection, 
five with evidence of RPC. All were admitted 
as an emergency with vaginal bleeding with or 
without abdominal pain. Two women had a failed 
MTOP; one had a subsequent STOP and the other 
had a subsequent successful MTOP. One woman 
had a failed STOP; products of conception were 
not identified at operation and a subsequent 
ultrasound scan showed a viable pregnancy. The Results
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FIGURE 7  Differences on semantic differential scales between 2 weeks and 3 months after TOP (preference arms only). Note that a 
positive difference indicates that the experience was less ‘positive’ at 3 months than at 2 weeks.
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woman subsequently underwent a successful STOP. 
There were three cases of uterine trauma: two 
cervical lacerations at STOP that required suturing 
and one uterine perforation (see SAE below).
It might be expected that women experiencing 
complications may find the method of TOP less 
acceptable. Table 38 shows the acceptability (would 
women opt for the same method again) at 2 weeks 
and 3 months after the procedure for those who 
had and had not experienced a complication. 
Acceptability was much lower for those women 
experiencing a complication. The difference is 
even greater at 3 months than 2 weeks, though 
based on far fewer responses. In fact, of the 21 
women who gave a timely response on both 
occasions, seven said ‘yes’ both times, seven said 
‘no’ both times, and seven changed their response 
from ‘yes’ to ‘no’.
Serious adverse events
There was one SAE during the trial. A 29-year-
old women who had previously had a loop 
electrosurgical excision procedure was admitted for 
STOP at 9+3 weeks of pregnancy (preference arm). 
She received misoprostol (400 µg) to prime the 
cervix. At operation the cervix could not be dilated 
and a decision was made to convert to MTOP. 
Mifepristone (200 mg) was given and the patient 
returned 2 days later for misoprostol (800 µg 
vaginally). She received a further three doses of 
misoprostol (400 µg) orally that day and then five 
doses of gemeprost (1 mg vaginally) the following 
day without passage of products of conception. 
The patient opted to go home and return for a 
second attempt at STOP 2 days later. At operation 
the cervix was dilated sufficiently to allow a 9-mm 
suction curettage. Following evacuation of products 
of conception there was significant haemorrhage. 
Laparoscopy confirmed a haemoperitoneum and 
at laparotomy the cervix was found to be almost 
completely separated from the uterine body. A 
hysterectomy was performed and a small defect 
in the bladder was repaired. The patient was 
transfused 2 units of blood. Postoperatively a 
ureteric injury was suspected because of a watery 
vaginal loss and confirmed with an intravenous 
urogram. The patient was taken back to theatre 3 
days after the initial laparotomy where a cystoscopy 
and retrograde pyelogram identified a right 
uretero-peritoneal leak. A further laparotomy 
was therefore performed and the right ureter 
reimplanted. Subsequent postoperative progress 
was uneventful. 
Costs
Standard costs
Clinic attendance costs are shown in Table 39. 
These were assumed to be the same for women 
having MTOP and STOP. The additional standard 
costs for MTOP and STOP are shown in Tables 40 
and 41. The total standard costs for MTOP and 
STOP were £261.37 and £489.91 respectively.
Individual-level unit costs
Individual-level unit costs and resource usage based 
on method of TOP and in the two arms of the trial 
are shown in Appendices 3 and 4 respectively.
Total cost
Total costs for each TOP method and for women 
assigned to the randomised and preference arms DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 30  Bleeding after discharge (as reported at 2-week follow-up)
Bleeding since discharge
p-valuea Excessive (%) Heavy (%) Moderate (%) Minimal (%) None (%)
Preference Medical 3.6 36.7 45.0 13.4 1.4 < 0.001
Surgical 2.1 18.1 42.2 32.8 4.8
Randomised Medical 5.3 37.2 36.3 19.5 1.8 < 0.001
Surgical 0.0 20.0 35.7 38.3 6.1
Combined Preference 2.9 28.1 43.7 22.4 3.0 0.162
Randomised 2.6 28.5 36.0 29.0 4.0
a  p-value from Mann–Whitney test.
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FIGURE 8  Amount of vaginal bleeding after TOP as reported at 2 weeks.
TABLE 31  Distribution of time (days) taken to return to work between trial groups
n Median Range p-valuea
Preference Medical 323 4 0–63 0.484
Surgical 256 3 0–33
Randomised Medical 80 3 1–23 0.940
Surgical 69 3 0–47
Combined Preference 579 3 0–63 0.034
Randomised 149 3 0–47
a  p-value from Mann–Whitney test.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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FIGURE 9  Distribution of days taken to return to work.
TABLE 32  Distribution of time (days) taken to return to normal activity
n Median Range p-valuea
Preference Medical 443 3 0–63 0.128
Surgical 387 3 0–37
Randomised Medical 101 3 0–32 0.298
Surgical 106 2 0–18
Trial arm Preference 830 3 0–63 0.032
Randomised 207 2 0–32
a  p-value from Mann–Whitney test.
0.00
0.05
0.15
0.10
Randomised
P
r
o
p
o
r
t
i
o
n
Number of days to return to work
60 40 20 0
Preference
60 40 20 0
FIGURE 10  Distribution of days taken to return to normal activity.Results
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TABLE 34  TOP-related admissions
Admissions
Randomised Preference
Surgical Medical Surgical Medical
Planned overnight stay
Sociala 2 0 6 4
Cervical priming 1 0 2 0
Medical (non-gynaecological) problem 0 0 1 0
Total planned 3 0 9 4
Unplanned overnight stay (during initial admission)
Complications 0 2 4 18
Retained products of conception 1 1 14
Haemorrhage 1 3 3
Failed MTOP 1
Aborted following day after additional cervagem 0 1 0 5
Products of conception passed late on day of admission 0 1 0 5
Moderate/heavy vaginal bleeding 0 0 0 4
Vomiting 0 0 0 1
Unplanned overnight stay (following emergency admission)b 0 0 2 4
Total unplanned 0 4 6 37
a  No support at home.
b  Indications for stay were infection (n = 1), RPC and evacuation of RPC (n = 1) in PS group, and RPC and evacuation of 
RPC (n = 3) or medical management (n = 1) in PM group.
TABLE 35  Percentage of women experiencing a planned and unplanned admission
Admissions n Per cent (n) admitted Difference (95% CI)
Planned admissions
Preference Medical 823 0.5 (4) –0.8 (–1.7 to 0.2)
Surgical 705 1.3 (9)
Randomised Medical 162 0.0 (0) –0.4 (–0.9 to 0.05)
Surgical 187 0.4 (3)
Unplanned admissions
Preference Medical 823 4.5 (37) 3.6 (2.1 to 5.2)
Surgical 705 0.9 (6)
Randomised Medical 162 0.5 (4) 0.5 (0.01 to 1.0)
Surgical 187 0.0 (0)Results
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TABLE 36  Percentage of women experiencing complications
n Per cent experiencing complications Difference (95% CI)
Preference Medical 823 5.1 2.4 (0.5 to 4.3)
Surgical 705 2.7
Randomised Medical 162 4.3 2.2 (–1.6 to 5.9)
Surgical 187 2.1
TABLE 37  Complications
Complication Frequency Per cent
Haemorrhagea 14 19.4
Retained products of conceptionb 46 63.4
Infection 6 8.3
Failed 3 4.2
Uterine trauma 3 4.2
Total 72 100
a  Three women also had other complications: two with RPC and one with RPC and infection.
b  Five women also had infection.
TABLE 38  Acceptability of procedure for those experiencing or not experiencing complications (at 2 weeks and 3 months after 
termination)
Complications at 2 weeks
No (n = 1252) Acceptability 88.3%a Crude difference 29.6% (95% CI 16.8 
to 42.4) Yes (n = 58) Acceptability 58.6%
Complications at 3 months
No (n = 381) Acceptability 88.5% Crude difference 56.6% (95% CI 36.9 
to 76.4) Yes (n = 22) Acceptability 31.8%
a  Percentage of women who would opt for the same method again.
are shown in Table 42. MTOP is cheaper than 
STOP primarily due to the lower standard costs.
Cost-effectiveness analysis
The ICERs in the two arms of the trial are shown 
in Table 43. To gain one more successful TOP (i.e. 
an uncomplicated TOP without the need for an 
unplanned admission) cost more with a surgical 
procedure in both arms of the trial.
Discrete choice experiment
A total of 310 women attending 58 CoSH clinics 
were approached by the research nurse (average 
of 5.3 per session, range 0–10). We recruited up to 
the point where 100 women agreed to participate; 
210 declined to take part. The characteristics of the 
study group are shown in Table 44.
Table 45 shows the results from the regression 
analysis. Four of the five attributes had coefficients DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 39  Clinical attendance costs
Category Grade/source
Unit cost (£) 
2007–8 prices
Quantity per 
individual
Cost (£) 
excluding 
overheads
Cost (£) 
including 
overheads
Staff
Nurse practitioner NHS Band 7 0.727 25 19.27 24.67
Outpatient nurse NHS Band 3 0.274 25 7.25 9.28
Phlebotomist NHS Band 2 0.246 15 3.73 4.76
Other inputs
Ultrasound scan NHS Trust 66.48 1 66.48 85.09
Chlamydia screen NHS Trust 14.23 1 14.23 18.21
Full blood count NHS Trust 2.35 1 2.35 3.00
Haemoglobinopathy 
screen
NHS Trust 18.58 1 18.58 23.79
Total 168.80
TABLE 40  Additional costs for MTOP
Category Source
Unit cost (£) 
2007–8 prices
Quantity per 
individual
Cost (£) 
excluding 
overheads
Cost (£) 
including 
overheads
Mifepristone BNF 13.94 1 13.94 13.94
Staff (all) NHS Trust 58.00 1 58.00 74.24
Misoprostol 
(800 µg)
BNF 0.67 1 0.67 0.67
Doxycycline 
(200 mg)a
BNF 3.72 1 3.72 3.72
Total 92.57
BNF, British National Formulary.
a  Seven-day course.
TABLE 41  Additional costs for STOP
Category Source
Unit cost (£) 
2007–8 prices
Quantity per 
individual
Cost (£) excluding 
overheads
Cost (£) including 
overheads
Staff (excluding those 
involved in operation)
NHS Trust 58.00 0.843a 48.91 62.61
Misoprostol (400 µg) BNF 0.33 1 0.33 0.33
Operationb NHS Trust 9.92 20 198.35 198.35
Surgeon MC5605 100,683 0.00021 20.98 26.85
Anaesthetist MC5605 100,683 0.00021 20.98 26.85
Doxycycline (200 mg)c BNF 3.72 1 3.72 3.72
Metronidazole (1 g) BNF 2.40 1 2.40 2.40
Total 321.11
a  Correction to allow for reduced mean length of time on ward compared with MTOP cases (380 min vs 451 min, 
p < 0.001).
b  Cost per minute.
c  Seven-day course.Results
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TABLE 42  Total costs for MTOP and STOP
Total costs (£)
Difference p-value Medical Surgical
Whole sample 287.78 (n = 940) 498.12 (n = 831) 210.34 0.00
Randomised arm 287.04 (n = 174) 496.71 (n = 174) 209.67 0.00
Preference arm 287.93 (n = 766) 498.48 (n = 657) 210.55 0.00
TABLE 43  Incremental cost-effectiveness ratio (ICER)
Mean cost (£) Mean effect ICER (£) 95% CI
Preference arm MTOP 287.93 0.97 12,959.10 6458.39 to 
54,613.19 STOP 498.48 0.99
Randomised arm MTOP 287.04 0.97 7979.60 4187.67 to 
34,882.89 STOP 496.71 1.00
TABLE 44  Characteristics of DCE study group (n = 100)
Mean age (years) 25.1 (SD 7.9)
Stated income level (n)
Zero 26
< £10,000 31
£10,000–£19,999 22
£20,000–£30,000 16
> £30,000 5
Marital status (n)
Single no partner 20
Single with partner 65
Married/living with partner 15
Maximum level of educational qualification (n)
No qualification 4
GCSE 11
A Levels 24
Degree 47
Higher degree 14
GCSE, General Certificate of Secondary Education; SD, standard deviation.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 45  Regression results for the DCE
Attribute (interpretation) Coefficient SE z p-value
Conscious (prefer to be unconscious) –0.0999 0.0384 –2.6 0.009
Counselling (prefer access to counselling) 0.4298 0.0382 11.24 0.000
Days delay (prefer 7 days to 14 days) 0.4842 0.0384 12.62 0.000
Analgesics –0.0409 0.0383 –1.07 0.286
Overnight stay (prefer no overnight stay) –0.04424 0.0389 –11.37 0.000
Constant 0.00461 0.0380 0.12 0.904
SE, standard error.
TABLE 46  Marginal rate of substitution
Attribute gain Additional days wait to termination for attribute gain
Conscious during termination 0.0999/0.4842 =  0.21
Counselling provided 0.4298/0.4842 =  0.89
Overnight stay avoided 0.4424/0.4842 =  0.91
that were statistically significantly different 
from zero; only the need for analgesics was not 
statistically significant. Based on the size of the 
regression coefficients, three attributes had an 
almost equal impact on women’s preferences: the 
provision of counselling, the number of days’ delay 
to the procedure and the possibility of the need 
for an overnight stay. Being conscious or not had a 
lesser impact on women’s preferences.
We were also interested in the number of additional 
days that women were prepared to wait (trade-off 
or MRS between waiting and the other significant 
service attributes) for the termination procedure 
(Table 46). Women would be prepared to wait 
approximately one extra day to ensure access 
to post-termination counselling and to avoid an 
overnight stay following a termination.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Recruitment
Of the 69 who were referred, 41 initially consented 
when contacted by the researcher and altogether 30 
women from the PS (n = 11), PM (n = 9), RS (n = 6) 
and RM (n = 4) arms of the trial were interviewed. 
Of those who were not interviewed, 14 gave no 
reply, six declined, three hung up, one moved 
house, and six postponed or did not attend and did 
not reply or hung up on further telephone  calls. 
Letters were written to two women who had not 
provided a telephone number. A further nine who 
had been referred were not followed up because 
numbers had been met in the respective arms of 
the trial. An interval of at least 5 weeks was given 
between the procedure and the interview date and 
no interviews were carried out more than 18 weeks 
after the procedure. Difficulties in recruitment in 
the random arms of the trial are reflected in the 
numbers recruited onto the substudy.
Interviewee and non-
interviewee characteristics
The characteristics of the substudy group are 
shown in Table 47. The mean age of participants 
was 24.7 (range 16–38) years. Two-thirds (n = 21) 
were educated to A-level standard and above, 
and two-thirds were employed. Of the nine who 
were married and cohabiting, six had previous 
live births, while among the 20 who were single, 
five had previous live births. Five women had 
had a previous TOP. In comparison, the mean 
age of non-participants was 23.4 years. Two-fifths 
had educational qualifications of ‘A’ levels and 
above, and half were employed. Just under half 
had previous live births, but only one-sixth were 
married or cohabiting. Those who were interviewed 
thus tended to be older, more educated, in a long-
term relationship, and more likely to be in paid 
work.
Of the women who opted for the preference arm of 
the trial, 4 of 20 were less than 9 weeks’ gestation, 
compared with 7 of 10 in the randomised arm. Of 
17 women who had a surgical termination, eight 
had live births, compared with 3 of 13 who had 
a medical termination. They also tended to be 
older (mean age 25.5 versus 23.7 years). Of the 30 
women, two were asylum-seekers, two were British 
Asians, and two were economic migrants from 
Africa and the EU.
Experiences and 
understandings of the trial
Women’s reasons and motivations for seeking TOP 
were not within the remit of this study, although 
they were sometimes revealed in the course of the 
interviews. Access to TOP is an important policy 
topic, and one about which there are significant 
political and moral debates, but in this study 
women tended to describe their experiences of 
seeking TOP in mainly procedural terms.
Of the 30 women in the substudy, 23 approached 
their family doctor in the first instance to arrange 
for a termination. At the first point of contact with 
primary care to seek TOP, most women did not 
describe explicit obstacles to referral. Only one 
participant encountered a doctor who declined 
to refer her for TOP on grounds of conscience. 
However, 10 of 30 did experience difficulties that 
they characterised as related to being adequately 
informed about the treatment options available to 
them. Information available to them in primary 
care was variable: some general practices provided 
written information, while others referred women 
to information available at the hospital. 
Women’s response to uneven provision of 
information varied. Some were dissatisfied, but 
others felt that they were not in a position to 
process detailed information about referral and 
treatment options because of its psychosocial 
impact on them. For example, one participant told 
us that:
I don’t think I could have dealt with knowing 
everything there and then…because I didn’t 
want to have the information that day. I just, 
I was having enough problems dealing with 
everything, I didn’t want to have it in black and 
white in front of me (5132 RS).
It is now well established that women seeking 
help for reproductive health problems have a 
Chapter 4 
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TABLE 47  Substudy group characteristics
Characteristic MTOP (n = 13) STOP (n = 17) All (n = 30)
Age
21 and below 6 3 9 (30%)
22–30 6 12 18 (60%)
Over 30 1 2 3 (10%)
Education
GCSE 4 5 9 (30%)
A level 5 5 10 (33%)
First degree 3 4 7 (23%)
Higher degree 1 3 4 (13%)
Income
Unassigned 1 0 1 (3%)
Nil 0 6 6 (20%)
< £10,000 7 2 9 (30%)
£10,000–£20,000 4 6 10 (33%)
> £20,000 1 3 4 (13%)
Partner status
Unassigned 1 0 1 (3%)
Single 9 11 20 (67%)
Cohabiting 0 5 5 (17%)
Married 3 1 4 (13%)
Gestation
6–8 weeks 6 5 11 (37%)
9–11 weeks 6 11 17 (57%)
12–14 weeks 1 1 2 (7%)
Previous live births
Unassigned 1 0 1 (3%)
0 9 9 18 (60%)
1 0 5 5 (17%)
2 or more 3 3 6 (20%)
Previous TOP
Yes 2 3 5 (17%)
No 11 14 25 (83%)
GCSE, General Certificate of Secondary Education.
preference to consult female professionals,64 and 
in this study participants indicated that encounters 
with male doctors took on a greater formality, 
while their female counterparts seemed to be 
more empathic. Women seemed also to experience 
greater satisfaction with services provided by 
family planning clinics. Seven women initially 
sought TOP through a family planning clinic. 
Two of the women who had initially sought TOP 
through general practice subsequently moved on 
to a family planning clinic, one because she was 
uncertain about whether TOP was appropriate, and 
the other because of change in area of residence. 
Onward referral to the hospital service from family 
planning clinic could be accomplished swiftly 
and without complication. However, referral DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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from general practice imposed a further burden 
on women, who had to take on additional co-
ordinating work to chase up appointments and 
referrals with local administrative staff. 
Because of their area of residence, four women had 
a choice of hospital. Their decisions were based 
mainly on the earliest appointment available rather 
than distance, and one was advised by the family 
planning clinic to have it at the RVI because they 
were uncertain about how many weeks pregnant 
she was and her local hospital had stricter limits on 
gestational age. The normal waiting time between 
referral and appointment at the hospital was 14 
days, with around 7 days between assessment and 
the actual procedure. The shortest waiting time 
recorded was 2 days between seeking TOP and 
hospital assessment, with a further 2-day wait 
for the procedure. However, 11 of 30 women 
waited more than 14 days to be referred, and one 
(an asylum-seeker) waited more than 21 days. 
Delays for women occurred at the referral stage, 
with pregnancy testing sometimes holding up a 
referral. However, two women started the medical 
procedure at their first visit to the RVI after they 
were assessed. In some cases delays were due to 
women being unable to keep an appointment 
or requiring counselling before the procedure. 
Once women were referred to the hospital, some 
had trouble locating the clinic and were reluctant 
to ask for directions, suggesting a degree of 
stigma attached to attending the TOP clinic. The 
assessment clinic could be a busy place; two women 
felt that there were a lot of people to see in one 
day, and for another two the clinic felt rushed as 
one was ‘bundled off in different directions’.
The literature suggests that women’s decisions to 
seek TOP are pragmatic ones65 and that women 
prefer rapid access to services characterised by 
supportive non-judgemental staff. We cannot 
make confident claims about participants’ reasons 
for seeking TOP, but qualitative data suggest that 
empathic service provision in primary care was 
preferred by them. In this case, women’s accounts 
of help-seeking were largely procedural, and 
factors that shaped this were primarily related to 
organisational processes.
Experiences of trial participation itself were 
dominated by accounts of (1) the clinical procedure 
and its contexts and (2) data collection. Like 
participants in other clinical trials,66 participants 
in the TOPS trial accounted for their involvement 
through the notion of ‘helping’ in some way. 
They made reference to the benefits of medical 
research and women’s experiences that triggered 
the desire to help. They also reflected on abortion 
as an unpalatable and painful experience that 
was somehow compensated for by research 
participation. All except one of the women made 
references to the idea of ‘helping’ in some form or 
other as their reason for being involved. Altruistic 
involvement was the most common feature of 
accounts of motivation and half of the participants 
in the substudy described their involvement in this 
way. For example, one younger respondent said 
that:
I just feel though…as though it is a good thing 
because if it helps other people that’s why 
when I was talking to me family about it they 
were saying ‘Ah but what you doing it for?’ and 
I was, like, well if it’s going to benefit somebody 
else then, well, that’s all that matters really 
(3618 RS).
Eight women expressed their reason for 
volunteering as having to do with the important 
role of research as contributing to knowledge. 
Other women asserted an ethical obligation to 
help:
With a study like that I mean it, it…there’s 
only certain people obviously that are suitable 
to take part in a study like that, people that 
are pregnant and are having a termination 
and you know a lot of people I think wouldn’t 
be prepared to talk about it and wouldn’t be 
prepared to participate in this study and since 
I, you know, I felt OK about it then I thought 
well you know, I should, I should do it (4062 
PS).
Other women reflected on the pain of their 
experiences and their empathy with women in the 
same position as being the trigger for volunteering:
It’s a horrible situation where you are going 
into something that you don’t know anything 
about and you don’t even know which method 
would be best for you, so I think it would be 
better if people did know which would be 
better so (4564 RM).
Because this was a partial preference trial, 
participants had three possible pathways through 
it. They could (1) choose (prefer) STOP, (2) choose 
(prefer) MTOP, or (3) choose to be allocated to one 
of the randomised arms of the trial. At enrolment 
into the trial the question of randomisation posed 
a problem for participants. Some women had 
difficulty deciding a preference:Qualitative substudy results
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When I was sitting in the room with, like, the 
lady and she was saying we can do it for you 
on the computer and just pick a random if you 
want to be part of that study and things, I was 
just kind like ‘Urgh! I don’t know, I don’t know’ 
but I eventually picked medical (4304 PM).
On the other hand, the process of randomisation 
was also described as a solution to problems of 
decision: 
About each, er, each method and what it 
involves and I just thought there was so many 
pros and cons of each one that I really couldn’t 
decide which one would be better for me and 
then when I was told about the, the research 
that you were doing I just thought it would be 
better seeing as I couldn’t personally decide 
anyway ’cos I just thought each method had 
good and bad points, I just thought it would be 
better to do the research (4564 RM).
Although women who had a preference should not 
have entered the randomisation arms of the trial, 
they often sought to oblige staff by offering to do 
so:
I asked the researcher, I said ‘Well you know, 
can I do the random thing, and then if it 
comes up as a surgical can I change my mind?’ 
and she went ‘No, if you’ve got a preference 
that’s the one you’ve got to have’… Because 
I’d already stated that I had a preference she 
couldn’t just put me in the random thing 
because she already knew that I already had a 
preference (4336 PM).
Participation in follow-up data collection meant 
that women had to revisit what they perceived as 
an essentially private experience. Some women 
had the opportunity to come back into the hospital 
for the 2-week follow-up. The contingencies of 
everyday health care meant that the circumstances 
in which this took place were not always ideal:
Er, and then there was another girl there as 
well and she sort of said ‘You know, will you 
do it together’? and I’ve never met this girl 
and we both said ‘No’ and then she put me in 
the same room where I’d had all my scan and 
everything, which was really unpleasant and 
I think if I’d been prepared for that it would 
have been OK but I’d been expecting to see T, 
in the cosy room you know (4062 PS).
More than one-third (n = 13) thought that the 
questions they had to answer were easy. However, 
there were some difficulties with the length of the 
questionnaire and the scale questions:
Some things I didn’t really understand like, just 
the, er, when they have numbers like from zero 
and then going up.
Interviewer: It’s a scale isn’t it?
Yeah and it’s like, some of the words don’t 
really make sense, and for me I would have 
to elaborate or write something underneath, 
because it doesn’t.
Interviewer: Did you do that though?
Em, on some of them, yeah, because I just 
thought it just doesn’t make sense (4760 RM).
A small number of participants attributed benefits 
to participating in the study that either stemmed 
from feeling that they were ‘not alone’ in their 
experience or because they found the experience 
in some way cathartic. More generally, women 
were appreciative of approaches to informed 
consent that enabled understanding and provided 
opportunities for questions to be asked. However, 
there are some indications that the time scale of 
recruitment and maintaining the right balance of 
information are issues to be addressed in future 
research. 
It is unsurprising that women’s accounts of their 
understanding of the research itself centred on 
decision-making between MTOP and STOP. 
However, they referred mainly to the study 
providing some objective evaluation of the two 
procedures, rather than discovering women’s 
subjective preferences. Over one-third of the 
women referred to finding out women’s preference 
for a particular method, with one interviewee 
referring to statistical approaches. One-third of 
the women spoke about the research in terms of 
effectiveness, that is, which method was ‘best’ or 
‘better’, which method was ‘best in the long term’, 
and which was safer. However, participants also 
referred to the improvement of services for women, 
focusing on improving care during and after the 
procedure, making women more ‘comfortable’ and 
reducing the ‘emotional strain’ of the procedure. 
A small number of participants also referred to 
the trial more specifically as being able to assist in 
women’s choices:DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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I guess you’re trying to, er, trying to see 
whether it actually has an impact on people 
physically and psychologically to do the kind 
of well being after the event depending on 
which, which method they go for because I 
suppose the NHS the medical, er, the medical 
way would actually be cheaper, more efficient 
and if it doesn’t have, you know, any poorer 
implications compared to the surgical method 
then that’s going to be something that is 
possibly advocated more and you use that to 
help people make decisions I suppose (4648 
PS).
Participants framed the benefits of involvement in 
the trial in altruistic terms, but also saw a cathartic 
effect in talking about their experiences. Only 
three participants did not describe such a benefit 
from being involved in the trial.
Decision-making and 
preferences
This study was not concerned with the processes 
which led women to seek a termination in the 
first place. However, because it was a partial 
preference trial, the means by which women 
decided on their preferences were important. The 
substudy interviews provided accounts of how 
past experiences of both childbirth and surgical 
procedures shaped women’s decision-making. In 
deciding between medical and surgical procedures, 
only a few women in the substudy referred to 
advice from professionals as an influencing factor 
in making their choice.
Similarly, four women in the substudy were 
concerned about what was involved in the surgical 
procedure. In their accounts of surgery, the 
women used terms such as ‘dangerous’, ‘risky’, 
‘brutal’, ‘horrific’, ‘serious’, ‘harsh’ and ‘invasive’. 
A participant in the PS arm of the trial referred to 
it as ‘being under the knife’ but felt that it needed 
to be called something else ‘as it didn’t require 
any stitches’. A participant in the RM arm of the 
trial, on the other hand, referred to the ‘tools 
and things’ that had to be used in the procedure. 
Another PS participant had to put aside the idea 
of ‘flushing away something that would be human’, 
or it would have changed her mind about having 
a surgical termination. Concerns about general 
anaesthesia may have led some women to enter the 
PM arm of the trial, either because of assessment 
of ‘potential’ risks or previous experiences. Other 
women spoke of a more general fear of surgery – 
not knowing what to expect, and how their bodies 
would react. Three women described anxiety about 
injections, in the form of a ‘fear of needles’, and 
two of these opted for medical termination. A 
participant in the PM arm of the trial described 
this anxiety thus:
I was a bit scared of the surgical thing. I just 
thought I didn’t want to be put to sleep, I 
didn’t like the idea of the needles, I didn’t like 
the idea of waking up and that, you know, that 
feeling of, kind of, well that’s it over (4304 
PM).
A small number of women in the substudy referred 
to the emotional trauma involved in the medical 
procedure; often these were linked particularly to 
the pain and the sight of the fetus. Four women 
who underwent a medical procedure would prefer 
to have a surgical procedure instead if the situation 
arose again. One RM participant was profoundly 
affected by seeing the expelled fetus:
But now looking back to it, I would go with the 
surgical one. I think you’re going to get pain 
with each one so I think, you know, whether 
I got the same amount of pain with that one 
would just be very unlucky really but, you know, 
I’d know what to expect but with the surgical 
one. There’s no chance that I’d see the fetus 
so that would be what would be, what would 
sway me towards that one if I had to do it again 
(4564 RM).
However, other women saw MTOP as offering 
greater control and confidentiality. Importantly, 
they saw MTOP as procedurally easier. For 
example:
And I think at the end of the day it was quicker 
for me and quicker for them at the hospital 
just to do the tablets, it was easier, you weren’t 
having anaesthetic people and it wasn’t an 
operating theatre or anything like that, you 
were just in a ward, with a bed, think it was 
easier (5042 PM).
Other women in the PM arm described this 
method as more ‘natural’, a view also taken by 
participants in other qualitative studies.67,68
The idea of ‘control’ was elaborated on in the 
interviews with women who tried to explain their 
reasons for choosing the medical procedure in spite 
of the drawbacks of the method. For example, one 
RM participant felt that being under an anaesthetic Qualitative substudy results
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was being ‘detached’ and therefore she preferred 
the medical method, where she could assume a 
degree of responsibility for what was happening. 
Another was anxious about ‘not know[ing] what’s 
going on’ and not being ‘in control’. A PM 
participant opted to both be in control and to 
be ‘responsible’. ‘I just wanted to see it through 
myself ’, she said.
The speed of the surgical procedure was 
acknowledged by 9 of 30 participants in the 
substudy. A number of women reflected on the fact 
that waiting for the medical process to happen was 
problematic. A PS participant said that:
…the nurse talked me through it and said you 
have this and then, you know, you’ll start to 
have pain and then you know the fetus might 
come out and then that might not happen and 
you might have to have more and then wait 
another few hours and then if it still doesn’t 
happen then you can stay in overnight and 
then I was like ‘Oh my God’ that’s just getting 
worse and worse and worse (3648 PS).
Other participants in the surgical arms were very 
clear that they wanted to be unconscious during the 
procedure. Rather than be in ‘control’ as women 
who preferred the medical option wished, they 
wanted instead to be ‘completely oblivious’ and not 
know that anything had happened. One said that 
she did not want to ‘see it coming away’; another 
sought to avoid the experience of ‘something 
coming out of me’, and another was pleased that 
she didn’t have to ‘live through it’. Six women 
referred to the surgical procedure as offering them 
the advantage of it being ‘done properly’ all in one 
go and three were glad it did not involve a second 
visit. This sense of finality was also expressed in the 
following ways: wanting an ‘end’ to it, having it all 
to be ‘fixed’, ‘done and dusted in one day’, ‘all over, 
gone’.
Women’s perspectives on 
the conjoint analysis (DCE)
The novel component of this qualitative substudy 
was that it followed-up the DCE. It is important to 
note that this was not intended to ‘verify’ the results 
of the DCE by applying it to the actual study group, 
but was rather intended to develop a lay analysis of 
its results.
In the interview, women were shown a flash card 
describing the results of the DCE in summary form. 
The flash card showed the order of factors affecting 
preferences for MTOP or STOP. Interviewees 
were asked if they agreed or disagreed with the 
relative importance of these factors, and to give 
their reasons. They were also asked why they 
thought these features were ranked in this way, and 
whether there were other aspects of the experience 
that needed to be considered. The results of 
this process are interesting, but not conclusive. 
Some women distinguished between the ranking 
features according to their personal experience as 
opposed to what they would recommend on behalf 
of women in general. Others found it difficult to 
respond to the question or to retain a firm view.
Women’s responses to these questions were collated 
and analysed according to how they would rank 
the features themselves (Table 48). The findings 
from this exercise differed significantly from 
the results of the DCE. While ‘waiting time’ was 
overall the most important (20 women ranked it 
in first place, while 7 ranked it in second place), 
counselling was considered the second most 
important feature (6 put this in first place and 11 
in second place). ‘Consciousness’ was overall the 
third most important feature as six women put it 
in first place, and four women in second place. 
However, the choices of women in the sub-study 
appeared to be closely linked to their experience 
of the termination. For women who had had a 
medical termination, ten out of the 13 put waiting 
time as their top priority, while ten out of 17 who 
had had a surgical termination did so. As a medical 
termination can only be carried within a certain 
number of weeks of gestation, this may explain 
why timing was more significant to these women, 
particularly those with a specific preference for the 
procedure. 
I think it was good because I had a chance 
to go through the things in my head and be 
absolutely certain that was what I wanted to do 
(4062 PS).
However, 11 women felt that the waiting time was 
far too long, and for two of them the waiting was 
the worst part of the experience. They considered 
going to a private clinic to speed up the process. 
One said that:
As soon as you find out you’re pregnant you 
just want it over with. I would have quite 
happily gone in that day (5042 PM).
While for most women, a short waiting period 
was much preferred, the expectations and stresses DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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TABLE 48  Top three factors influencing women’s choice of method of TOP
Waiting time Counselling Consciousness
Rank position 1st 2nd 1st 2nd 1st 2nd
PM 6 2 3 3 1 0
PS 4 5 2 5 5 0
RM 4 0 1 1 0 1
RS 6 0 0 2 0 3
Total 20 7 6 11 6 4
MTOP, n = 13; STOP, n = 17.
associated with it were subject to a number of 
different interpretations according to women’s 
circumstances. One participant, who was 
ambivalent about having the termination in the 
first place, appreciated that the procedure was 
quick: 
Yeah, it was pretty quick, I was quite shocked 
at how quick it was actually…I thought it was a 
bit hurried but coming to think about it now it 
was better that way…’cos then you didn’t have 
a chance to sit and think about it and worry 
about it (5002 PM).
Apart from gestational age, women’s household 
living arrangements and experience of morning 
sickness could also be factors that affected their 
sense of urgency. For example:
And that it, it seemed like forever ’cos by that 
stage I had really bad morning sickness and 
I just, I could hardly function [laughs]. It was 
horrible, er, and ’cos I live in a shared house 
with my sister and her friend and I didn’t want 
to tell them about the pregnancy test, I was 
trying to hide it from them (4578 RS).
While being unconscious was more of an issue 
for those who had had a surgical termination, 
counselling appeared to be important to those 
who had had the medical procedure: 8 of 13 
rated counselling in first and second place, while 
9 of 17 in the surgical arm did so. This might be 
an indication of the level of distress that these 
women underwent. However, interviews provided 
a mixed view of counselling. Some women equated 
counselling with personal support that they were 
able to access from family and friends, while it was 
more specific for others. Access to counselling was 
uneven across the 30 women. Of the 15 women 
who elaborated on their views that counselling was 
important, equal numbers expressed the opinion 
that counselling was more important before, after, 
or both before and after the procedure. Among 
this group, 10 women had support from other 
sources, and of these, five did not think counselling 
was necessary. Six women felt they did need 
counselling. For example:
I think you automatically look at what you’ve 
been through and think well it’s like afterwards, 
when I think I could have done with seeing 
someone for once, er, I don’t know, it’s, I 
wouldn’t like anyone to feel the way I felt and 
not be able to talk to anyone professionally 
about it. I mean family members, yeah, but 
they don’t really understand if they haven’t 
been through it (4552 PS).
Five women had experienced formal counselling. 
This compared counselling favourably to support 
from family and friends:
Yeah, it was good to talk to someone out of 
the whole equation… It’s not like friends and 
family and everyone was telling us to think 
things ‘Oh just do what you want’ and I didn’t 
know what I wanted. So it was just nice to talk 
to someone out of the whole equation (3796 
PS). 
In contrast, five women in the surgical arm put 
‘being asleep or awake’ in first place compared with 
only one in the medical arm. A participant in the 
PM arm described why she rated being asleep as 
more important than any of the other features:
Er, you got a bit of a shock but you had to 
check to see what you passed and I got a bit 
of a shock… They said just leave it and we’ll 
check it for you but I guess because I was at 
the point where I was absolutely desperate to Qualitative substudy results
58
pass something and so I didn’t have to have the 
operation, er I, and it was quite large so you…
not like you could not see it I guess (4400 PM).
When women were asked if they thought other 
features should be included in the list, 18 women 
had suggestions to make. Six women mentioned 
that a friendly and sensitive attitude of medical and 
nursing staff towards them was important. Four 
women suggested that information should be one 
of the features. Privacy was also referred to by two 
women, and post-TOP care and support by another 
two women.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Introduction
This trial sought to determine the acceptability, 
clinical effectiveness and cost of MTOP and STOP 
at less than 14 weeks of pregnancy. Despite poor 
recruitment to the randomised arm of the trial, the 
results show that, at 2 weeks after the procedure, 
women in the surgical arms were more likely to 
opt to have the same method again compared 
to women having MTOP. This difference in 
acceptability at 2 weeks was found to increase 
with gestational age at abortion and the greater 
acceptability of STOP persisted at 3 months. 
Women having MTOP were more likely to report 
symptoms during their admission and they had 
higher pain scores. Further, MTOP was associated 
with more unplanned emergency admissions and 
more complications. Consistent with these findings, 
women’s experiences of care were generally more 
negative and they were less satisfied with MTOP. 
However, STOP was more costly due to much 
higher standard costs. Whether STOP would be 
considered cost-effective depends on the value 
placed on increased effectiveness for this increased 
cost. Despite these differences, many women chose 
MTOP and found the procedure acceptable.
Comparison with prior 
studies
Although the procedure for STOP is consistent 
in prior studies of abortion prior to 14 weeks, a 
number of different medical regimens have been 
employed; early randomised trials employed 
prostaglandins alone1,69 or mifepristone alone.70 
A systematic review of medical methods for first-
trimester abortion concluded that combined 
mifepristone and prostaglandins was more effective 
(in terms of achieving complete abortion) than 
prostaglandins or mifepristone alone.71 Single-
agent regimens are no longer recommended in 
the UK.9 Therefore, in order to allow meaningful 
comparisons, studies quoted in the following 
discussion are limited to those in which MTOP 
was attempted using mifepristone followed by 
prostaglandins.
Trial design
The primary outcome (acceptability) and the 
design (partially randomised patient preference) of 
this trial were stipulated in the Health Technology 
Assessment (HTA) Commissioning Brief. Although 
a randomised clinical trial would be the most 
scientifically rigorous design for evaluating 
MTOP and STOP, it cannot deal with the post-
randomisation effects of patient’s preferences on 
treatment outcomes.72 Participant preferences may 
affect compliance and motivation, introducing 
bias that affects the internal validity of a trial. 
Thus in the case of TOP, women randomised to 
their preferred procedure may be better motivated 
and report better outcomes, while women who do 
not receive their preferred method may be less 
motivated, may not report accurately during follow-
up and may even drop out of the trial.73 Effects of 
preference are likely to be more apparent where the 
outcome measure is subjective and self-reported by 
the patient. In addition patients’ preferences may 
also have a ‘therapeutic effect’, similar to a placebo 
effect, directly influencing outcomes.74 Where 
strong preferences exist, as appears likely with 
TOP method,17,20 a large number of participants 
may refuse randomisation, adversely affecting 
the external validity of the trial and limiting the 
generalisability of the results.72
The approach taken to deal with women’s 
preferences in this trial was to employ a partially 
randomised preference design. This design takes 
women’s preferences into account in the allocation 
of TOP method, generating two groups of women 
in whom motivational factors should have been 
optimised by allowing them to choose their own 
method of TOP and two groups of randomised 
women in whom motivational factors should have 
been equalised. This allows the independent 
effect of women’s preferences to be examined, 
thus providing information on the benefits of 
providing a choice.75 A disadvantage of this 
design is that the outcome (acceptability) may 
be affected by uncontrolled confounders in the 
preference groups, which may bias the results.76 
An alternate approach would have been to use a 
fully randomised preference trial in which, after 
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consent and before randomisation, women’s 
preferences were recorded and taken into account 
in the analysis.77 Although a potential criticism of 
this design is that ignoring patients’ preferences 
and proceeding with randomisation is unethical, 
this may not be the case if the treatments being 
offered are believed to be effective and patients 
give fully informed consent.72 It is still unclear 
whether patient preferences significantly affect the 
validity of randomised trials. In a systematic review 
of predominantly partially randomised preference 
trials, King et al.73 found that while preferences 
led to a substantial proportion of people refusing 
randomisation, there was little evidence that 
outcomes differed between randomised and 
preference groups across the trials. In contrast, a 
recent systematic review of eight fully randomised 
preference trials in musculoskeletal medicine 
found that, after adjustment for baseline scores 
and categorical variables of trial and treatment 
allocation, preferences were associated with 
treatment effects; patients who were randomised to 
their preferred treatment had a standardised effect 
size greater than that of those who were indifferent 
to the treatment assigned.72 Perhaps surprisingly 
this review also showed that participants who did 
not receive their preference were more likely to 
return their first follow-up questionnaire, although 
overall response rates were similar.
Baseline characteristics
Comparison of the baseline characteristics 
revealed a number of differences between the three 
allocation groups. Within the preference groups, 
women opting for STOP were more advanced in 
their pregnancy and were more likely to smoke, 
to be educated up to GCSE level and to have had 
a prior live birth. However, the only difference 
between women in the randomised and preference 
groups was that mean age was slightly greater (1.2 
years) in the preference arm, a difference similar 
to that reported in the systematic review of fully 
randomised patient preference trials.72 No such 
differences in participant characteristics were 
reported in the two smaller partially randomised 
preference trials of TOP method conducted in the 
UK,17,18 although Henshaw et al.17 did find that 
women preferring STOP had a greater distance to 
travel to hospital. This parameter was not recorded 
in the present study.
Trial recruitment
Only 19% of women recruited to the study were 
prepared to have their method of termination 
randomly assigned. Changes to the written 
information given to women, emphasising the 
absence of evidence that one method was superior 
and the value of randomisation, failed to increase 
randomisation rates which remained much lower 
than in our pilot trial conducted in 2002; of the 
284 suitable women at 9–13 weeks of pregnancy 
in the pilot, 49% were prepared to be randomised 
to MTOP or STOP. The achieved randomisation 
rate was also much lower than prior partially 
randomised trials of TOP method conducted in the 
UK, which reported randomisation rates of 54%17 
and 82%.18
We can speculate on the reasons for these 
differences. It is possible that knowledge of 
abortion methods, particularly MTOP, has 
increased over recent years. Certainly the 
availability and acceptance of MTOP, both in 
Newcastle upon Tyne and nationally, has increased 
dramatically; medical procedures accounted for 
35% of all abortions in 20074 compared with only 
12% in 2001 and 0% in 1991 (the year mifepristone 
was licensed in the UK).5 With improved knowledge 
and an increasing emphasis on choice, stressed in 
the NHS literature on TOP supplied by the Trust, 
women in the current study may have felt more 
empowered to state a preference. The accounts of 
women participating in the qualitative substudy are 
informative in this context: decisions about mode 
of TOP were mainly founded on issues around 
control and on prior experiences (either personal 
or those of friends/relatives), some of which related 
to MTOP. Further, while some women may have 
agreed to randomisation to ‘oblige’ staff, most of 
the randomised women interviewed chose this 
option as a means of resolving their difficulties in 
deciding on a preferred method.
The problem of explaining the rationale and 
process of randomisation to participants in clinical 
trials is well known78 and some of the women 
interviewed voiced difficulties understanding 
these concepts. We considered the possibility that 
personnel involved in patient assessment for TOP 
and trial recruitment could have influenced the 
proportion of women opting for randomisation. 
In both the previous studies conducted in 
Aberdeen,17,18 (A Templeton, University of 
Aberdeen, 2008, personal communication) and 
in our pilot trial, medical staff were involved in 
both processes. In contrast, in the current study DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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women were predominantly assessed by nurse 
practitioners and all recruitment was undertaken 
by research nurses. The fact that recruitment rates 
were the same for each research nurse suggests 
that the process of recruitment was conducted in a 
consistent manner. However, randomisation rates 
were higher in women seen by one of the nurse 
practitioners, suggesting that despite attempts to 
standardise the dialogue about the trial, women’s 
views on randomisation were influenced, albeit 
to a small degree, by the health professional who 
introduced the study. Although recruitment rates 
did not seem to be influenced by involvement of 
medical staff, the small number of women assessed 
by them precludes any firm conclusions.
Preferences
Slightly more than half (54%) of the women 
who expressed a preference opted for a medical 
procedure. It is difficult to draw meaningful 
comparisons with prior studies because of 
variations in study design and service/user attitudes 
to medical abortion. In a review of 12 studies of 
women at ≤ 9 weeks of pregnancy published prior 
to 1994, Winikoff21 reported that ‘in most trials’ 
60–70% of women chose medical abortion. In the 
partially randomised preference trial of Henshaw 
et al.17 conducted in Aberdeen, 72 of 156 (46%) 
women at ≤ 9 weeks of pregnancy in the preference 
arm preferred MTOP, while in the subsequent trial 
from the same unit only 15 of 77 (19%) of women 
at 10–13 weeks of pregnancy preferred MTOP.
In order to better understand the reasons 
underlying women’s choice of abortion method, we 
collected the reason(s) for procedure preference in 
all women in the preference arm immediately after 
recruitment. We attempted to group stated reasons 
into broad categories to facilitate interpretation 
and comparison with previous studies, but 
acknowledge this required several assumptions 
and resulted in an oversimplification of the data. 
Awareness during the procedure (which is closely 
linked to, but not synonymous with, a desire to 
avoid general anaesthesia) was cited by nearly 60% 
of women opting for MTOP. Previous studies have 
reported that 37–59% of women stated fear of 
anaesthesia or surgery as the reason for choosing 
MTOP at less than 9 weeks’ gestation.17,46 Ashok 
et al.79 reported that 67% of women preferring 
MTOP at 10–13 weeks perceived being conscious/
aware as an advantage of the method, while 78% 
saw avoiding anaesthesia as an advantage. In 
contrast, 27% of women opting for STOP stated 
they wanted to be unconscious/unaware of the 
procedure and a further 15% did not want to 
pass or see the fetus. A desire to be unconscious 
was deemed important/advantageous by 39% 
of women who opted for STOP in the study by 
Henshaw et al.,17 but by 94% of those opting for 
STOP at 10–13 weeks.79 All these prior studies also 
identified that women with a preference for MTOP 
perceived this as a more ‘natural’ procedure with 
fewer complications/psychological problems.17,46,79 
For a small proportion of women the avoidance 
of an additional visit and the greater likelihood of 
avoiding an overnight stay were important factors 
in choosing STOP.
The importance of ‘control’ during the abortion 
procedure was further emphasised and developed 
by the women who participated in the qualitative 
component of the study. Women who preferred 
STOP sought to control their exposure to the 
experience of the procedure (which was achieved 
with finality while they were unconscious). Opting 
for STOP ensured they would not see the fetus and 
were less likely to experience pain. In contrast, 
women who sought MTOP wanted to exercise a 
degree of control over the process itself. Awareness 
was seen as assuming responsibility for what was 
happening. Consistent with views of participants in 
other qualitative studies,65 several of the women in 
the preference MTOP group described the MTOP 
procedure as more ‘natural’ in contrast to STOP 
which was perceived as ‘harsh’ and ‘brutal’.
Strength of preference
We sought to gain more quantitative information 
about women’s strength of preference by recording 
WTP. When assessed prior to TOP, the maximum 
amounts that women were prepared to pay to 
have their preferred option (rather than their less 
preferred option) were similar for the two methods 
(mean £373 for MTOP, mean £432 for STOP). At 
2 weeks after abortion, women in the preference 
arm were prepared to pay more for their preferred 
option, but there were no differences in mean 
maximum WTP values for each method in the 
randomised arm (MTOP £193 versus STOP 
£216) or the preference arm (MTOP £329 versus 
STOP £357). Gibb et al.38 are the only other group 
to compare strength of preference for abortion 
method by WTP. In their small study of 50 women 
there were no differences in mean WTP values 
between women preferring MTOP and STOP (both 
before and after abortion). Despite only two women 
being zero-payers, mean WTP values were lower Discussion
62
(MTOP £103, STOP £48) than those recorded in 
the present study. These values were also lower 
than the amount women were prepared to pay for 
their choice of TOP method in the study of Howie 
et al.27 from the same unit (median £311, range 
£40–500).
The WTP method has been advocated as a way of 
eliciting public preferences for alternate health-
care programmes.80 We found the method simple 
and quick to administer, a key consideration in 
the present study in view of the large number of 
outcomes being collected. However, the method 
has several limitations. Convergent validity is low,81 
although other preference elicitation methods 
used in economic analyses, e.g. conjoint analyses 
and the various health status violation techniques, 
also have problems with consistency.82 A further 
limitation is the extent to which WTP can be 
associated with ‘ability to pay’.83 Gibb et al.38 
found that WTP for TOP method was positively 
associated with social class and the importance 
women attached to having a choice, supporting 
the validity of the technique in this population. 
We found a correlation between stated WTP and 
women’s income, providing some support for the 
internal validity of the measure in this study. Based 
on the present findings, and those of Howie et al.,27 
it can be concluded that the majority of women 
attach significant value to being able to choose 
their method of abortion. Further, while most 
women express a preference for abortion method, 
the strength of this preference, as assessed by the 
amount they are willing to pay to attain it, is similar 
for MTOP and STOP.
Creinin20 in his small randomised trial of MTOP 
and STOP sought to determine strength of 
preference using a VAS. Mean VAS scores were 
similar for those women in each group (STOP 93%, 
MTOP 63%) who found the method to which they 
were randomised acceptable (as determined by 
their choice for future abortion method). No other 
VAS data were presented. These results appear to 
support the conclusion of the present study that 
the strength of preference women have for their 
preferred method of TOP (whether that be the 
method chosen for their index abortion or for a 
future abortion) is similar for MTOP and STOP.
Service attributes
In an attempt to identify key factors that shape 
women’s preferences for TOP services, we 
conducted a DCE in a sample of non-pregnant 
women attending a family planning clinic. The 
rationale for selecting this patient group was to 
ascertain the expectations and views of potential 
future users of TOP services. From the attributes 
considered, provision of counselling, procedural 
waiting time, need for overnight stay and 
consciousness during the procedure significantly 
shaped women’s preferences. We were able to 
further develop this analysis in the substudy. The 
women interviewed prioritised waiting time above 
counselling and consciousness. The significance of 
waiting time was also emphasised by some women 
during their interviews. The high priority given by 
women to avoidance of an overnight stay supports 
the use of this measure of effectiveness in the trial.
It is reasonable to assume that waiting time was 
not relevant to women’s choice of TOP method 
as the waiting times for MTOP and STOP after 
recruitment to the trial were very similar (usually 
less than 7 days and always less than 10 days). 
The RCOG standard for waiting time from first 
appointment with the referring doctor to the 
procedure is 3 weeks;9 over the duration of the 
trial this standard was met in nearly 90% of 
pregnancies less than 14 weeks’ gestation. However, 
in other units this standard is met in less than 
50% of cases.84 This study identified delays both 
before and after referral from primary care and 
the barriers faced by women seeking abortion; 
82% of 140 GPs surveyed considered themselves 
‘broadly anti-abortion’ and the authors emphasised 
the need to evaluate alternative approaches that 
bypass traditional gatekeepers to abortion care.84 
These barriers were also highlighted by some 
women participating in the substudy (see below). 
Availability of counselling is also unlikely to 
have impacted on women’s preferences for TOP 
method. Women in the trial were not given routine 
follow-up appointments for counselling. Rather, 
in keeping with national guidance,9 they were 
all given a contact telephone number to access a 
trained counsellor provided as part of the NHS 
service.
Acceptability
Acceptability was the primary outcome of the 
trial and we chose to assess this by determining 
the proportion of women who would opt to have 
the same procedure again. This measure was 
chosen for two reasons: (1) it was easy to collect, 
particularly using text messaging (perceived to be 
a novel means of optimising data collection in this 
participant group); and (2) virtually all previous DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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studies comparing MTOP and STOP had reported 
future choice as a measure of acceptability, allowing 
the results to be incorporated into existing 
evidence. At 2 weeks after the procedure, compared 
with women randomised to MTOP, women 
randomised to STOP were more likely to opt to 
have the same procedure again (69% versus 94% 
respectively). This finding is consistent with prior 
randomised trials: 74% versus 87% (p < 0.001) in 
the study of Henshaw et al.17 in women ≤ 9 weeks’ 
gestation, and 63% versus 92% (p < 0.001) in the 
study of Creinin20 in women < 7 weeks’ gestation. 
A smaller difference (70% versus 79%, p < 0.001) 
was reported by Ashok et al.18 in women at 10–13 
weeks of pregnancy, although the results from 
randomised and preference arms were combined. 
No differences were reported in the small trial of 
Rosen et al.69
In keeping with prior studies,79 women in the 
preference arms were more likely to regard 
their chosen method as acceptable. Consistent 
with the results in the randomised arm, more 
women choosing STOP than MTOP opted 
to have the same procedure again (96.5% 
versus 80.9% respectively at 2 weeks), an effect 
maintained at 3 months (95.6% versus 79.0%). In 
contrast, Henshaw et al.17 found no difference in 
acceptability between women who preferred STOP 
and those who preferred MTOP (90% versus 95%), 
although numbers were much smaller (n = 156). 
Results from prior prospective cohort studies 
comparing STOP and MTOP before 9 weeks’ 
gestation have found conflicting results in terms 
of procedure acceptability. However, the extent to 
which women chose their method of abortion in 
these studies varied; in most of the earlier studies 
reporting high acceptability rates with MTOP, the 
procedure was not generally available and women 
themselves sought out access to medical abortion.24 
In more recent cohort studies where women had 
choice of abortion method, STOP has been found 
to be either as acceptable85 or more acceptable86 
than MTOP.
Surgical TOP remained more acceptable to 
women in both arms of the trial at 3 months after 
the procedure. Only 26 of 382 (7%) women who 
provided responses at both time points changed 
their responses, of whom 16 (13 in PM and 3 in 
RM arms) would no longer opt for MTOP in the 
future. Howie et al.27 reported 2-year follow-up 
data from 80% of the women participating in the 
partially randomised preference trial of Henshaw 
et al.17 Of those women originally allocated to 
treatment according to preference, 89% in both 
the MTOP and STOP groups opted for the same 
procedure in future. In contrast, 64% of women 
randomised to MTOP, but 87% randomised to 
STOP opted for the same procedure (95% CI for 
difference in proportions –39 to –1, p < 0.05). 
These findings support the conclusion that more 
women regard STOP as acceptable.
Acceptability of MTOP declined as gestational age 
increased such that by 13 weeks’ gestation only 
50% of women opted to have MTOP again. In 
contrast, the acceptability of STOP remained high 
(> 90%) between 5 and 13 weeks. Studies on early 
MTOP have consistently shown that procedure 
failure and more pain and bleeding than expected 
are predictors of not choosing MTOP again.24,87–89 
The likelihood of each of these predictors increases 
with gestational age.15,89 Of particular relevance 
is the increase in need for surgical evacuation 
following MTOP because of ongoing pregnancy 
or missed/incomplete abortion, which has been 
reported to increase from 0.9% at 9–10 weeks to 
7.9% at 12–13 weeks of pregnancy.15 Unsuccessful 
medical therapy has also been shown to reduce 
acceptability in a randomised trial of medical and 
surgical management of early pregnancy failure.90 
Although we did not undertake a detailed analysis 
of predictors of acceptability, we did confirm that 
acceptability at both 2 weeks and 3 months was 
reduced in women experiencing complications.
Semantic rating/satisfaction
To further assess women’s experiences of the 
abortion procedure we used semantic differentials 
constructed using bipolar adjectival scales as end 
points on a graphic Likert scale. The instrument 
is easy to use and has been shown to be internally 
consistent and valid.91,92 Rather than develop a 
new set of adjectival pairs, we utilised the 12 pairs 
employed by Henshaw et al.17 and Ashok et al.79,93 
in their studies of the acceptability of MTOP and 
STOP. At both 2 weeks and 3 months after the 
procedure, MTOP was rated significantly lower on 
all 12 bipolar adjectives in the preference group 
and on 11 of 12 in the randomised group, clearly 
indicating that women rated their experiences of 
MTOP more negatively than their experiences 
of STOP: MTOP was felt to be more unpleasant, 
more disagreeable, harder and more painful, 
while STOP was felt to be milder, more agreeable, 
faster and safer. These experiential effects were 
greater than those reported by Henshaw et al.17 who 
found that MTOP was rated lower on six of the 
12 adjectives in their randomised arm but only on Discussion
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one of the 12 in their preference groups (MTOP 
was more painful). However, the fewer significant 
differences may have been explained by the much 
smaller sample size in the Aberdeen study. Ashok et 
al.93 analysed their data by totalling the scores for 
each adjectival pair to give an estimate of change 
in ‘self-esteem’ before and after abortion. More 
women randomised to MTOP at 10–13 weeks of 
pregnancy had a fall in ‘self-esteem’.
Fewer women having MTOP rated their overall 
care as excellent. Again this result was consistent 
across both trial arms and at both time points. 
Women were less satisfied with the technical and 
interpersonal aspects of care, but not the waiting 
time for MTOP. Although satisfaction data were 
not reported in previous randomised trials, two 
cohort studies comparing MTOP and STOP have 
measured overall satisfaction with care; Slade et 
al.86 found no difference in mean scores on the 
Satisfaction with Care Scale, but Jensen et al.,24 
using a 5-point scale, reported higher mean 
satisfaction scores with STOP. Taken together the 
results of the present study and those of most prior 
studies suggest that experiences of care are more 
negative and satisfaction lower with MTOP, likely 
contributing to the lower acceptability of medical 
abortion prior to 14 weeks of pregnancy.
Psychological outcome
Anxiety and depression, as assessed by HADS 
or Edinburgh Postnatal Depression Scales 
(EPDS), have consistently been shown to fall after 
abortion.26,85,86,93 Consistent with prior randomised 
trials26,93 and cohort studies85,86,94,95 that have used 
HADS or EPDS as a means of screening for anxiety 
and depression, we found no difference in mean 
scores between women having MTOP and STOP. 
The proportion of ‘clinical’ cases of anxiety and 
depression during the first month after abortion 
(inferred, for example, by the proportion of 
women with HADS > 10) has also been found to be 
similar in women having MTOP and STOP (6–28% 
for anxiety and 2–10% for depression).26,85,86,93 
Interestingly, Ashok et al.,93 in addition to the 
HADS, measured anxiety levels using a VAS before 
and after TOP at 10–13 weeks; women randomised 
to STOP were more anxious prior to the procedure, 
but less anxious following abortion than women 
randomised to MTOP. No such differences were 
recorded in the preference arm. Long-term follow-
up studies of women having first-trimester abortion 
have generally found no evidence of an increased 
risk of anxiety or depression, but these studies have 
not differentiated between MTOP and STOP.96–98
The IES has been used for over 20 years as a 
measure of stress reactions after traumatic events.40 
The scale is based on the two common responses 
to stress: intrusion, involving unbidden thoughts 
and images, bad dreams and strong feelings related 
to the event; and avoidance, involving denial 
of thoughts and feelings related to the event.40 
Systematic review has shown that the two-scale 
structure is stable over different types of traumatic 
events (e.g. injury, illness and bereavement) and 
has convergent validity with observer-diagnosed 
post-traumatic stress disorder.99 Compared with 
the mean IES scores reported here, Broen et 
al.100 reported slightly lower mean scores on 
both subscales at 10 days after induced abortion 
(method not defined). Thereafter IES avoidance 
scores remained unchanged (at 8–10 points) at 
6 months, 2 years and 5 years after TOP, while 
IES intrusion scores fell reaching a mean value 
of 3.6 points at 5 years. The proportion of IES 
intrusion ‘cases’ (defined as those with a score 
> 19) fell from 24% at 10 days to less than 5% at 
2 and 5 years after TOP, while the proportion of 
IES avoidance cases increased slightly from 12% to 
19%.100 As emphasised by the authors, the IES is 
not a measure of post-traumatic stress disorder.99 
Rather, classification as a ‘case’ infers that the 
person suffers some degree of mental distress. 
Many women have avoidance symptoms after 
induced abortion and the incidence appears to be 
influenced by culture; Rue et al.101 reported that 
36% of American women reported three or more 
avoidance symptoms compared with only 3% of 
Russian women. The incidence of post-traumatic 
stress disorder in these populations, as determined 
by the Traumatic Stress Institute’s Belief Scale, was 
14% and 1% respectively.
Women randomised to MTOP had higher scores 
on both subscales at 3 months and on the intrusion 
subscale at 2 weeks after the procedure. No 
differences were evident between women opting 
for MTOP and STOP. The only study to compare 
IES scores after MTOP and STOP was reported by 
Slade et al;86 in their study mean scores on the two 
subscales were almost identical to those reported 
here and were similar in the two TOP groups at 4 
weeks post procedure. However, within the medical 
group, those women who had seen their fetus 
(56%) were more likely to experience intrusive 
events (nightmares, unwanted thoughts and 
images). Mean gestational age at MTOP was more 
advanced in the current study and it is possible 
that the difference in IES intrusion scores relates to 
a higher proportion of women seeing their fetus. 
One could speculate that women in the preference DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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group were less affected and/or better prepared for 
this eventuality.
Side effects
The procedure of MTOP was associated with more 
pain and more gastrointestinal symptoms than 
STOP. These results are in agreement with previous 
randomised trials and cohort studies.12,17,20,86 
The incidence of side effects during MTOP has 
varied substantially between different studies. 
For example, the proportion of women reporting 
vomiting and diarrhoea has varied between 0–49% 
and 0–43% respectively.18,20,88,102 The incidence 
and severity of symptoms is influenced by the 
dose and route of administration of misoprostol;88 
gastrointestinal symptoms and fever are more 
common with oral administration.88 We found that 
a similar proportion of women (~ 22%) having 
MTOP and STOP were still bleeding 2 weeks 
after the procedure, although more women in the 
MTOP group reported heavy blood loss. Duration 
of bleeding has consistently been reported to be 
longer after MTOP than STOP and longer after 
abortion at 10–13 weeks compared with abortion 
at ≤ 9 weeks.16,18,20,24,86 Further, bleeding in excess 
of expectations (either in terms of amount or 
duration) has been reported more frequently 
after MTOP.86 In their cohort study, Slade et al.86 
found that more women reported ‘disruption of 
activities’ after MTOP than STOP (44% versus 
15% respectively); this could be explained as a 
consequences of differences in symptomatology. 
We sought to determine the impact of TOP by 
ascertaining when women returned to normal 
activities. There were no differences in this measure 
or the time taken to return to work between 
groups; reassuringly, around 90% of women had 
returned to normal activity/work by the 2-week 
follow-up.
Effectiveness
We chose to assess the overall clinical effectiveness 
of MTOP and STOP using unplanned/emergency 
admission requiring an overnight stay. We reasoned 
that this would capture all significant procedure-
related morbidity. Feedback from women during 
our pilot trial also underscored that this was an 
important outcome for women; in addition to the 
disruption of domestic and work-related activities, 
a high proportion of women had not informed 
their partners or parents of their TOP, making 
unplanned overnight stay a significant problem. 
Rates of unplanned or emergency admission were 
higher in the MTOP group in both the randomised 
and preference arms; overall 4.2% of women 
having MTOP had an unplanned overnight stay 
compared with 0.7% of women having STOP. 
Most of these admissions were overnight stays on 
the day of the MTOP procedure due to failure to 
achieve complete uterine evacuation. As the study 
had limited precision to estimate differences in 
specific complications, we reported the overall 
rate of complications that included haemorrhage, 
incomplete abortion, failed abortion and suspected 
pelvic infection. Complication rates were more 
common after MTOP, although this difference only 
achieved statistical significance when comparing 
preference arms. Overall 5.0% of women having 
MTOP experienced a complication compared with 
2.6% of women having STOP.
Previous randomised trials have tended not to 
report complication rates, presumably because 
of the small numbers of women recruited. 
However, in their randomised preference trial 
of MTOP and STOP at 10–13 weeks’ gestation, 
Ashok et al.18 reported ‘failure’ rates within 8 
weeks of abortion, i.e. failure to achieve complete 
uterine evacuation without the need for a second 
procedure [subsequent surgical (re)curettage or 
medical regimen]. In this study, 11 of 203 (5.4%) 
undergoing MTOP and 5 of 242 (2.1%) undergoing 
STOP had a failed TOP, a difference that was not 
statistically significant.
Several studies have reported single-unit 
comparative studies of MTOP and STOP. Jensen et 
al.24 reported primary procedure failure (defined 
as the need for suction curettage) in 18% of 150 
women having MTOP and 4.6% of 151 women 
having STOP at up to 9 weeks’ gestation. The 
high ‘failure’ rates may partly reflect the MTOP 
regimen used (single dose of 400 µg misoprostol 
orally) and the fact that emergency curettage was 
not based on evidence of products of conception. 
In a study of 932 women undergoing abortion 
at ≤ 9 weeks of pregnancy, surgical curettage 
for ‘presumed retained products of conception’ 
and ongoing pregnancy was more common in 
women having MTOP than STOP (9.8% versus 
5.5% respectively).103 More women having MTOP 
were admitted overnight during their TOP (3.8% 
versus 0% respectively), but rates of presentation 
as an emergency were similar (9.0% versus 8.8% 
respectively). Rates of emergency admission with 
overnight stay were not reported. Hamoda et al.104 
reviewed 1927 consecutive cases of abortion at 9–13 
weeks’ gestation. Detailed analysis of 1076 cases of Discussion
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MTOP was reported together with basic outcomes 
of 851 women having STOP. No statistical 
comparisons of the two methods were performed. 
In total 4.2% of MTOP cases required surgical 
evacuation: 1.9% for incomplete abortion, 0.5% for 
retained sac and 1.5% for continuing pregnancy; 
a further 0.4% of women required emergency 
curettage because of bleeding. Surgical evacuation 
rates increased from 2.7% at 64–70 days’ gestation 
to 8.0% at 85–91 days. Haemorrhage (blood loss 
> 500 ml) occurred in eight women (0.8%) and 
suspected pelvic infection in 12 (1.1%). Repeat 
surgical evacuation, haemorrhage and suspected 
pelvic infection occurred in 0.8, 0.1 and 0.3% of 
STOP cases respectively.
Useful comparator data on complication rates also 
come from large prospective series of a single TOP 
method. Ashok et al.12 reviewed 4132 consecutive 
cases of MTOP up to 9 weeks of pregnancy. In 
total 2.3% of cases required surgical evacuation: 
1.6% for incomplete abortion, 0.3% for missed 
abortion and 0.3% for continuing pregnancy. 
Surgical intervention rates were not influenced by 
gestational age (comparing groups up to 49 days’ 
and 50–63 days’ gestation) or by the misoprostol 
regimen (comparing one or two doses of 
misoprostol), although continuing pregnancy rates 
were higher with the single-dose regimen (0.6% 
versus 0.1%). Rates of haemorrhage and infection 
were not reported. No woman experienced 
uterine trauma (cervical laceration or uterine 
perforation), although two women underwent 
laparoscopy (and one a subsequent laparotomy) 
for suspected perforation. Hakim-Elahi et al.105 
reviewed complications in 170,000 first-trimester 
STOPs performed in three New York clinics; repeat 
surgical evacuation was required in 0.4% of cases 
and sepsis/mild infection developed in 0.5%. Rates 
of cervical tear and uterine perforation amounted 
to only 0.01% each. No information was given on 
mean gestational age or the relationship between 
gestation and complication rates.
Thus the complication rates encountered in 
the present study were broadly in keeping with 
previous studies. Further, they support the overall 
conclusion that STOP is more effective than MTOP, 
being associated with lower failure rates (and hence 
lower rates of surgical evacuation) and lower rates 
of unplanned and emergency admission. 
Costs and cost-effectiveness
The overall cost of STOP was greater than MTOP 
due to the higher inpatient standard costs, notably 
the operation (theatre), surgeon and anaesthetist 
costs, which accounted for 50% of the total cost 
of STOP. Thus even though complication rates 
(and costs) were higher with MTOP, the medical 
procedure was cheaper. STOP might still be cost-
effective if the gain in effectiveness (measured 
here as avoidance of overnight stay) is worth 
paying for. The usefulness of this measure of cost-
effectiveness depends on an understanding of 
the value of successfully completing TOP on the 
day of admission and thus avoiding unplanned or 
emergency overnight stay. The National Institute 
of Health and Clinical Excellence (NICE) sanctions 
new technologies according to an approximate 
threshold of £20,000–£30,000 per quality-adjusted 
life-year (QALY).106 If this decision guide were to 
be applied to a choice between MTOP and STOP, 
at an ICER of about £8000 per QALY (randomised 
arm), each overnight stay avoided would have to 
be worth at least approximately one-quarter of a 
QALY (or the equivalent of about 3 months in full 
health).
The national tariffs for STOP and MTOP are £504 
and £432 respectively.107 Thus our costs for STOP 
approximate the tariff, but those for MTOP are 
substantially lower. We can speculate on the causes 
of this discrepancy. It may relate to differences 
in costing methods; national tariffs are derived 
from average costs over all NHS Trusts (over 
300). Alternatively (or in addition), complication 
rates (and particularly surgical evacuation rates) 
related to MTOP may be lower in Newcastle 
upon Tyne than other units. However, even if this 
were the case, which seems unlikely in view of the 
comparability of complication rates with previous 
studies, this could not account for the differential 
cost.
There have been no recent studies of abortion 
costs from the UK. Creinin20 in his randomised 
trial of abortion methods below 9 weeks’ gestation 
estimated that STOP was 10% more expensive than 
MTOP. However, his assessment of resource use was 
limited to staff time and did not estimate actual 
monetary costs. Afable-Munsuz et al.108 assessed 
costs of MTOP models from data gathered from 
a sample of 11 abortion care settings. The total 
episode cost for providing MTOP ranged from 
$252 to $460. In 2001–2 the average self-paying 
woman in the USA was charged $372 for STOP, 
but Grimes and Creinin109 provide strong evidence 
that charges are below market value and that the 
genuine cost is ‘several times higher’. The only 
cost-effectiveness study identified from a literature 
search of the last 10 years was also conducted in the 
USA and compared dilatation and evacuation and DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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MTOP in the second trimester.110 STOP was found 
to be less costly and more effective than MTOP. 
However, standard costs are higher for second-
trimester MTOP.
It is important to emphasise that the policy for 
abortion provision (that must be funded and 
resourced) is not necessarily to move from one 
method to another. Rather, based on the results 
of the present study, there is a strong argument 
for considering making both methods available 
and giving women the choice. The costs provided 
can help inform any policy defined by a mix of 
MTOP and STOP in a range anywhere from 0% 
MTOP to 100% MTOP, but which, in the context 
of choice, ideally reflects women’s preferences. It is 
therefore up to the decision-maker to weigh up any 
gain from changing the mix against any loss from 
taking resources from other aspects of health-care 
provision.
Participants’ experiences of 
involvement in the trial
One of the aims of the qualitative substudy was to 
better understand the factors that shape women’s 
experiences of the health service contexts in which 
clinical trials are undertaken. In addition, we 
wished to identify those factors that promote and 
inhibit women’s involvement in clinical trials on 
TOP.
Existing work on the ways that participants 
understand and enact their participation in 
clinical trials has tended to focus on older people 
participating in studies of the management of 
chronic illness, particularly cancer111,112 and 
cardiovascular disease,113 where the time horizons 
for consent, recruitment and trial participation are 
often extended over many months. This research 
has highlighted the difficulties that participants 
face in conceptualising and responding to 
randomisation processes and dealing with 
therapeutic misconception.114,115 An important 
motive in such research has been the perceived 
need to better understand processes of informed 
consent with the hope of improving recruitment, 
and retention into trials.116
Research on participation in clinical trials of 
abortion differs in several important respects 
from research in other areas. First, participants 
tend to be young and are normally quite healthy. 
Second, although a clinical procedure is at issue, 
participation is not normally a matter of treatment. 
Third, the procedure itself is normally a single 
event and not a matter of management over an 
extended period. Finally, the time horizons in 
which women seek a termination, consent to enter 
a trial and undergo the procedure are highly 
compressed. Indeed, because these horizons are 
limited by the Abortion Act, timeliness of TOP is a 
matter of central importance. Qualitative research 
on experiences of participation in trials of TOP 
is limited – in a structured narrative review,65 we 
identified 18 qualitative studies. Of these, only 
three were embedded in studies comparing MTOP 
and STOP and all were conducted in the USA in 
the 1990s, two relating to home administration of 
mifepristone.65,117
Our review65 highlighted rapid access to services 
characterised by supportive non-judgemental staff 
appeared to characterise positive responses to TOP. 
Participants in the present study also sought rapid 
access to abortion services and were concerned 
about the ways that professionals evaluated 
them. Those attending family planning clinics 
experienced a smoother pathway to secondary 
care that required them to invest less work in 
negotiating and co-ordinating their own care. 
Once in the hospital service, rapid assessment 
and treatment was important to women. The 
accounts of participants in this trial fit well with 
qualitative and observational data from the 
wider literature: unobstructed entry into care, 
supportive professionals and quick access to TOP 
were important. Women responded negatively to 
problems that retarded or obstructed their rapid 
progress along the clinical pathway. We know that 
participants were under significant psychosocial 
pressure in the period that they negotiated access 
to TOP, but their accounts of this are largely 
procedural in form. 
Like participants in other clinical trials,66,118 
participants in this trial accounted for their 
involvement through the notion of helping in 
some way; women’s accounts of enrolling into 
the trial were organised through a set of ideas 
about altruism in which an unpleasant experience 
(TOP) was compensated by helping others 
through participation in research. For some this 
was framed as a general ethical obligation, but 
for others different levels of personal benefit were 
also described. Their accounts of the trial itself 
were dominated by the problem of allocation to 
an arm of the trial (which was itself an important 
component of negotiating preferences), in which 
the question of randomisation played a significant 
part. Letting the computer ‘choose’ the method of Discussion
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TOP remained something that some participants 
found hard to understand. In combination with 
what seems a strong set of pre-existing preferences, 
this led to poor recruitment into the randomisation 
arm of the trial. This is because the partial 
preference trial design enabled women to construct 
their choice to participate in altruistic terms. It also 
meant that they could control what that altruistic 
choice meant in practice, by choosing the arm of 
the trial that represented the mode of TOP that 
they actually preferred.
Limitations of research
The main limitation of the study was the poor 
follow-up rates, particularly at 3 months after 
the procedure. By a combination of interview 
(at both hospital and community clinics), postal 
questionnaire, text messaging and web-based 
participant entry we were able to capture primary 
outcome data from 70% of participants, 10% more 
than we predicted. One of the major benefits of 
the purpose-designed computer system was the 
ability to collect data by text messaging and the 
internet. However, only 4% of participants utilised 
each of these approaches, with the majority of 
women (53%) preferring contact by telephone. As 
a result we were able to collect complete secondary 
outcome data from a minority of women. Methods 
of data collection were more limited at 3 months 
(being confined to postal, telephone or web-based 
questionnaires). This may account for the low rate 
of data collection at this time (21%). The difficulties 
obtaining follow-up data on women after abortion 
have been highlighted previously, with response 
rates typically between 60% and 75% within the 4 
weeks after the procedure, falling to as low as 30% 
thereafter.18,26,27,86,97,100
Generalisability of results
Despite the high proportion of women who 
declined randomisation, we believe the results 
of the trial are generalisable. We acknowledge 
that some aspects of the abortion service offered 
in Newcastle upon Tyne may differ from those 
provided elsewhere in the UK. Women referred 
for abortion were assessed in a nurse-led abortion 
clinic rather than by a medical professional in 
a general gynaecological outpatient clinic. This 
system minimised delays and is popular with 
women and those making referrals.119 We believe 
this aspect of service provision is very unlikely 
to have influenced the trial findings. While the 
procedures of MTOP and STOP followed national 
guidance,3 virtually all STOPs were performed by 
two consultant gynaecologists. Rates of incomplete 
abortion, and by inference the associated 
morbidity, are influenced by the seniority of the 
surgeon as well as gestational age, ranging from 
2% when the surgeon was a consultant to 12% 
with a senior house officer and from 0% at 5–6 
weeks’ gestation to 12% at 12–13 weeks’ gestation.7 
It is therefore possible that incomplete abortion 
associated with STOP may be slightly lower in this 
trial than in other services.
Conclusions
In this randomised preference trial of medical and 
surgical abortion in pregnancies less than 14 weeks’ 
gestation, MTOP was associated with more negative 
experiences of care and lower acceptability, as 
determined by fewer women opting for the same 
procedure in the future. The acceptability of 
MTOP declined with increasing gestational age. 
Although MTOP was less costly, it was less clinically 
effective than STOP, being associated with more 
unplanned admissions and more complications. 
The trial provides further evidence that women 
value the option to choose abortion method; over 
80% of participants expressed a preference, of 
whom just over half opted for MTOP. The majority 
of those choosing MTOP were satisfied with their 
care and would choose the same method again in 
the future.
A large number of participants declined 
randomisation in this trial reflecting, at least in 
part, strong preferences about abortion method. 
While this generates concern about the external 
validity of the trial and the generalisability of the 
results, the anticipated impact on future patient 
outcomes also depends on the nature of the 
changes in clinical practice that are implemented in 
response to the trial results. If, as here, the results 
do not support the unambiguous superiority of 
one treatment over another, and there is evidence 
of strong preferences, then the policy response 
which best reflects all the study data would be to 
continue doing what was done in the trial, i.e. to 
offer patients choice. In these circumstances, we 
would argue that the generalisability of the overall 
conclusion drawn from the study data will be 
enhanced in comparison to that based upon a more 
traditional trial design.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
69
Implications for health care
Provision of abortion care varies substantially across 
England and Wales; a national survey in 2000 
found that, of those units with facilities for abortion 
before 13 weeks, only 32% of NHS units and 41% 
of specialised non-NHS units provided both MTOP 
and STOP.120 Even fewer (21%) NHS units provided 
both methods after 13 weeks.120 While provision 
of MTOP has increased since 2000,2 there is 
increasing concern that access to STOP, particularly 
after 12 weeks of pregnancy, is declining.121 This 
study provides persuasive evidence that a patient-
centred abortion service should offer women the 
choice of medical or surgical termination up to 14 
weeks’ of pregnancy.
Surgical TOP was more costly than MTOP, but 
more effective (as determined by lower rates 
of unplanned overnight stay and emergency 
admissions). STOP might still therefore be cost-
effective if this gain in effectiveness is felt to be 
worth paying for. The results of the DCE indicated 
that women felt that avoidance of overnight stay 
was an important service attribute. Another key 
attribute, also emphasised by many of the women 
interviewed, was waiting time. There is evidence 
of barriers to referral within primary care,84 and 
similar concerns were identified by some of the 
women interviewed. As complication rates increase 
with gestational age at abortion,2 it is important 
that women can access abortion services as quickly 
as possible; subsequent to completion of this trial 
a system of direct access has been introduced that 
allows women seeking abortion to refer themselves 
to the termination service.122
In order to make an informed choice about 
abortion method, women need high-quality 
information about their options. Evidence suggests 
that most leaflets from abortion services in England 
and Wales contain insufficient information to 
enable informed decision-making.123 This study 
provides important information that should be 
incorporated into a national evidence-based 
decision-aid leaflet.124
Summary of key 
recommendations for 
practice
1.  Patient-centred abortion services should offer 
women the choice of abortion method up to 14 
weeks’ of pregnancy.
2.  In order to make an informed choice about 
abortion method, women need high-quality 
information about their options.
3.  Abortion services should be accessible to 
women including direct access options. Where 
GPs are uncomfortable referring women for 
abortion, systems need to be in place to ensure 
they are redirected promptly.
Recommendations for 
future research
1.  Audit of provision of MTOP and STOP in 
England and Wales: the last national survey 
of abortion provision was in 2000 and there is 
an urgent need to reaudit available NHS and 
specialised non-NHS services.
2.  Exploration of barriers to offering women the 
choice of TOP method and ways of improving 
accessibility to TOP services. The Faculty of 
Family Planning and Reproductive Health 
have expressed concern regarding provision of 
STOP services, particularly after 12 weeks of 
pregnancy.121 The barriers to development and 
maintenance of this service, particularly within 
the NHS sector, need exploring.
3.  Comparison of MTOP and manual vacuum 
aspiration under local anaesthetic in 
pregnancies below 9 weeks’ gestation: many 
women would prefer not to have MTOP, but 
also fear general anaesthesia. Manual vacuum 
aspiration is a safe and effective method of 
early abortion,125 but has never been compared 
with MTOP in a UK population.
4.  Comparison of MTOP and STOP after 
14 weeks’ gestation: surgical abortion 
after 14 weeks necessitates dilatation and 
evacuation. The only randomised trial 
comparing dilatation and evacuation with the 
currently recommended regimen for MTOP 
(mifepistone/misoprostol) was abandoned 
because of poor recruitment.126 There is an 
urgent need to compare the acceptability and 
effectiveness of late abortion methods.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Termination of Pregnancy 
 
 
 
Your Questions Answered (1) 
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What will happen at the hospital clinic? 
 
 
•  You will be seen by a specialist nurse or doctor. 
 
•  They will take all your medical details, check your blood pressure and examine your 
abdomen (tummy). 
 
•  They will perform a scan through your abdomen to find out the size of the pregnancy. 
For this you need a full bladder. 
 
•  You will be asked if a swab can be taken from the neck of the womb (cervix) to see if 
there is an infection (chlamydia). This involves passing a speculum into the vagina 
(similar to having a smear). 
 
•  A blood sample will be taken to find out your blood group and to check you are not 
anaemic. 
 
•  You should be in the hospital clinic for no more than an hour.  
 
•  Remember; if your doctor has given you a letter please bring this to the clinic. 
 
•  You will be given a prescription for antibiotics to reduce the risk of infection. You 
should start these the day before the termination. 
 
 
 
What methods of termination of pregnancy (abortion) are available? 
 
Surgical 
 
•  Termination is undertaken by an operation under a general anaesthetic. 
 
•  You are admitted to the Day Unit (Ward 39) or the Gynaecology Ward (Ward 40) on 
the morning of operation. 
 
•  Before the operation it is necessary to insert some tablets (prostaglandin) into the 
vagina to prepare (soften) the cervix.  
 
•  A few hours later you will be taken to the operating theatre where an anaesthetic 
(injection) is given into the back of your hand. Appendix 1 
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•  When you are asleep the cervix is gently opened and the pregnancy removed. The 
operation takes 5-10 minutes. 
 
•  Sometimes women experience crampy tummy pain just before or after the operation. 
 
•  Most women go home later the same day after they have recovered from the 
anaesthetic. 
 
 
Medical 
 
•  You are admitted to the Gynaecology Ward (Ward 40). 
  
•  Termination is undertaken by tablets in two parts. 
 
•  The first part involves taking an oral tablet (Mifepristone) which helps prepare the 
womb by altering the hormone balance needed for the pregnancy to continue. This is 
usually given on the ward after you have been seen in the out-patient clinic. You can 
go home after taking this tablet. 
  
•  The second part involves coming into hospital 2 days later (at around 8.30 AM) when 
different tablets (prostaglandin) are inserted into the vagina. These stimulate the 
womb to expel the pregnancy.  
 
•  If the pregnancy is less than nine weeks size, abortion usually occurs within four 
hours of the tablets but if not, further prostaglandin tablets are given. You can go 
home 1-2 hours after passing the pregnancy providing you feel alright. There is a one 
in 10 chance that abortion does not occur before going home at 4.30 pm. This is not a 
problem but you may experience heavier bleeding and pain at home.  
 
•  If the pregnancy is 9 weeks or more, further prostaglandin tablets are usually 
required. These are repeated until the pregnancy is passed. This may mean staying 
overnight. There is a 3-4 in 100 chance the tablets don’t work in which case you 
would be offered a surgical termination.   
 
•  Prior to passing the pregnancy it is usual to experience vaginal bleeding and crampy 
tummy pain. This tends to be worse in pregnancies over 9 weeks. Most women only 
need simple pain killers, but stronger injections are available if needed. 
 
 
Which is the ‘best’ method of termination? 
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•  At present there is insufficient evidence to be certain whether one method of 
termination is preferable.  More research is needed to find out which method is most 
acceptable to women.  
 
•  Some women, especially during medical termination, feel sick and have vomiting and 
diarrhoea.  
 
•  Overall 3-5 out of every 100 women will experience pain and/or bleeding after a 
medical or surgical termination requiring them to seek medical advice.  In about half 
of these cases, the termination is not complete, and an operation is necessary to 
empty the womb.   
 
•  More serious problems (such as severe infection or bleeding and damage to the 
womb) are much less common (less than 1 in 100 women).  
 
•  We need your help to find out which method of termination is most acceptable 
to women in order that we can improve our services.  A research study is being 
carried out at the Royal Victoria Infirmary to find out more about women’s 
experiences of medical and surgical termination.  You may be invited to take part. If 
so, this will be fully explained and it is up to you to decide whether or not to take part.  
 
•  The method of termination will be decided once you have spoken to the specialist 
nurse or doctor.  
It is helpful to keep an open mind until you have had the opportunity to discuss this. 
 
 
What happens if I am undecided about the termination? 
 
•  The decision to terminate a pregnancy is always difficult. Some women remain 
undecided if this is the right option for them 
•  If you have doubts about whether to go through with the termination, it is important to 
share these with the specialist nurse or doctor 
•  Some women benefit from further counselling before they decide what to do. The 
important thing is to make the right decision and not feel rushed into doing something 
you really don’t want to do.  
 
 
What about future contraception? 
 
•  It is important to have effective contraception  
•  The specialist nurse or doctor will discuss future contraception with you and there are 
information leaflets available in the clinic.  
•  Whatever contraceptive method you choose, we will ensure this is prescribed before 
you go home.  
 Appendix 1 
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If you wish to cancel your appointment or you think you may be late please ring 
the Out Patients Department on 0191 2825900  
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2.1  Protocol authorisation signatories
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Denise Howel, Statistician
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Kathryn Oliver, Trial Manager
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I agree to comply with the study protocol, the 
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Professor Stephen RobsonAppendix 2 
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4 Glossary
AE  Adverse Event
GA  General Anaesthetic
GCP  Good Clinical Practice
GP  General Practitioner
HADS  Hospital Anxiety and Depression Scale
HTA  Health Technology Assessment
IES  Impact of Events Scale
IMP  Investigational Medicinal Product
NHS  National Health Service
PM  Preference Medical
PS  Preference Surgical
RCOG  Royal College of Obstetricians and 
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RS  Randomised Surgical
RVI  Royal Victoria Infirmary
SAE  Serious Adverse Event
SUSAR  Serious Unexpected Suspected Adverse 
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5 Protocol summary
Full title  A randomised preference 
trial of medical versus 
surgical termination of 
pregnancy less than 14  
weeks’ gestation
Short title:  TOP study
Protocol version:  1
Protocol date:  9 February 2004
Chief investigator:  Professor Stephen Robson
Sponsor:  Department of Health, 
Research and Development, 
Health Technology 
Assessment Programme
Funder:  Department of Health, 
Research and Development, 
Health Technology 
Assessment Programme
Study design:  A partially randomised 
preference trial comparing 
surgical and medical 
termination of pregnancy  
up to 14 weeks’ gestation. 
Follow-up will be conducted 
at 2 weeks and 3 months
Study intervention:  Surgical or medical 
termination of pregnancy
Objectives:   To determine differences in 
efficacy, acceptability and cost
Primary outcome  Acceptability, determined by 
preferred method of a future 
variable: termination
Study site:  Royal Victoria Infirmary, 
Newcastle upon Tyne
Study population:  2232 eligible women
Study duration:  3 years
6 Responsibilities
Sponsor
Department of Health, R&D, Health Technology 
Assessment Programme
Trial management
The following functions falling under the 
responsibility of the sponsor will be delegated to 
the Newcastle Clinical Trials Unit.
•  Authorisation: including CTA request, research 
ethics committee opinion, notification of 
protocol amendments and the end of trial.
•  GCP and conduct: including GCP 
arrangements, management of IMP (free of 
charge), emergency and safety procedures.
•  Pharmacovigilance: including defining 
adverse events/reactions, reporting of SUSARs, 
notifying investigators of SUSARs, annual 
listings and safety report.
Trial conduct at site
Investigator responsibilities:
•  Study conduct and the welfare of study 
subjects.
•  Familiar with the use of the investigational 
medicinal product as described in the product 
information, administration according to the 
protocol and drug accountability.
•  Compliance with the protocol, documentation 
of any protocol deviations and reporting of all 
serious adverse events.
•  Screening and recruitment of subjects.
•  All trial-related medical decisions.
•  Provision of adequate medical care in the event 
of an adverse event.
•  Obtaining site-specific assessment from local 
ethics committee:
  – Assistance will be provided by the CTU.
•  Obtaining R&D approval from the appropriate 
Trust and abide by the policies of research 
governance.
•  Compliance with the principles of GCP.
•  Obtain written informed consent from 
participants prior to their participation.
•  Qualified by education, training and 
experience to assume responsibility for the 
proper conduct of the trial and shall provide a 
current signed and dated curriculum vitae as 
evidence.
•  Availability for study meetings and in the case 
of an audit.Appendix 2 
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•  Maintenance of study documentation and 
compliance with reporting requests:
  – Maintaining a project file, including copies 
of study approval, list of subjects and their 
signed informed consent forms.
  – Documenting delegation of tasks to study 
personnel, e.g. co-investigators, research 
nurse.
  – Ensure data collected is accurate and 
complete.
  – Updating the CTU regarding the progress 
of the trial.
  – Ensure subject confidentiality is maintained 
during the project and archival period.
•  Ensure archival of study documentation for 
a minimum of 12 years following the end of 
the study, unless local arrangements require a 
longer period.
7 Background
Unwanted pregnancy is a major health issue; 
worldwide an estimated 53 million abortions are 
performed each year, resulting in up to 100,000 
maternal deaths.1 In 2002 nearly 185,000 
pregnancy terminations were performed in 
England and Wales of which 78% were funded by 
the NHS. The majority of abortions are performed 
before 13 weeks of pregnancy (87%) and by surgical 
methods (86%).2 In 2000, 64 of 194 (33%) units 
with facilities for termination of pregnancy before 
13 weeks provided both medical and surgical 
methods, while among the 130 units with only 
one method available, surgical termination of 
pregnancy was the only option in 79%.3 Prior 
to 14 weeks’ gestation surgical termination can 
be performed by vacuum aspiration (VA). This 
procedure, performed under general anaesthesia, 
has been the ‘method of choice’ since the 1960s; 
VA is currently used in 81% of abortions performed 
prior to 10 weeks’ gestation and 92% of those 
performed at 10–12 weeks.2 The technique is 
safe and efficacious; major complications (uterine 
perforation, pelvic sepsis and haemorrhage 
requiring blood transfusion) occur in 0.2–0.9% of 
cases.2,4,5 However, up to 5% of women return to 
hospital with post-abortion symptoms, of which 
50–65% require surgical evacuation for retained 
products.4,5 Complication rates increase with 
gestation,2,4–6 with incomplete abortion reported 
in up to 12% of cases ≥ 12 weeks.5 Cervical 
preparation with prostaglandins facilitates cervical 
dilatation and reduces complications.7 It is 
recommended, if the woman is under 18 years of 
age or at gestation > 10 weeks, using misoprostol 
400 µg vaginally 3 hours prior to surgery.7
Medical abortion using mifepristone, an anti-
progesterone, and prostaglandins has been 
available since the 1980s. For abortions up to 63 
days’ gestation, evidence suggests that mifepristone 
(200 mg orally) followed 36–48 hours later by 
either gemeprost (1 mg vaginally) or misoprostol 
(800 µg vaginally) are equally safe and effective, 
with 95–97.5% of women achieving complete 
abortion.8–10 Because of much lower costs, 72% of 
units use misoprostol.5 Complete abortion rates 
with single-dose mifepristone/misoprostol fall from 
98.5% at ≤ 49 days to 96.7% at 50–63 days10 but 
are much greater after 63 days.11 For women at 
49–63 days, if abortion has not occurred 4 hours 
after administration of misoprostol, a second dose 
(400 µg vaginally or orally) may be administered.7 
Between 64 and 91 days’ gestation, efficacy is 
increased if the initial dose of misoprostol is 
followed by repeated doses of 400 µg.12 However, 
even using up to a maximum of five further doses, 
the need for surgical evacuation increased from 
0.9% at 9–10 weeks to 7.9% at 12–13 weeks.12
A Cochrane systematic review of medical versus 
surgical methods of first trimester termination 
of pregnancy identified only five relevant trials, 
mostly with small numbers.13 Although the authors 
concluded that prostaglandins alone seemed to be 
less effective than surgical abortion, only one trial 
of mifepristone/prostaglandins was included.14 The 
review suggested there was inadequate evidence 
to comment on the acceptability and side effects 
of medical versus surgical abortions. A partially 
randomised preference trial of medical and surgical 
termination of pregnancy between 10 and 13 weeks 
has subsequently been reported.15 Side effects 
(vomiting, diarrhoea and abdominal pain) were 
higher in the medical group, although there was no 
difference in the rates of major complications up to 
8 weeks.
Available evidence suggests that 17–85% of 
women requesting first-trimester termination of 
pregnancy have a preference for either a medical 
or surgical procedure.13–16 The most common 
reason cited for preferring a medical termination 
of pregnancy is the avoidance of surgery and/or 
anaesthesia.13,17 The large variation in reported 
preference rates may be explained by factors such 
as gestational age, prior experience and time to 
access the procedure.13,16–18 Preference for surgical 
termination of pregnancy appears to increase with 
gestational age;14,15 early in pregnancy women 
appear to perceive the medical procedure as easier 
and more natural while later it is perceived as 
more stressful (related to concerns about pain and DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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seeing the fetus).16–18 If a woman has a preference 
for one method she is unlikely to be enrolled in a 
randomised trial or she may refuse the allocated 
method.17 To represent the full range of service 
users, randomised trials need to include preference 
arms.
Service users’ evaluations of the care they have 
received are clearly important in the context of 
current initiatives to develop a more patient-
centred NHS. Patient satisfaction with their care is 
the most commonly used indicator in research on 
patient evaluations,19 but definitions of satisfaction 
vary, and different measures incorporate different 
dimensions of the construct, such as adequacy, 
suitability and acceptability. A common problem 
with satisfaction measures is that they exhibit 
ceiling effects, i.e. most patients report being 
satisfied, and distinctions between care of different 
quality are often not observed. This is likely to be 
a particular problem in areas such as termination 
of pregnancy, where patients are widely observed 
to experience a sense of relief after the procedure. 
Most studies of women’s views about termination of 
pregnancy have reported procedure acceptability; 
typically women have been asked whether they 
would opt for the same method in the future or 
recommend the method to a friend;13,17,20 data 
from randomised trials indicate that acceptability 
of both methods before 9 weeks gestation is high 
(63–92%), with 2–36% of women randomised to 
surgical termination of pregnancy preferring a 
medical procedure in future and 22–37% of women 
randomised to medical termination of pregnancy 
preferring a surgical termination of pregnancy.13,15 
Where women have a preference for one method, 
typically ≥ 90% would choose the same method in 
the future.14,16–18,20 Acceptability may be lower at 
later gestations; in the only randomised trial of 
abortion methods between 10 and 13 weeks, more 
women opted for VA again than medical abortion 
(79% versus 70% respectively).15 However, response 
rates were low (< 50%). The results reported above 
are based on the ‘single question with a binary 
outcome’ approach to assessing acceptability. Such 
measures are simple to collect and report but 
provide limited information, particularly about 
why respondents hold the views they do. One 
supplementary approach is to ask respondents to 
rate specific features of their care thereby providing 
information about the reasons underlying 
acceptability judgements. Using a semantic 
differential rating scale, Henshaw et al.14 identified 
that in randomised women, medical abortion 
rated lower on six of the bipolar adjectives, with 
pain showing by far the largest difference. Vacuum 
aspiration was also rated less painful in women 
allocated according to preference.
The psychological effects of termination of 
pregnancy have recently been reviewed.21 The 
authors concluded that termination of pregnancy 
rarely causes immediate or lasting negative 
psychological consequences in healthy women. 
Indeed several studies reported positive outcomes 
such as relief.21 Henshaw et al.14 performed 
a partially randomised preference trial of 
termination of pregnancy < 9 weeks and found 
no differences in depression, anxiety or low self-
esteem 2 weeks after the procedure22 nor, in a much 
smaller number, 2 years later.23 Whether medical 
termination of pregnancy is associated with more 
adverse psychological consequences after 9 weeks’ 
gestation is not known.
Although many studies have reported the outcomes 
of first-trimester termination of pregnancy, very 
few have randomised the method of abortion, and 
only one has included women beyond 9 weeks of 
pregnancy, despite the fact this group constitutes 
over 40% of termination of pregnancies.15There is 
a need for a partially randomised preference trial 
comparing VA with current methods of medical 
abortion. In addition to patient acceptability the 
trial needs to determine the clinical and cost 
effectiveness of the two methods.
In 2002 a pilot randomised trial of medical versus 
surgical termination in women at ≥ 9 weeks’ 
gestation was commenced at the Royal Victoria 
Infirmary (RVI)), Newcastle upon Tyne. Women 
not expressing a preference for one method were 
randomised to medical or surgical termination of 
pregnancy. All women were offered follow-up at 2 
weeks post procedure. Due to limited availability of 
the research nurse, recruitment was only possible 
from selected clinics. 
Of 408 women at 9–13 weeks, 284 (70%) were 
suitable and agreed to participate in research, of 
which 139 (49%) were prepared to be randomised 
to medical or surgical termination of pregnancy. 
Outcome data at 2 weeks was obtained in 75 
(53%) and included emergency admission rates, 
psychological scales (Impact of Event Scale, 
Hospital Anxiety and Depression Scale) and 
satisfaction with care. The pilot study information 
has been used to inform recruitment and precision 
calculations for the proposed trial. 
During the pilot study women were divided into 
two gestational age groups: 9–13 weeks and Appendix 2 
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14–20 weeks based on ultrasound. Methods of 
medical and surgical termination of pregnancy 
in the 9–13 week group were identical to those 
proposed in the present application. Psychological 
impact was measured using the Impact of Event 
Scale (IES) and Hospital Anxiety and Depression 
Scale (HADS). Clinical outcome was measured 
using blood loss (as determined by drop in 
haemoglobin), unplanned (emergency) admission 
and symptoms (pain, diarrhoea, vomiting and 
vaginal bleeding). A follow-up visit at the Royal 
Victoria Infirmary was arranged for all women in 
the trial and key outcomes collected at this point by 
clinical enquiry and questionnaire. Updated data 
on recruitment and follow-up (as at March 2004) 
indicated that for the 9–13 week group, data on 
IES at 2 weeks post procedure was available from 
a total of 65% of randomised women. Statistical 
analysis of the psychological and clinical data has 
not been undertaken.
There is some indication that the follow-up 
rate (using clinic visits and selected telephone 
contact) is lower in the surgical arm. This could 
be explained by women undergoing a surgical 
termination of pregnancy feeling less in need of 
reassurance about the termination of pregnancy 
outcome, and therefore being less willing to attend 
the follow-up visit. However, a 95% confidence 
interval for the difference in follow-up rates 
between arms is 2% to 31%, i.e. the data are 
consistent with either a difference of little or of 
real practical importance. Telephone follow-up 
was only used for the latter part of the pilot study, 
and we anticipate that we can obtain key outcome 
data in all arms for a greater proportion of women 
in future by offering a choice by way of place and 
method of follow-up.
There is a clear policy impetus to understand, 
qualitatively, women’s preferences for medical 
or surgical termination of pregnancy and the 
decision-making processes that lead both to 
these preferences and to encounters with health 
services. The personal and political sensitivities 
that surround termination of pregnancy are now 
well established, and have important consequences 
for research in the field. The most important of 
these is resistance to inquiry into decision-making 
and action where this may threaten the moral 
viability of the woman’s decisions. This means 
although termination of pregnancy is one of the 
most common surgical procedures in the UK, 
little work has been done that will contribute to 
robust understanding of preferences for types of 
procedures, and even less qualitative work that has 
investigated this problem. Instead, the objective 
of much research in the field has been aimed at 
understanding decision-making on termination in 
relation to promoting access or reducing delays in 
referral to clinical services. Recently, this approach 
has led to an important qualitative study in the UK. 
In this study, Kumar et al.24,25 have shown that most 
women prefer not to discuss their decision with 
clinicians, but prefer instead to receive information 
and prompt referral. Unease about discussing 
personal aspects of termination has also been 
registered amongst professionals, especially nurses 
and midwives (this may also explain the paucity 
of social science research in the field).26 Factors 
affecting the choice of method of termination 
are already known to be highly complex, and 
organised mainly in relation to social rather than 
clinical factors.27 The problem of decision-making 
and preferences around termination is therefore 
quite unlike any other arena of clinical research, 
especially other areas where approaches to shared 
decision-making have become prominent in recent 
years.28
The personal and professional sensitivities around 
termination of pregnancy require a highly sensitive 
approach to research. In this trial of surgical 
versus medical termination, women’s preferences 
and responses are being intensively investigated 
through measures of experiences of care; strength 
of preference; psychological outcomes; cost-
effectiveness; satisfaction with care; and also by 
clinical measures of morbidity including experience 
of symptoms and emergency admission.
The intensive investigation of women’s experiences 
and preferences within the trial provides a point 
of departure for the qualitative substudy. This 
will draw on data collected within the economic 
substudy of strength of preferences, and is an 
optional final phase of the trial experienced 
by a subgroup of 32 women. Qualitative 
substudies within trials tend to be used either 
as initial (reconnaissance) studies to assist in 
decision-making about instrument design, study 
organisation and recruitment; or as formative 
process evaluations of ongoing work.29 In the 
present study, we intend to take a different tack, 
using the qualitative investigation as a means 
of illuminating women’s responses to (1) the 
experience of participating in the trial, and (2) 
their perspectives on the results of the economic 
study of strength of preference. Directly focusing 
on these topics will provide useful data, but will 
also indirectly open up earlier decision-making 
processes and questions of access to investigation. DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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A key problem in qualitative studies of personally 
sensitive experiences and actions is that of the 
subject being forced to construct an account that 
provides a justification for action in the face of 
anticipated moral judgements by an external 
authority;30 this makes for bias in accounts and 
we have adopted an approach to study design 
and data collection that is explicitly intended to 
move the focus of subjects’ accounts away from 
personal justification towards a wider explanatory 
perspective. We will do this by asking subjects to 
act as lay interpreters of data collected elsewhere 
in the study (refer to conjoint analysis, section 15), 
focusing on the preferences and actions of ‘notional 
others’31 and to use this interpretive function 
as a starting point for their own accounts. This 
approach means that its design and application do 
not risk confounding recruitment and retention of 
subjects, or other data collection, where these are 
already likely to be a challenge.
8 Objectives
This is a non-commercial study to determine the 
acceptability, efficacy and cost of medical versus 
surgical termination of pregnancy.
Primary objectives
To determine the acceptability of medical and 
surgical termination procedures as determined by 
their preferred method for any future TOP.
Secondary objectives
To compare experiences of care, strength of 
preference, psychological impact, efficacy and cost-
effectiveness of surgical versus medical termination.
Qualitative substudy
The aim of the substudy is to better understand 
the foundations of women’s preferences and 
decision-making about method of termination. The 
objectives are:
1.  to identify, describe and understand women’s 
motives for joining the trial and their 
experiences of participation in it
2.  to identify, describe and understand women’s 
personal experiences of seeking termination 
and decision-making about method of 
termination
3.  to identify, describe and understand women’s 
perspectives on data collected on ‘strength of 
preference’ and the model developed from 
conjoint economic analysis.
9 Study design
This is a partially randomised controlled 
preference trial comparing two procedures for 
termination of pregnancy at less than 14 weeks’ 
gestation. Termination can be performed surgically 
(the uterus is evacuated under general anaesthetic) 
or medically (tablets given to procure abortion); 
it is unclear which of these methods is more 
acceptable to women. This design ensures the 
inclusion of women who have a prior procedure 
preference (preference group) and those who do 
not (randomised group), and will therefore reflect 
the population of a normal clinical setting.
Primary outcome measures
The primary outcome variable is acceptability 
of the procedure at 2 weeks after the procedure; 
participants will be asked if they would have the 
same method of termination again.
Secondary outcome measures
A secondary comparison of acceptability of the 
procedure will also be determined at 3 months 
after the procedure. Additional secondary outcome 
variables are strength of preference for the 
procedure, measured after 2 weeks; experiences of 
care, psychological impact, efficacy and satisfaction 
with care, measured at 2 weeks and 3 months after 
the termination procedure.
Further analysis will be performed to explore 
the relationships between willingness to pay, 
satisfaction and acceptability measures.
In order to better understand women’s decisions 
regarding termination of pregnancy the study will 
include a qualitative component. A conceptual 
model of preferences will be developed via conjoint 
analysis in a group of non-pregnant women, and 
then explored via interview in a sample of women 
who have participated in the trial 2 weeks after 
their termination procedure.Appendix 2 
92
Table of events
Visit 1 (baseline) 2 3
Time Up to –2 weeks 0 +2 weeks +3 months
Inclusion/exclusion screening ✗
Written informed consent ✗
Randomisation if applicable ✗
Reason for preference if applicable ✗
Demography ✗
Medical history ✗
Concomitant medication ✗
Ultrasound ✗
Strength of preference ✗ a ✗
Termination procedure ✗
Adverse events ✗ ✗ ✗
Concomitant medication ✗ ✗ ✗
Acceptability ✗ ✗
Satisfaction with care ✗ ✗
Experience of care ✗ ✗
Impact of Event Scale ✗ ✗
Hospital Anxiety and Depression Scale ✗ ✗
Quality of Life (EQ-5D) ✗ ✗
Consent for qualitative substudy ✗
Qualitative interview ✗
a  Only determined prior to procedure in the preference group.
The study involves up to three hospital visits; 
the third visit is currently only part of normal 
care for those patients where it is unclear if 
medical abortion has been complete or who are 
experiencing problems. However, the RCOG has 
recently recommended that all women should be 
offered a follow-up appointment within 2 weeks of 
abortion.7
Alternative methods of collecting the primary 
and secondary outcome data will be discussed at 
baseline to ensure maximum follow-up.
•  The third visit can be performed in a 
community clinic (based within sexual and 
reproductive health services), rather than the 
hospital setting.
•  If participants fail to attend the 2-week follow-
up visit, contact and data collection will be 
attempted by telephone, followed by postal 
questionnaire (with an option to complete 
the questionnaire via the internet). Also if 
agreeable, a final option of text message 
will be used to elicit primary outcome data; 
text messaging may also be used for a visit 
reminder.
•  3-month follow-up data will be collected via 
postal or web-based questionnaire.
From month 10 of recruitment, 32 women (8 from 
each arm) will be invited to join the qualitative 
substudy during the 2-week follow-up visit. A 
convenient time will be arranged by the researcher 
to perform this interview.
Definition of end of study
The end of the study will be the last participant’s 
final study contact, at 3-months follow-up.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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10  Subject population
This is a single-site study and will be conducted at 
the RVI in Newcastle upon Tyne, a busy NHS unit 
which undertakes nearly 1300 terminations a year. 
A total of 2232 women requesting termination of 
pregnancy are required for inclusion into the study.
10.1 Inclusion criteria
•  Women requesting and accepted for 
termination of pregnancy at less than 14 weeks’ 
gestation (as determined by ultrasound).
•  Women under 16 years of age will be 
approached where they are determined to be 
Gillick competent (by the clinical practitioner) 
and where a parent/legal representative is 
present.
•  Ability to give written informed consent.
10.2 Exclusion criteria
•  Pre-existing medical disorder which is an 
indication for either medical or surgical TOP.
•  Non-English-speaking women (apart from 
French, Mandarin, Cantonese, Bengali, Urdu 
and Arabic) due to limited availability of 
interpreters. 
•  Previous participation in this trial. 
•  Current participation in a ‘drug’ related trial.
Substudy
This sample is neither intended to be statistically 
representative nor to be a maximum variation 
sample; sampling will be purposive and sequential. 
Every woman entering the trial in the period after 
10 months recruitment will be invited to join the 
qualitative substudy at 2-week follow-up. We expect 
a high rate of refusal to join this substudy and of 
attrition amongst those who do. This means that 
although inclusion and exclusion criteria will be 
the same as those for the main trial, the sample 
entering the qualitative substudy will be highly 
selected.
11  Subject recruitment
At the time of referral, all women are provided 
with standard hospital information about the 
choices and risks of termination of pregnancy. This 
information leaflet explicitly states that there is no 
medical evidence that one method of termination 
is ‘better’ than the other and research is currently 
being conducted at the RVI to better inform this 
choice. For reasons of confidentiality the study 
information sheet will not be sent to women prior 
to their consultation visit.
The initial consultation at the unit involves 
acceptance for termination and discussion of 
choices and risks. A nurse practitioner will discuss 
the available options and risks of termination, 
and then those women eligible for the study will 
be approached for interest in the study. Interested 
women will then discuss the study in detail with 
a research nurse and discuss their preference 
options. Written study information will be 
provided, along with opportunity for questions and 
time to consider the study. Willing participants will 
sign a consent form along with the research nurse, 
and confirm their decision for randomisation or 
preference for a medical or surgical termination.
For those women less than 16 years of age (minor), 
a parent or legal representative shall also have 
the study explained and have opportunity to ask 
questions. The parent or legal representative will 
provide written consent at the same time as and in 
addition to the minor’s consent. For the purposes 
of this study, a suitable legal representative would 
be a close relative: sibling (age > 16), aunt/uncle or 
grandparent.
Unaccompanied women, or accompanied women 
with unsuitable representatives, of less than 16 
years will not be considered for the study.Appendix 2 
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12  Study interventions
12.1 General information
Termination of pregnancy (TOP) is the commonest 
gynaecological procedure. It can be performed 
surgically or medically as described in section 1 
(Background).
Vaginal bleeding and mild abdominal pain are 
normal post surgical and medical procedure. 
Nausea, vomiting and diarrhoea may also be 
experienced. There is also a risk of infection. 
Pain relief and antibiotics are provided as part of 
normal care.7 Occasionally abortion is incomplete 
and surgical evacuation is required. Major 
complications of surgical termination are rare, 
but include uterine perforation, pelvic sepsis and 
haemorrhage.
Misoprostol is widely used in the UK to induce 
medical abortion and in cervical preparation 
for surgical termination, even though this is an 
unlicensed indication. Therefore for the purposes 
of this study misoprostol will be treated as an 
investigational medicinal product (IMP).
The Summary of Product Characteristics for 
mifepristone is included in Appendix A. This will 
be prescribed and administered as per normal 
practice.
12.2 Use within the study
Misoprostol will be presented as 200-µg tablets, 
packaged and labelled as an IMP.
Surgical termination
Women will be admitted to the Surgical Day Unit 
where they will receive misoprostol 400 µg vaginally 
3 hours prior to the estimated time of surgery.7 
Following induction of general anaesthesia and 
mechanical dilatation of the cervix, the uterus 
will be evacuated using vacuum aspiration with 
a 9–12 mm curette. In the absence of excessive 
bleeding or other problems, women will be 
discharged 1–2 hours after the procedure.
In line with RCOG recommendations,7 surgical 
termination will only be performed after 6 weeks’ 
gestation because of the high failure rate (relative 
risk 2.9) at very early gestations. The appointment 
for surgical termination will be timed in line with 
this recommendation.
Medical termination
At an initial appointment participants will be given 
mifepristone 200 mg orally on the gynaecological 
ward by the nursing staff. After 36–48 hours, they 
will be admitted to the gynaecological ward where 
they will receive misoprostol 800 µg vaginally at 
approximately 8.30 a.m. Following administration 
of misoprostol, participants will receive oral 
paracetamol (500 mg) plus dihydrocodeine (10 mg) 
or diclofenac (75 mg), or parental diamorphine 
(5 mg) as required and as per normal practice. 
At the time of the termination participants will 
receive rectal metronidazole (1 g), followed by oral 
doxycycline (200 mg) daily for 7 days, commencing 
on the day of the termination. In the absence of 
excessive bleeding, participants will be discharged 
1–2 hours after passage of the uterine contents.
Subsequent management will depend on gestation 
period.
Less than 9 weeks
•  If the contents of the uterus have not 
been passed 4 hours after misoprostol 
administration, a second dose of misoprostol 
(400 µg) will be administered vaginally or orally 
(depending on preference and amount of 
bleeding).7
•  Subsequently, if abortion does not occur 
and bleeding is not excessive, women will be 
routinely discharged between 4.30 and 5.00 
p.m. The abortion occurs at home and women 
return for follow-up after 2 weeks.
9–13 weeks
•  If the contents of the uterus have not 
been passed 3 hours after misoprostol 
adminstration, further doses of misoprostol 
(400 µg) will be given vaginally (or orally if 
bleeding is heavy) at 3-hour intervals up to a 
maximum of four further doses.7
•  If the contents are still not passed, an 
ultrasound scan will be performed. In 
cases of an ongoing pregnancy, missed or 
incomplete abortion, surgical evacuation will be 
performed.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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13  Randomisation
Participants with a procedure preference will 
decide whether to opt for a medical or surgical 
termination. Participants with no preference, and 
willing to be allocated a procedure at random, 
will be randomised using a computer system with 
web-based access for trial personnel (PowerTrial). 
Randomisation will be stratified according to 
gestation (< 9 weeks and between 9 and 13 weeks) 
and for previous termination of pregnancy.
14  Study data
14.1 Data collection
Baseline demographic data, including medical 
history and method of any previous termination, 
education level, occupation and income, will be 
collected by the nurse practitioner or research 
nurse for all participants. Contact details (including 
where possible mobile phone numbers) and 
availability will also be collected.
Those expressing a procedure preference at 
baseline will be asked to nominate one or more 
reasons from a list of eight, developed as part of 
the pilot trial.
1.  General anaesthetic (GA): want to be asleep 
(PS).
2.  Fear of GA or desire to be awake and in control 
(PM).
3.  Fetus: do not want to see fetus (PS).
4.  Pain: perceived medical as more painful (PS).
5.  Visits to hospital: wanted minimum (PS).
6.  Duration of procedure: less time in hospital 
(PS).
7.  Previous experience (i.e. had prior TOP): PM 
or PS.
8.  Other (< 5% of responses).
All participants will be invited to return for 
an outpatient (hospital or community clinic) 
assessment 2 weeks after the procedure. Outcome 
data will be collected at 2 weeks (by interview and 
questionnaire) and at 3 months (by questionnaire) 
after the procedure. For women who do not attend 
their visit for 2-week follow-up, collection of 
outcome data will be attempted where previously 
agreed via telephone interview, mobile text 
message and postal or web-based questionnaire. All 
visits and telephone interviews will be conducted by 
a research nurse.
Acceptability
This will be determined at 2 weeks and 3 months 
after the procedure by responses to the closed 
question ‘If you ever have another termination of 
pregnancy, would you opt for the same method?’ 
This simple question has been used in previous 
preference trials of TOP14,15 and can, if necessary, 
be easily determined by phone or text message.
Strength of preference
To measure women’s strength of preference for 
medical or surgical termination we will measure 
willingness to pay. This technique is being 
increasingly used in health technology assessment32 
and has been used previously for assessing strength 
of preference for abortion method.23,33 Interviews 
will be conducted, using the payment card 
method,34 in all women in the preference arm prior 
to the procedure where they will be asked to state 
their maximum ‘willingness to pay’ amount for the 
termination method they have chosen. Interviews 
will also be conducted on all women in both the 
randomised and preference arms at 2 weeks after 
the procedure when they will be asked to state their 
maximum ‘willingness to pay’ amount to receive 
their preferred option at a future date. The validity 
of women’s responses will be tested by examining 
the correlation between stated ‘willingness to pay’ 
and level of income.
Satisfaction with care
The methodological pitfalls of measuring 
satisfaction with care have been reviewed recently.35 
Women will be asked to rate the quality of care 
during the termination and the counselling and 
support afterwards using a 5-point Likert scale 
(from excellent to poor) at 2 weeks and 3 months 
after the procedure. Measures in which patients 
are asked to rate the quality of aspects of their care 
show greater response variability than measures 
which seek direct ratings of satisfaction36 and are 
better predictors of whether patients will return 
to the same doctor in the future.36 For analysis 
we will distinguish those who rate their care as 
excellent from the remainder as this provides 
better discrimination.37 A similar assessment has 
been used in our pilot trial. Ratings of care will be 
supplemented by information on satisfaction with 
care from the qualitative study.
Experience of care
To provide information about the reasons 
underlying acceptability judgements, we will use a 
semantic differential rating technique administered 
at 2 weeks and 3 months post procedure. This 
instrument uses a pair of opposite adjectives (for 
example, ‘painless–painful’) as end points on 
a graphic Likert scale. Women will be asked to 
indicate their experience by placing a mark on Appendix 2 
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the scale. Twelve bipolar adjectives will be used, 
scored along an evaluation dimension representing 
a positive or negative attitude ranging from 3 to 
–3. Rating scores are quick and easy to complete 
and have been used previously to measure attitude 
towards termination of pregnancy.14,38
We plan to undertake a further analysis to explore 
the relationships between willingness to pay, 
satisfaction and acceptability measures. 
Distress, anxiety and depression
Distress will be measured using the IES at 2 weeks 
and 3 months after the procedure. This 15-item 
scale measures subjective distress to a specific event 
(in this case termination of pregnancy)39 and is 
the most likely to pick up a difference in actual 
experience of having one procedure rather than 
another. Two subscales measure intrusion and 
avoidance and both are likely to arise differently 
from the procedures under comparison. Anxiety 
and depression will be measured using the HADS 
at 2 weeks and 3 months after the procedure. This 
is a widely used 14-item self-report scale designed 
for medical patients.40 Depression is the main 
problem service providers have been concerned 
about.21 Both the IES and HADS have been used in 
women after termination of pregnancy21–23 and in 
our pilot study. 
Quality of Life (EQ-5D)
This is a six-itemed validated questionnaire 
developed by a European committee to provide a 
preference-based measure of quality of life, needed 
for the economic evaluation.41
Emergency admission
Efficacy will be determined by comparing the 
rates of emergency admission (on the day of the 
procedure or after discharge) at 2 weeks and 3 
months after the procedure. All women will be 
questioned about adverse events at the 2-week 
and 3-month follow-up to ensure that data are 
also captured for admissions or visits to another 
hospital or their GP. The rationale for choosing this 
outcome is that it is likely to include all women with 
significant procedure-related morbidity due to (1) 
incomplete abortion, missed abortion or ongoing 
pregnancy (all of which require surgical evacuation) 
and (2) pelvic infection without retained products 
of conception. Further there is evidence to suggest 
that women experiencing a failed termination 
(requiring surgical evacuation) or excessive pain 
and/or bleeding (resulting in admission) are more 
likely to classify the experience as unsatisfactory42 
and to opt not to have the same procedure again in 
the future.20,42
Frequency and extent of symptoms
The incidence of nausea, vomiting, diarrhoea, 
dizziness and abdominal pain on the day of the 
procedure will be recorded as well as an assessment 
of the severity of pain (using a 10-cm visual 
analogue scale) and analgesic use. Symptoms after 
discharge will be ascertained at the 2-week follow-
up visit by the research nurse. Specifically the 
duration and severity of vaginal bleeding and pain 
as well as the length of time taken off work and to 
return to normal activity will be recorded.15
Concomitant medications will be recorded at 
baseline and at the time of the termination 
procedure by abstraction from the medical 
notes. Women will be asked about concomitant 
medications at 2-week follow-up.
Substudy
Semi-structured interviews: 32 participants will 
be invited to take part in one semi-structured 
interview with a trained interviewer. The highly 
selected nature of the sample, and the topic 
sensitivity, mean that decision-making and 
experiences of termination will be their indirect 
rather than direct focus. Interviews will be of up to 
90 minutes duration and will be divided into two 
discrete sections.
In part 1 women will be asked about general issues 
connected with their experience of entering and 
participating in the trial, and their understanding 
of its design and methods. This part of the 
interview will indirectly elicit accounts of their 
experience of referral pathways into the service 
and trial, specific accounts of their experiences of 
termination, and its outcome. 
In part 2 the interviewer will describe and 
demonstrate outcomes of a conjoint analysis (refer 
to section 15) using structured questions and 
flashcards. Subjects will be invited to comment on 
the model derived from conjoint analysis from the 
perspective of a ‘notional other’,31 and will also be 
asked about the ‘fit’ between the ‘willingness to pay’ 
model and their own experiences.
With the consent of the participant, each interview 
will be audio-recorded using an unobtrusive 
mini-disk recorder and conference microphone, 
and later transcribed. Where participants do not 
consent to recording, handwritten notes will be 
made.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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14.2 Data handling
Study data collected will be entered directly, where 
possible, to avoid transcription errors, into a 
web-based PowerTrial data capture system by the 
research nurse, or participant for the web-based 
questionnaires. The remaining study data will be 
entered from paper source. Audit trail and full 
daily back-up will be provided.
Data will be collected to standards required by CFR 
Title 21, part 11, and EU Directive 2001/20/EC, 
and adhere to the Data Protection Act 1998.
The quality and retention of study data will be the 
responsibility of the Newcastle Clinical Trials Unit. 
All study data will be archived in line with current 
University policy (currently 12 years).
15  Statistical considerations
15.1 Statistical analysis
The analysis strategy will be similar to that used in 
a partially randomised preference trial of treatment 
for depression.43 The trial will contain four 
intervention groups: 
1. randomised to medical termination (RM)
2. randomised to surgical termination (RS)
3. preference for medical termination (PM)
4. preference for surgical termination (PS).
The analysis will be on an intention-to-treat basis 
(although it is anticipated that women will always 
get the randomised or preferred intervention). 
Those in either medical arm (RM or PM) who 
subsequently receive surgical intervention, due to 
incomplete or missed abortion, will be analysed as 
per the assigned medical arm.
Baseline variables: although randomisation should 
balance out baseline characteristics, it will be 
important to compare these in the four groups to 
see if those who are prepared to be randomised 
differ from those who have a preference. If 
so, there are problems in extrapolating any 
conclusions from the randomised arms to the 
general population.
Primary analysis
Main comparison of randomised arms
1.  Comparison of proportions of women finding 
the procedure acceptable. We will also 
investigate the interaction between past history 
of TOP and intervention group on acceptability 
and gestational age (as a continuous variable) 
and intervention group on acceptability.
2.  Comparison of mean values on psychological 
and rating scales.
3.  Comparison of proportions of women rating 
care as ‘excellent’.
4.  Comparison of WTP between those women in 
the two randomised groups.
Secondary analysis
Secondary comparison of medical and surgical arms 
(preference and randomised subgroups combined)
1.  Comparison of proportions of women finding 
the procedure acceptable and rating the 
quality of care as ‘excellent’: the comparison 
will adjust for key baseline variables using 
logistic regression. We will also investigate 
the interaction between past history of TOP 
and intervention group on acceptability, and 
gestational age (as a continuous variable) and 
intervention group on acceptability.
2.  Comparison of mean values of psychological 
and rating scales: the comparison will adjust 
for key baseline variables using multiple 
regression.
3.  Comparison of proportions of women 
with emergency admission and particular 
symptoms: the comparison will adjust for key 
baseline variables using logistic regression.
4.  Comparison of WTP between those women in 
the combined groups.
Tertiary comparison of combined preference and 
randomised groups
The aim of this comparison is to determine if 
receiving a preferred intervention improves key 
outcomes. Comparisons will be of acceptability, 
psychological and rating scales with methods as for 
secondary comparisons.
Cost-effectiveness analysis
Cost data relating NHS resource use (in both 
primary and secondary care) will be collected 
following established methods44 up to 3 months 
post termination for both surgical and medical 
interventions. This will include data relating to 
the initial procedure, hospital stay, follow-up 
care as inpatients, any additional interventions 
and outpatient appointments. Data relating to 
GP consultations specifically for follow-up care 
relating to the TOP will be collected using the 
postal questionnaire at 3 months and, if agreed 
previously, by telephone where this is not returned. 
Data relating to secondary and primary follow-up 
care and any interventions required will be used to 
compare the burden placed on the patient’s own 
resources when using either medical or surgical 
termination. The cost-effectiveness analysis will be Appendix 2 
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expressed as the cost per successfully completed 
termination. Extensive one-way and multivariate 
sensitivity analysis will be undertaken in the 
analysis of the final results.45
Clinical effectiveness analysis
Previous studies have used a variety of measures of 
clinical effectiveness but emphasis has been placed 
on failed TOP (with an ongoing viable pregnancy), 
incomplete abortion and presumed pelvic 
infection. Based on our proposed sample size, the 
precision with which we could detect differences 
in each of these complications is limited. Hence 
we have opted to use a combined measure of 
effectiveness which captures unplanned time spent 
in hospital, a key outcome for women.
Our definition of ‘emergency admission’ includes:
1.  unplanned overnight stay on the day of 
termination
2.  emergency hospital assessment or admission 
after discharge.
All cases of incomplete abortion, missed abortion, 
ongoing pregnancy (all of which require surgical 
evacuation) and pelvic infection without retained 
products of conception will therefore be included in 
this outcome. A very small number of women may 
be admitted to other units but we would anticipate 
collecting clinical outcome data from their hospital 
discharge summary and/or via our follow-up.
Qualitative substudy
Conjoint analysis or discrete choice experiment
In order to identify the key factors that shape 
women’s preferences for termination services 
we will conduct a discrete choice experiment 
(DCE). This technique measures the strength of 
individual’s preferences for the various attributes of 
a clinical intervention46 and has been successfully 
used in research relating to the provision of services 
for women.47 Interviews will be conducted with 
a sample of 100 non-pregnant women recruited 
from local contraception/sexual health clinics. 
Women will first be asked if they are interested 
in participating in a research interview, before 
provision of an information sheet, an informed 
discussion and written consent. These interviews 
will begin prior to recruitment for the main study. 
Previous research suggests this sample size should 
be adequate to provide precise parameter estimates 
with the number of attributes and choices we will 
use.48 This sampling frame has been chosen to 
reduce the data collection burden on the trial 
sample and to avoid interference with women in 
the trial forming and stating preferences.
Qualitative analysis
We will use a model of preference developed 
from the discrete choice experiment as the basis 
for a semi-structured interview with 32 women (8 
from each of the four groups: preference surgical, 
preference medical, randomised surgical and 
randomised medical). A conventional model of 
qualitative analysis will be used.49 The analytic 
product of this work will be (1) a comparative 
model of preferences and their normative 
constraints and (2) a model of contextual features 
that affect decision-making about termination of 
pregnancy.
Interview transcripts will form the formal data 
for analysis. Following the conventional model of 
constant comparative analysis of transcribed data 
set,49 transcripts will be interpreted iteratively, 
developing themes (or categories) within 
respondents’ discourse. To facilitate qualitative 
analysis, and to provide an audit trail for 
governance purposes, we will use QSR software to 
manage data transcripts, coding and memoing. 
Initial thematic analysis will be conducted by 
the qualitative researcher. Transcripts will be 
searched for common themes and deviant cases 
(in relation to part 1 of the interview). Themes will 
be indexed (as ‘codes’) and searches for discrete 
instances of codeable items of speech will be 
undertaken in both cumulative comparisons (i.e. 
between interviews in the same arm of the trial) 
and condition comparisons (i.e. across interviews 
gathered from different arms of the trial). This 
will provide a robust account of the common 
themes relating to women’s responses of joining 
and participating in the trial, and these themes 
(and deviant cases) will be recorded in a simple 
frame.50 Because part 2 of each interview will 
involve some structured questions (and flashcards 
showing simple histograms of quantitative data), 
direct thematic comparisons will be made across a 
range of responses, and some simple quantification 
of results will also be possible. Once initial analysis 
has been undertaken by the qualitative researcher, 
qualitative inter-rater checking will be undertaken 
on a sample of cumulative and condition 
comparisons. This will add value to analysis51 and 
will enable secure claims about the quality of data 
to be made.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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15.2 Sample size calculation
The power of the study is based on the main 
comparison of acceptability between women 
randomised to medical or surgical TOP. Assuming 
the acceptability of medical termination to be 
75%, we would need responses from 335 women 
in each randomised arm to detect a difference in 
acceptability of 10% (i.e. from 75% to 85%) with 
a significance level of 5% and power of 90%. We 
believe this difference in the level of acceptability 
is important for both consumers and providers; a 
similar difference was employed by Ashok et al.15 
in their large randomised comparison of abortion 
methods.
Based on the power calculation we need primary 
outcome data on 670 women randomised to 
medical or surgical TOP at < 14 weeks’ gestation. 
In order to achieve this number we calculated:
1.  1116 women need to be randomised (assuming 
40% of women randomised fail to attend 
for follow-up and primary outcome data are 
therefore not available)
2.  2232 women need to be recruited (assuming 
50% of women agreeing to participate in 
the study have a preference for medical or 
surgical TOP and are therefore not suitable for 
randomisation)
3.  3188 women need to be approached (assuming 
30% of women accepted for TOP will decline 
involvement in the study).
Justification for assumptions
All three assumptions were based on our 
experience from an earlier pilot trial conducted 
at the RVI involving women requesting TOP at 
9–13 weeks’ gestation. For reasons detailed in 
Kumar et al.25 we believe our assumption of 60% 
follow-up is conservative. Further, previous trials 
conducted in the UK have reported that 54%14 
and 82%15 of recruited women undergoing TOP 
at < 9 weeks and 9–13 weeks respectively were 
prepared to have their method of TOP determined 
by randomisation. Thus our estimate of 50% may 
also be conservative. The proportions of women 
accepted for TOP who agreed to join these two 
randomised preference trials were not reported. 
Data from non-randomised studies conducted 
in the UK suggest 87–93% of similar women are 
prepared to participate in studies involving follow-
up (including psychological questionnaires) after 
TOP, suggesting our assumption of 70% (based on 
the pilot study) is realistic.
16  Compliance and withdrawal
In order to increase the proportion of participants 
returning for follow-up after 2 weeks, an option to 
attend a community clinic has been incorporated 
in the design, thus allowing ease of access and 
evening appointments.
A range of contact processes are also included to 
maximise capture of primary and secondary data 
where participants fail to attend the 2-week follow-
up visit. These include telephone contact (up to 
two attempts) for all participants to capture the 
primary variable, and postal questionnaires or a 
web-based questionnaire option. For agreeable 
participants text messaging will be used for a visit 
reminder at week 2 and collection of the primary 
variable (up to two attempts).
Following reasonable attempts to capture data 
and non-response, participants will be considered 
lost to follow-up. Participants who withdraw 
their consent following the procedure will not be 
replaced.
17  Data monitoring
17.1 Discontinuation rules
The trial may be prematurely discontinued on 
the basis of new safety information, or for other 
reasons given by the Trial Steering Committee (see 
below), regulatory authority or ethics committee 
concerned.
17.2 Monitoring, quality control and 
assurance
The trial will be managed through the Clinical 
Trials Unit (CTU), University of Newcastle in 
accordance with the EU Trials Directive, the 
Research Governance Framework for Health 
and Social Care and MRC Guidelines for Good 
Clinical Practice in Clinical Trials. Professor S. 
Robson will have overall responsibility for the 
day-to-day conduct of the trial supported by the 
nurse coordinator, CTU Trial Manager and Trial 
Management group (TMG). The TMG will include 
the principal investigators, co-applicants and nurse 
representation.
The Trial Steering Committee (TSC) will be 
chaired by Professor Alan Templeton, University 
of Aberdeen, to include two other independent 
members and two lay members. It is proposed the 
TSC will meet twice during the first year of the 
trial and then annually. Their role is to monitor 
and supervise the trial, to ensure it is conducted to Appendix 2 
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high standards in accordance with the protocol, the 
principles of GCP, and with regard to patient safety.
The Trial Manager will ensure that the study 
is conducted in accordance with GCP through 
a combination of central monitoring and site 
monitoring visits.
Central monitoring
•  All documentation essential for study initiation 
will be reviewed prior to site authorisation.
Site monitoring
•  Consent forms will be reviewed as part of the 
study file and the presence of a copy in medical 
records confirmed.
•  Consent forms will be compared against the 
study participant identification list.
•  Inclusion/exclusion criteria will be reviewed for 
20% of participants.
•  Serious adverse events will be verified against 
medical records.
•  The presence of essential documents in the 
study file will be checked.
•  Management of the IMP will be reviewed 
periodically.
All monitoring findings will be reported and 
followed up with the appropriate persons in a 
timely manner. A final site visit will be performed 
at the end of the study:
•  to complete final monitoring requirements, as 
above
•  to review archiving of study site documentation.
18  Pharmacovigilance
18.1 Definitions
An ‘adverse event’ (AE) is any untoward medical 
occurrence which does not necessarily have a causal 
relationship with the treatment.
A ‘serious adverse event’ (SAE) is any untoward 
medical occurrence or effect that at any dose:
•  results in death
•  is life-threatening
•  requires hospitalisation or prolongation of 
existing inpatients’ hospitalisation
•  results in persistent or significant disability or 
incapacity.
‘Life-threatening’ in the definition of a serious 
adverse event or serious adverse reaction refers to 
an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event 
which hypothetically might have caused death if it 
were more severe.
Medical judgement should be exercised in deciding 
whether an adverse event or reaction is serious 
in other situations. Important adverse events or 
reactions that are not immediately life-threatening 
or do not result in death or hospitalisation but may 
jeopardise the subject or may require intervention 
to prevent one of the other outcomes listed in the 
definition above, should also be considered serious.
An ‘adverse reaction’ is an untoward or unintended 
response to an investigational medicinal product 
(IMP) related to any dose administered.
A ‘suspected unexpected serious adverse reaction’ 
(SUSAR) is a severe adverse reaction, the nature of 
which is not consistent with the applicable product 
information.
18.2 Expected adverse reactions
18.2.1 Expected side effects of the 
termination procedure
Some degree of abdominal pain and vaginal 
bleeding is expected during and after a medical 
or surgical termination of pregnancy. Major 
complications are uterine perforation, pelvic sepsis 
and haemorrhage (requiring blood transfusion).
18.2.2 Expected adverse reactions to 
misoprostol
Misoprostol may cause diarrhoea, abdominal 
pain, nausea, vomiting, headache, dizziness and, 
more rarely, chills and fever. Uterine bleeding, 
sometimes heavy and prolonged, may occur. Very 
frequent uterine contractions are observed in the 
hours following prostaglandin intake.
18.2.3 Expected adverse reactions to 
mifepristone
Refer to Appendix A, Summary of Product 
Characteristics.
18.3 Protocol specifications
For the purposes of this protocol all non-serious 
adverse drug reactions and serious adverse events 
will be recorded.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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The incidence of nausea, vomiting, diarrhoea, 
dizziness, abdominal pain and bleeding will be 
recorded following explicit questioning; all other 
adverse drug reactions will be recorded as AEs.
The following are expected serious adverse events 
which are being explicitly recorded during the 
study: emergency admissions for incomplete 
abortion, missed abortion, or ongoing pregnancy 
(all of which require surgical evacuation) and pelvic 
infection without retained products of conception. 
These events will not be considered SAEs for 
reporting purposes, as described below.
18.4  Reporting serious adverse events
All SAEs, as specified by the protocol above, shall 
be reported to the Newcastle CTU immediately by 
fax or email.
The initial report must contain the following 
minimum information:
1.  study identifier
2.  subject’s unique study number
3.  age
4.  event description
5.  start date of event
6.  reason for seriousness, i.e. death, life-
threatening, hospitalisation, disability/
incapacity or other
7.  date of termination procedure
8.  causality to procedure (medical or surgical) or 
mifepristone or misoprostol
9.  reporter’s name and date.
The follow-up report must contain all of the above, 
plus:
1.  gender
2.  stop date of event
3.  mifepristone and misoprostol (dose, route, 
duration dates)
4.  concomitant medication (name, dose, route, 
duration dates, indication)
5.  outcome, including diagnosis
6.  reporter’s name and date.
The CTU must report all SAEs which are also 
unexpected adverse drug reactions to the 
regulatory authority and ethics committee 
concerned within 15 days (7 days if life-threatening 
or resulting in death). Therefore it is very 
important that the initial report is faxed or emailed 
to the CTU within 24 hours of discovery.
19  Ethical considerations
Prior to commencement of the trial, a Clinical Trial 
Authorisation will be obtained from the MHRA 
and favourable opinions will be sought from the 
Research Ethics Committee and Trust R&D.
Information sheets will be provided to all eligible 
subjects and written informed consent obtained 
prior to any study procedures.
Non-English-speaking subjects will be included 
where possible: as part of the NHS service 
interpreters are provided at the initial consultation; 
and translation of the information sheet will be 
provided in six additional languages (choice of 
languages based on demand for translation services 
at the RVI).
20  Finance and insurance
The NHS Trust has liability for clinical negligence 
that harms individuals toward whom they have a 
duty of care. NHS Indemnity covers NHS staff and 
medical academic staff with honorary contracts 
conducting the trial.
The NIHR Health Technology Assessment 
programme is funding this study. The Newcastle 
Primary Care Trust are providing additional funds 
to support the community clinics used for follow-up 
visits.
21  Study reporting
Results of the study will be reported to the HTA, 
and be available on their web site. Participants may 
have access to the results on request.
All data collected during the study, and any 
intellectual property arising from the use of those 
data, shall be owned by the University of Newcastle.Appendix 2 
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Appendix A: Mifepristone, summary of product characteristics
Exelgyn Laboratoires 
 
6 Rue Christophe Colomb 
75008 Paris 
France 
 
Telephone:   +44 (0)1491 642 137 
Facsimile:   +44 (0)1491 642 137 
Medical Information direct line:  
+44 (0)800 7316 120 
Freephone 
Medical Information e-mail:   exelgyn.uk@btinternet.com 
Medical Information facsimile:   +44 (0)800 7316 120 
 
 
Document last updated on the eMC: Tue 04 December 2001 
Mifegyne  
 
1. NAME OF THE MEDICINAL PRODUCT   
  Mifegyne    
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION   
  Each tablet contains: Active Ingredient – Mifepristone 200mg    
 
3. PHARMACEUTICAL FORM   
  Light yellow, cylindrical, bi-convex tablets    
 
4. CLINICAL PARTICULARS   
 
  4.1 Therapeutic indications    
 
(1) Medical termination of intra uterine pregnancy of up to 63 days gestation.  
(2) Softening and dilatation of the cervix uteri prior to mechanical cervical dilatation 
for pregnancy termination.  
(3) For use in combination with gemeprost for termination of pregnancy between 13 
and 24 weeks gestation.  
(4) Labour induction in fetal death in utero  
For termination of pregnancy mifepristone may only be administered in 
accordance with the Abortion Act 1967 as amended by The Human 
Fertilisation and Embryology Act 1990.  
As a consequence, when used for termination of pregnancy, mifepristone and any 
treatment necessary to effect complete termination of the pregnancy can only be 
prescribed by a medical doctor and administered in a NHS or non NHS hospital or 
centre (having approval to undertake termination of pregnancy). The product will 
 DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Fertilisation and Embryology Act 1990.  
As a consequence, when used for termination of pregnancy, mifepristone and any 
treatment necessary to effect complete termination of the pregnancy can only be 
prescribed by a medical doctor and administered in a NHS or non NHS hospital or 
centre (having approval to undertake termination of pregnancy). The product will 
be administered under the supervision of a medical practitioner.  
 
  4.2 Posology and method of administration    
 
(1) Therapeutic termination of pregnancy of up to 63 days gestation.  
600mg of mifepristone (3x200mg tablets) by mouth in a single dose. The dosage is 
independent of body weight.  
Unless abortion has already been completed, gemeprost 1.0mg p.v should be given 36 – 48 hour 
later in the treatment centre.  
(2) Softening and dilatation of the cervix 
600mg mifepristone by mouth 36-48 hours prior to the planned operative 
procedure.  
(3) For use in combination with gemeprost for termination of pregnancy 
between 13 – 24 weeks gestation  
600mg mifepristone (3x200mg tablets) is taken by mouth 36-48 prior to scheduled 
prostaglandin termination of pregnancy  
The patient must return to the treatment centre 36-48 hours later, the 
recommended procedure for therapeutic termination of pregnancy with gemeprost 
must then be followed. See gemeprost SPC  
(4) Labour induction for fetal death in utero  
600 mg of mifepristone (200mg x 3 tablets) in a single oral daily dose for two 
consecutive days.  
Labour should be induced by the usual methods if it has not started within 72 hours 
following the first administration of mifepristone.  
If the patient vomits shortly after administration of the mifepristone she should 
inform the doctor.  
 
 
  4.3 Contraindications    
 
Suspected ectopic pregnancy  
Pregnancy not confirmed by ultrasound scan or biological tests  
Chronic adrenal failure  
Severe Asthma not controlled by therapy  
 Appendix 2 
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Known allergy to mifepristone or any component of the product  
Inherited porphyria  
If gemeprost is used, any contraindication to gemeprost (see gemeprost product 
information).  
 
  4.4 Special warnings and special precautions for use    
WARNINGS 
In the absence of specific studies, mifepristone is not recommended in patients with:  
Renal failure, hepatic failure or malnutrition.  
Patients with prosthetic heart valves or who have had one previous episode of infective 
endocarditis should receive chemoprophylaxis according to the current UK recommendations.  
1 ) Medical termination of pregnancy of up to 63 days gestation 
The method requires active involvement of the woman who should be informed of 
the requirements of the methods:  
- the necessity to combine treatment with prostaglandin to be administered at a 
second visit.  
- The need for a follow up visit within 10 to 14 days after intake of mifepristone to 
check that abortion is complete.  
- The possibility of failure of the method which may require termination by another 
method.  
In the case of a pregnancy occurring with an intra-uterine device in situ, this device 
must be removed before administration of mifepristone.  
The expulsion may take place before prostaglandin administration (in about 3% of 
cases). This does not preclude the follow up visit to check that the abortion is 
complete.     
-Risks related to the method 
- Failures  
The non-negligible risk of failure, makes the follow up visit mandatory to check that 
abortion is complete.  
- Bleeding  
The patient must be informed of the occurrence of prolonged vaginal bleeding (up 
to 12 days after intake of mifepristone) which may be heavy. Bleeding occurs in 
almost all cases and it not in any way proof of complete expulsion.  
The patient should receive precise instructions on whom she should contact and 
where to go in the event of any problems, particularly in the case of very heavy 
vaginal bleeding.  
A follow-up visit must take place within a period of 10 to 14 days after DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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administration of mifepristone to verify by the appropriate means (clinical 
examination, ultrasound scan, and Beta-HCG measurement) that expulsion has 
been completed and that vaginal bleeding has stopped or substantially reduced. In 
case of persistent bleeding beyond the control visit, its disappearance should be 
checked within a few days.  
If continuing pregnancy is suspected, a further ultrasound scan may be required to 
evaluate its viability.  
Persistence of vaginal bleeding at this point could signify incomplete abortion, or an 
unnoticed extra-uterine pregnancy, and appropriate treatment should be 
considered.  
In the event of continuing pregnancy diagnosed after the control visit, termination 
by another method will be proposed to the woman.  
Since heavy bleeding requiring hemostatic curettage occurs in 0 to 1.4% of the 
cases during the medical method of pregnancy termination, special care should be 
given to patients with hemostatic disorders with hypocoagulability, or with anemia. 
The decision to use the medical or the surgical method should be decided with 
specialised consultants according to the type of hemostatic disorder and the level of 
anaemia. 
2 ) Softening and dilatation of the cervix uteri prior to surgical pregnancy 
termination  
For the full efficacy of therapy, the use of Mifepristone must be followed 36 to 48 
hours later and not beyond, by surgical termination.  
-Risks related to the method 
- Bleeding  
The woman will be informed of the risk of vaginal bleeding which may be heavy, 
following intake of mifepristone. She should be informed of the risk of abortion prior 
to surgery (although minimal): she will be informed on where to go in order to 
check for the completeness of expulsion, or in any case of emergency.  
Other risks 
They are those of the surgical procedure.  
3 ) For use with gemeprost for termination of pregnancy between 13 – 24 
weeks. 
For the full efficacy of therapy, Mifepristone must be followed, 36 to 48 hours later 
by initiation of gemeprost.  
-Risks related to the method 
- Bleeding  
The woman will be informed of the risk of vaginal bleeding following intake of 
mifepristone. She should be informed of the risk of abortion prior to administration 
of gemeprost (although minimal): she will be informed on where to go in case of Appendix 2 
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emergency.  
Other risks 
They are those of gemeprost administration.  
A follow-up visit is recommended at an appropriate interval after delivery of the 
fetus to verify that vaginal bleeding has stopped or has substantially reduced. 
Persistence of vaginal bleeding could signify incomplete abortion and appropriate 
investigation/treatment should be considered.  
4 ) In all instances 
The use of mifepristone requires rhesus determination and hence the prevention of 
rhesus allo-immunisation as well as other general measures taken usually during 
any termination of pregnancy.  
During clinical trials, pregnancies occurred between embryo expulsion and the 
resumption of menses.  
To avoid potential exposure of a subsequent pregnancy to mifepristone, it is 
recommended that conception be avoided during the next menstrual cycle. Reliable 
contraceptive precautions should therefore commence as early as possible after 
mifepristone administration.  
PRECAUTIONS 
1 ) In all instances 
In case of suspected acute adrenal failure, dexamethasone administration is 
recommended. 1 mg of dexamethasone antagonises a dose of 400 mg of 
mifepristone.  
Due to the antiglucocorticoid activity of mifepristone, the efficacy of long-term 
corticosteroid therapy, including inhaled corticosteroids in asthmatic patients, may 
be decreased during the 3 to 4 days following intake of mifepristone. Therapy 
should be adjusted.  
A decrease of the efficacy of the method can theoretically occur due to the 
antiprostaglandin properties of non-steroidal anti-inflammatory drugs (NSAIDs) 
including aspirin (acetyl salicylic acid). Use non-NSAI analgesics.  
2 ) Medical termination of intra-uterine pregnancy with mifepristone and 
gemeprost 
Rare serious cardiovascular accidents have been reported following the intra 
muscular administration of the prostaglandin analogue sulprostone (withdrawn in 
1992). No such cases have been reported since analogues of PGE1 (gemeprost or 
misoprostol) have been used. For these reasons and as a special precautionary 
measure, the medical method is not recommended for use in women over 35 years 
of age and who smoke more than 10 cigarettes a day.  
Method of prostaglandin administration 
During administration and for a minimum of three hours following administration 
and in accordance with clinical judgement, the patients should be monitored in the DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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treatment centre, which must be equipped with the appropriate equipment.  
3 ) For the sequential use of mifepristone - prostaglandin, whatever the 
indication 
The precautions related to the prostaglandin used should be followed where 
relevant.  
The treatment procedure should be fully explained and completely understood by 
the patient. There is a Patient Information Leaflet available for each of the 
indications in the tablet carton. Prior to administration of mifepristone the 
appropriate leaflet should be given to the patient to read.  
 
 
4.5 Interaction with other medicinal products and other forms of 
Interaction  
 
 
In view of the single dose administration, no specific interactions have been 
studied. However, there could be interactions with drugs which modulate or inhibit 
prostaglandin synthesis and metabolism. See PRECAUTIONS above.  
 
 
  4.6 Pregnancy and lactation    
 
In animals (see section 5.3 Pre-clinical safety data), the abortifacient effect of 
mifepristone precludes the proper assessment of any teratogenic effect of the 
molecule.  
With subabortive doses, isolated cases of malformations observed in rabbits, but 
not in rats or mice were too few to be considered significant, or attributable to 
mifepristone.  
In humans, the few reported cases of malformations do not allow a causality 
assessment for mifepristone alone or associated to prostaglandin. Therefore, data is 
too limited to determine whetherthe molecule is a human teratogen.  
Consequently:  
- Women should be informed, that due to the risk of failure of the medical method 
of pregnancy termination and to the unknown risk to the fetus, the control visit is 
mandatory (see Section 4.4 special warnings and special precautions for use).  
- Should a failure of the method be diagnosed at the control visit (viable ongoing 
pregnancy), and should the patient still agree, pregnancy termination should be 
completed by another method.  
- Should the patient wish to continue with her pregnancy, the available data is too 
limited to justify a systematic termination of an exposed pregnancy. In that event, 
careful ultra-sonographic monitoring of the pregnancy should be carried out.  
Lactation 
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Mifepristone is a lipophilic compound and may theoretically be excreted in the 
mother's breast milk. However, no data is available. Consequently, mifepristone use 
should be avoided during breast-feeding.  
 
  4.7 Effects on ability to drive and use machines    
  None known.    
 
  4.8 Undesirable effects    
 
Most frequently reported undesirable effects (mifepristone) 
• Urogenital  
- Bleeding  
Heavy bleeding occurs in about 5% of the cases and may require hemostatic 
curettage in up to 0.7% of cases.  
- Very common uterine contractions or cramping (10 to 45%) in the hours following 
prostaglandin intake.  
- During induction of second trimester termination of uterine rupture has been 
uncommonly reported after prostaglandin intake. The reports occurred particularly 
in multiparous women or in women with a caesarean section scar.  
• Gastrointestinal  
- Cramping, light or moderate.  
- Nausea, vomiting.  
Other undesirable effects (mifepristone) 
• Hypersensitivity and skin  
- Hypersensitivity: skin rashes uncommon (0.2%), single cases of urticaria.  
- Single cases of erythroderma, erythema nodosum, epidermal necrolysis have also 
been reported.  
• Other systems  
- Rare cases of headaches, malaise, vagal symptoms (hot flushes, dizziness, chills 
have been reported) and fever.  
Undesirable effects (gemeprost)  
- nausea, vomiting or diarrhoea, and rarely hypotension (0.25%)  
 
 
  4.9 Overdose    
  Tolerance studies have shown that administration of doses of mifepristone of up to 
2g caused no unwanted reactions. Nevertheless, in the event of massive ingestion 
signs of adrenal failure might occur. Any suggestion of acute intoxication, therefore, 
 DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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requires treatment in a specialist environment.  
 
5. PHARMACOLOGICAL PROPERTIES   
 
  5.1 Pharmacodynamic properties    
 
Mifepristone is a synthetic steroid with an antiprogestational action as a result of 
competition with progesterone at the progesterone receptors.  
At doses ranging from 3 to 10mg/kg orally, it inhibits the action of endogenous or 
exogenous progesterone in different animal species (rat, mouse, rabbit and 
monkey). This action is manifested in the form of pregnancy termination in rodents.  
In women at doses of greater than or equal to 1mg/kg, mifepristone antagonises 
the endometrial and myometrial effects of progesterone. During pregnancy it 
sensitises the myometrium to the contraction inducing action of prostaglandins.  
Mifepristone induces softening and dilatation of the cervix, softening and dilatation 
has been shown to be detectable from 24 hours after administration of mifepristone 
and increases to a maximum at approximately 36 – 48 hours after administration.  
In the majority of cases, abortion will occur within 4 hours of administration of 
gemeprost.  
During the termination of pregnancy between 13 and 20 weeks gestation, 
mifepristone administered at a 600-mg dose, 36 to 48 hours prior to the first 
administration of prostaglandins, reduces the induction-abortion interval, and also 
decreases the dose of gemeprost required for the expulsion.  
Mifepristone binds to the glucocorticoid receptor. In animals at doses of 10 to 25 
mg/kg it inhibits the action of dexamethasone. In man the antiglucocorticoid action 
is manifested at a dose equal to or greater than 4.5 mg/kg by a compensatory 
elevation of ACTH and cortisol.  
Mifepristone has a weak anti-androgenic action which only appears in animals 
during prolonged administration of very high doses. 
 
 
  5.2 Pharmacokinetic properties    
 
After oral administration of a single dose of 600 mg mifepristone is rapidly 
absorbed. The peak concentration of 1.98 mg/l is reached after 1.30 hours (means 
of 10 subjects).  
There is a non-linear dose response. After a distribution phase, elimination is at first 
slow, the concentration decreasing by a half between about 12 and 72 hours, and 
then more rapid, giving an elimination half-life of 18 hours. With radio receptor 
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assay techniques, the terminal half-life is of up to 90 hours, including all 
metabolites of mifepristone able to bind to progesterone receptors.  
After administration of low doses of mifepristone (20 mg orally or intravenously), 
the absolute bioavailability is 69%.  
In plasma mifepristone is 98% bound to plasma proteins: albumin and principally 
alpha-1-acid glycoprotein (AAG), to which binding is saturable. Due to this specific 
binding, volume of distribution and plasma clearance of mifepristone are inversely 
proportional to the plasma concentration of AAG.  
N-Demethylation and terminal hydroxylation of the 17-propynyl chain are primary 
metabolic pathways of hepatic oxidative metabolism.  
Mifepristone is mainly excreted in faeces. After administration of a 600 mg labelled 
dose, 10% of the total radioactivity is eliminated in the urine and 90% in the 
faeces.  
 
6. PHARMACEUTICAL PARTICULARS   
 
  6.1 List of excipients    
 
Anhydrous colloidal silica 3mg, Maize Starch 102mg, Povidone 12mg, 
Microcrystaline cellulose 30mg, Magnesium Stearate 3mg.  
 
 
  6.2 Incompatibilities    
  None known.    
 
  6.3 Shelf life    
  Tablets - 36 months.    
 
  6.4 Special precautions for storage    
  None.    
 
  6.5 Nature and contents of container    
  Blister pack (PVC and Aluminum foil and carton) containing 3 tablets.    
 
  6.6 Instructions for use and handling    DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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The treatment procedure should be fully explained and completely understood by 
the patient.  
 
 
  Administrative Data    
 
7. MARKETING AUTHORISATION HOLDER   
  Exelgyn S.A., 6 rue Christophe Colomb, 75008 Paris, France    
 
8. MARKETING AUTHORISATION NUMBER(S)   
  Mifegyne Tablets 16152/0001    
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE 
AUTHORISATION 
 
  Renewal May 1999    
 
10. DATE OF REVISION OF THE TEXT   
  August 2001    
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Appendix B: Willingness to pay
Methods and questions
Women will be asked to state their WTP for their preferred method of termination at the following points.
1.  Pre TOP: for women expressing a preference and enrolled in the ‘preference arm’ we will ascertain the 
maximum amount WTP using the payment card method.
2.  Post TOP: all women who underwent TOP will be asked which method they would choose if 
undergoing a future TOP and if they would be willing to pay an amount to receive that preferred 
option at a future date. If they answer yes to this, we will ascertain the maximum amount WTP using 
the payment card method.
Questioning strategy (outline)
1.  Description of termination method.
2.  Choice of termination method.
3.  Willing to pay?
i. If no: asked why not
ii. If yes: payment card method used (see below).
4.  Then asked to explain the amount indicated. NB There is a need to categorise protest zeros from non-
demanders.
Payment card method
The concept of willingness to pay and the payment card method have been used previously in a study of 
women’s preferences in the termination of pregnancy.33
In this study, once respondents have indicated if they have a preference for a particular method of 
termination and that they would be willing to pay to access that method, they will be handed a card 
containing a list of values from £0 to £1000 and £1000+.
£0 £5 £10 £20 £30 £40 £50 £60 £70 £80 £90 £100 £110 £120 £140 £160 £180 £200 £225 £250 £275 
£300 £350 £400 £450 £500 £600 £700 £800 £900 £1000 £1000+
If £1000+, can you say what is the exact amount?
Respondents will be asked to put a cross by the amounts that they would definitely not pay and then to 
consider what would be the maximum amount they would be willing to pay by circling the relevant value. 
If respondents indicate ‘£1000+’ they will asked to write in the amount. All respondents will be asked an 
open-ended question regarding why they chose the amount indicated.
Other data to be collected
Income, age, age at which left education, occupation, previous operation with a general anaesthetic  
(yes/no).
Appendix C: Satisfaction with care
The E5 satisfaction measure assesses satisfaction with:
1. procedure overall
2. technical quality (thoroughness, carefulness, competence)
3. interpersonal manner (courtesy, respect, sensitivity, friendliness) of the staff
4. length of wait from request to procedure
5. using a five-choice evaluation scale:
Excellent Very good Good Fair PoorDOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Appendix D: Experience of care
Semantic differential rating for acceptability of procedure
Painless  Painful
3 2 1 0 –1 –2 –3
Happy  Sad
3 2 1 0 –1 –2 –3
Good  Bad
3 2 1 0 –1 –2 –3
Pleasant  Unpleasant
3 2 1 0 –1 –2 –3
Positive  Negative
3 2 1 0 –1 –2 –3
Safe  Dangerous
3 2 1 0 –1 –2 –3
Attractive  Unattractive
3 2 1 0 –1 –2 –3
Mild  Harsh
3 2 1 0 –1 –2 –3
Agreeable  Disagreeable
3 2 1 0 –1 –2 –3
Active  Passive
3 2 1 0 –1 –2 –3
Easy  Hard
3 2 1 0 –1 –2 –3
Fast  Slow
3 2 1 0 –1 –2 –3Appendix 2 
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Appendix E: Impact of Event Scale
Below is a list of comments made by people after stressful life events. Using the following scale, please 
indicate (with a ✗) how frequently each of these comments were true for you during the past seven days.
Not at all Rarely Sometimes Often
I thought about it when I didn’t mean to . . . .
I avoided letting myself get upset when I thought about 
it or was reminded of it
. . .
I tried to remove it from memory . . . .
I had trouble falling asleep or staying asleep because of 
pictures or thoughts about it that came into my mind
. . . .
I had waves of strong feelings about it . . . .
I had dreams about it . . . .
I stayed away from reminders of it . . . .
I felt as if it hadn’t happened or wasn’t real . . . .
I tried not to talk about it . . . .
Pictures about it popped into my mind . . . .
Other things kept making me think about it . . . .
I was aware that I still had a lot of feelings about it, but 
I didn’t deal with them
. . . .
I tried not to think about it . . . .
Any reminder brought back feelings about it . . . .
My feelings about it were kind of numb . . . .
Scoring: not at all, 0; rarely, 1; sometimes, 3; often, 5. Total = total the scores. DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Appendix F: Hospital Anxiety and Depression Scale
 
The statements below are about how you are feeling in yourself. 
Please read each statement and circle the number next to the answer which comes closest to how you 
have been feeling in the past week.  (Please make sure you answer every statement). 
a)  I feel tense or 'wound up': 
Most of the time...................................... 1 
A lot of the time ...................................... 2 
From time to time, occasionally.............. 3 
Not at all ................................................. 4 
b)  I still enjoy the things I used to enjoy: 
Definitely as much.................................. 1 
Not quite so much .................................. 2 
Only a little.............................................. 3 
Hardly at all ............................................ 4 
c)  I get a sort of frightened feeling as if  
  something awful is going to happen: 
Very definitely and quite badly ............... 1 
Yes, but not too badly............................. 2 
A little, but it doesn't worry me................ 3 
Not at all ................................................. 4 
d)  I can laugh and see the funny side of 
things: 
As much as I always could..................... 1 
Not quite so much now........................... 2 
Definitely not so much now .................... 3 
Not at all ................................................. 4 
e)  Worrying thoughts go through my mind: 
A great deal of the time .......................... 1 
A lot of the time ...................................... 2 
From time to time, but not too often ....... 3 
Only occasionally ................................... 4 
f)  I feel cheerful: 
Not at all ................................................. 1 
Not often................................................. 2 
Sometimes ............................................. 3 
h)  I feel as if I am slowed down: 
Nearly all the time...................................1 
Very often ...............................................2 
Sometimes..............................................3 
Not at all..................................................4 
i)  I get a sort of frightened feeling like  
  butterflies in the stomach: 
Not at all..................................................1 
Occasionally ...........................................2 
Quite often ..............................................3 
Very often ...............................................4 
j)  I have lost interest in my appearance: 
Definitely.................................................1 
I don't take as much care as I should .....2 
I take just as much care..........................3 
I take more care than I have previously..4 
k)  I feel restless, as if I have to be on the move: 
Very much indeed...................................1 
Quite a lot ...............................................2 
Not very much.........................................3 
Not at all..................................................4 
l)  I look forward with enjoyment to things: 
As much as I ever did .............................1 
Rather less than I used to.......................2 
Hardly at all.............................................3 
Not at all..................................................4 
m)  I get sudden feelings of panic: 
Very often indeed....................................1 
Quite often ..............................................2 
Not very often .........................................3 
Not at all..................................................4 Appendix 2 
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Most of the time...................................... 4 
g)  I can sit at ease and feel relaxed: 
Definitely................................................. 1 
Usually.................................................... 2 
Not often................................................. 3 
Not at all ................................................. 4 
n)  I can enjoy a good book or radio or TV  
  programme: 
Often.......................................................1 
Sometimes..............................................2 
Not often .................................................3 
Very seldom............................................4 DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Appendix G: Quality of Life Questionnaire (EQ-5D)
EQ-5D – This is Euro Qual – 5D for completion by the patient.  This is a standard 
questionnaire which is used in large research studies in similar populations. 
The next few questions are how you are at present.  For each of the five sets of statements 
below please circle the number that best describes your own health state today. 
 
1.  Mobility 
  I have no problems in walking about.................................................................................... 1 
  I have some problems in walking about ............................................................................... 2 
  I am confined to bed ............................................................................................................. 3 
 
2.  Self-Care 
  I have no problems with self-care......................................................................................... 1 
  I have some problems washing or dressing myself .............................................................. 2 
  I am unable to wash or dress myself..................................................................................... 3 
 
3.  Usual Activities 
  I have no problems with performing my usual  activities 
     (eg work, study, housework, family or leisure activities) .............................................. 1 
  I have some problems with performing my usual activities ................................................. 2 
  I am unable to perform my usual activities........................................................................... 3 
 
4.  Pain/Discomfort 
  I have no pain or discomfort................................................................................................. 1 
  I have moderate pain or discomfort ...................................................................................... 2 
  I have extreme pain or discomfort ........................................................................................ 3 
 
5.  Anxiety/Depression 
  I am not anxious or depressed............................................................................................... 1 
  I am moderately anxious or depressed.................................................................................. 2 
  I am extremely anxious or depressed.................................................................................... 3 
 
EQ-5D cont.d Appendix 2 
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Appendix 3  
Individual-level unit costs and resource 
usage for each method of TOP
MTOP (n = 960) STOP (n = 811) 
Resource category Unit cost (£) Number Mean Number Mean
Overnight stay 118.00 25 0.03 7 0.01
ERPC 483.79 25 0.03 10 0.01
Gemeprost 43.00 10 0.02 0 0.00
Misoprostol 0.17 642 0.93 11 0.02
Syntocinon 0.89 1 0.00 0 0.00
Metronidazole 2.40 5 0.01 2 0.00
Doxycycline 3.72 1 0.00 1 0.00
Cephalexin 2.83 5 0.01 1 0.00
Cocodamol 0.07 403 0.43 37 0.04
Codeine 0.08 19 0.03 92 0.18
Diclofenac 0.01 586 1.86 86 0.30
Morphine 5.00 0 0.00 3 0.00
Paracetamol 0.01 7 0.01 92 0.11
Pethidine 0.10 1 0.00 0 0.00
Trazodone 0.34 0 0.00 1 0.00
Cyclizine 0.07 6 0.01 8 0.01
Metoclopramide 0.06 0 0.00 1 0.00
Odansetron 3.14 2 0.00 3 0.00
Odansetron IV 5.39 0 0.00 2 0.00
Stemetil tab 0.07 1 0.00 0 0.00
Stemetil IM 0.54 139 0.15 8 0.01
ERPC, evacuation of retained products of conception.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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Appendix 4  
Individual-level unit costs and resource 
usage for each arm of the trial
TABLE 49  Randomised arm
MTOP (n = 174) STOP (n = 154)
Resource category Unit cost (£) Number Mean Number Mean
Overnight stay 118.00 4 0.03 0 0.00
ERPC 484.94 4 0.03 2 0.01
Gemeprost 43.00 2 0.02 0 0.00
Misoprostol 0.17 103 0.98 9 0.07
Syntocinon 0.89 0 0.00 0 0.00
Metronidazole 2.40 0 0.00 1 0.01
Doxycycline 3.72 0 0.00 0 0.00
Cephalexin 2.83 0 0.00 1 0.01
Cocodamol 0.07 71 0.46 10 0.06
Codeine 0.08 2 0.02 16 0.16
Diclofenac 0.01 95 1.85 25 0.42
Morphine 5.00 0 0.00 0 0.00
Paracetamol 0.01 0 0.00 16 0.09
Pethidine 0.10 0 0.00 0 0.00
Trazodone 0.34 0 0.00 0 0.00
Cyclizine 0.07 0 0.00 2 0.01
Metoclopramide 0.06 0 0.00 0 0.00
Odansetron 3.14 0 0.00 0 0.00
Odansetron IV 5.39 0 0.00 0 0.00
Stemetil tab 0.07 0 0.00 0 0.00
Stemetil IM 0.54 24 0.16 2 0.01
ERPC, evacuation of retained products of conception.Appendix 4 
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TABLE 50  Preference arm
MTOP (n = 786) STOP (n = 657)
Resource category Unit cost (£) Number Mean Number Mean
Overnight stay 118.00 21 0.03 7 0.01
ERPC 484.94 21 0.03 8 0.01
Gemeprost 43.00 8 0.03 0 0.00
Misoprostol 0.17 539 0.92 2 0.01
Syntocinon 0.89 1 0.00 0 0.00
Metronidazole 2.40 5 0.01 1 0.00
Doxycycline 3.72 1 0.00 1 0.00
Cephalexin 2.83 5 0.01 0 0.00
Cocodamol 0.07 332 0.42 27 0.04
Codeine 0.08 17 0.03 76 0.19
Diclofenac 0.01 491 1.87 61 0.26
Morphine 5.00 0 0.00 3 0.00
Paracetamol 0.01 7 0.01 76 0.12
Pethidine 0.10 1 0.00 0 0.00
Trazodone 0.34 0 0.00 1 0.00
Cyclizine 0.07 6 0.01 6 0.01
Metoclopramide 0.06 0 0.00 1 0.00
Odansetron 3.14 2 0.00 3 0.00
Odansetron IV 5.39 0 0.00 2 0.00
Stemetil tab 0.07 1 0.00 0 0.00
Stemetil IM 0.54 115 0.15 6 0.01
ERPC, evacuation of retained products of conception.DOI: 10.3310/hta13530  Health Technology Assessment 2009; Vol. 13: No. 53
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We look forward to hearing from you.